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Marek’s Disease virus (MDV) is a highly contagious, widespread and persistent neoplastic 
herpesvirus causing extensive lymphoblastic tumours in chickens. The virus is shed in feather 
dust and spread through inhalation.  Vaccines are available to protect against the effects of MDV 
but not replication of the virus and subsequent contamination of the environment leading to flock 
exposure.  Increased virulence in strains of MDV has been identified and currently available 
vaccines may not offer protection from the disease.  Disease outbreaks result in economic 
losses as well as welfare issues.  To break this cycle better methods of controlling MDV 
preventing both tumourogenesis and shedding of infectious virus must be developed.  Targeting 
specific MDV genes key to maintaining latency and viral replication using siRNA could potentially 
be used as a control strategy.  At the present time, many of the unique genes in MDV are largely 
uncharacterised.    
15 uncharacterised open reading frames (ORFs) were screened for expression in a MDV latent 
infection model in a non-producer MDV transformed chicken lymphoblast cell line, RPL-1.  Of 
these uncharacterised ORFs LORF1, LORF3, LORF11, LORF12, ANTISENSE, US2, MLTI, 
RLORF11, RLORF12, 23kDa and RLORF6 were expressed during latency.  To investigate the 
effect of post-transcriptional knockdown of these ORF products two 25-mer siRNA 
oligonucleotides were designed for each gene, transfected into RPL-1 cells and analyzed using 
growth rate as an indicator of changed phenotype over a period of 120 hours post-transfection.  
RPL-1 cells transfected with a nonsense siRNA oligonucleotide were used as the control group.  
No significant changes in transfected cell growth over the controls were identified in LORF3, 
ANTISENSE, RLORF12, LORF1, LORF11 or MLTI.  Increased RPL-1 cell growth was observed 
(adjusted p-value of 0.0094) in one of the two siRNA oligonucleotides specific for RLORF6 at 72 
hours post-transfection.  RLORF6 was further characterised using confocal microscopy 
techniques and was found to be localized in the nucleus but not the nucleolus of chicken embryo 
fibroblasts and chicken lymphoblastic cells.  
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Chapter 1 - Introduction
1.1 Herpesviridae
The Herpesviridae family is one of the oldest and largest of the viruses dating back an 
estimated 400 million years (sirnaMcGeoch and Gatherer, 2004). Herpesvirus species 
have been described infecting a diverse range of species, including fish (Wolf and 
Darlington, 1971), cetaceans (Arbelo et al., 2010), reptiles (Bicknese et al., 2010; Clark 
and Karzon, 1972) and even bivalves (Farley et al., 1972). Individual herpesviruses, 
however, typically have a very limited host range and many viruses infect only one host 
species.  The herpesviruses are unique among viruses and share several distinctive
factors which aid in defining them as a family (Pellett et al., 2006).  Firstly, the capsid 
contains double-stranded DNA encoding genes for nucleic acid metabolism, DNA 
synthesis and protein processing.  Secondly, synthesis of viral DNA and capsid 
assembly occurs within the nucleus of the infected cell while the final assembly of the 
viron takes place in the cytoplasm.  Thirdly, production of viral particles during lytic 
infection irreversibly damages the host cell resulting in its destruction.  Lastly,
herpesviruses are able to establish non-replicating latent infections with a later reversion 
to productive infection that facilitates virus survival from generation to generation even 
in small populations.  In latent infections, the viral genome is maintained outside the 
host cell chromosome allowing persistent infection often for the life of the animal
accompanied by continuous or sporadic viral shedding whenever there is a reversion to 
cytolytic infection, usually when the host is immunocompromised or under stress.    
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1.1.1 Taxonomic Classification
The order Herpesvirales encompasses all herpesviruses, but the vast majority of 
herpesviruses described to date are classified within the Herpesviridae family that is
subdivided into three main subfamilies designated Alphaherpesvirinae (), 
Betaherpesvirinae () and Gammaherpesvirinae () based on viral particle architecture 
and biological properties.  This was expanded with the addition of the Alloherpesviridae
and Malacoherpesviridae families to include herpesviruses infecting fish, amphibians 
and bivalves as outlined in table 1.1 (Davison et al., 2009; Pellett et al., 2006).  To date 
many recently described species of herpesviruses are still to be categorized.  The 
assignment of the formal taxonomic classification for each species of Herpesviridae is 
designated by the Herpesviridae Study Group of the International Committee on 
Taxonomy of Viruses (http://www.ictvonline.org) and usually incorporates a reference
to the definitive host species (Davison et al., 2009).  In addition to the formal name most 
species of viruses also have a designated acronym (for example HHV3 for Human 
Herpesvirus 3) and a common name (for example Varicella Zoster for Human 
Herpesvirus 3) both of which are often used to refer to the virus in the literature but have 
no formal taxonomic standing (Davison et al., 2009).  
The -herpesviruses are currently divided into four genera plus some recently 
discovered unassigned chelonid viruses as shown in table 1.1 (Davison et al., 2009).  
The Simplexvirus genus infects mammals and includes the well-studied Herpes Simplex 
Virus Type 1 and 2 (also known as or HSV-1/HSV-2 or Human Herpesviruses 1 and 2).  
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Varicellovirus also infects mammals and includes human Varicella Zoster Virus (VZV
or Human Herpesvirus 3) and Pseudorabies virus (Suid herpesvirus 1) infecting pigs.  
The Mardiviruses described to date all infect avian species and include Gallid 
herpesvirus 2 (also known as Marek’s Disease Virus type 1 or MDV), Gallid 
herpesvirus 3 (Marek’s Disease Virus type 2 or GaHV3) and Melagrid herpesvirus 1
(Herpesvirus of Turkeys or HVT).  The Iltoviruses also infect birds and include
Pacheco’s disease virus (Psittacid herpesvirus 1) and Infectious Laryngotracheitis
(Gallid Herpesvirus 1) the latter of which was formerly classified as a Mardivirus but 
was later found to be in a separate genus (Davison et al., 2009; Hughes and Rivailler, 
2007).  Features common to most of the-herpesviruses are a short reproductive cycle
resulting in rapid spread in cell culture with very efficient destruction of infected cells
and many species establish persistent infections in the dorsal root ganglia or other nerve 
cells (Pellett et al., 2006).  
-herpesviruses also include four genera and some unassigned viruses all infecting
mammals as shown in table 1.1 (Davison et al., 2009).  The Cytomegaloviruses infect
primates and include Human Cytomegalovirus (Human Herpesvirus 5).  
Muromegaloviruses infect rodents and includes Murid herpesvirus 1 (Mouse 
cytomegalovirus).  Roseolovirus infects humans and includes Human Herpesvirus 6 and 
Human Herpesvirus 7. Proboscivirus infects elephants and includes Elephant 
endotheliotropic herpesvirus (Elephantid herpesvirus 1).  Properties that are common 
but not exclusive to-herpesviruses include a slow reproductive cycle resulting in slow 
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growth in vitro and infected cells often becoming enlarged (cytomeglia).  The -
herpesviruses establish latent infections in a variety of cells such as salivary glands, 
kidney and lymphoreticular cells (Pellett et al., 2006).
The-herpesviruses contain four genera as well as some unclassified viruses all 
infecting mammals as outlined in table 1.1 (Davison et al., 2009).  
Lymphtocryptoviruses infect primates and include Epstein - Barr virus (EBV or Human 
Herpesvirus 4). The Rhadinovirus genus infects mammals and includes Kaposi’s
Sarcoma-Associated Herpesvirus (KSHV or Human Herpesvirus 8) and Murine 
Gammaherpesvirus 68 (Murid Herpesvirus 4). Macaviruses infect mammals and 
include Malignant Catarrhal Fever virus (Alcelaphine herpesvirus 1) and Sheep-
associated malignant catarrhal fever virus (Ovine herpesvirus 2).   Percaviruses also 
infects mammals and include Equine herpesvirus 2 and Badger herpesvirus (Mustelid 
herpesvirus 1). Common features of-herpesviruses include a particularly narrow host 
range often limited to the definitive host species, association with oncogenicity and 
replication in lymphoblastoid cells in vitro with a specificity for either T or B 
lymphocytes, although some viruses can also infect certain types of fibroblast and 
epithelial cell lines as well (Pellett et al., 2006).  MDV was originally classified as a -
herpesvirus based on common biological properties, but was subsequently classified as
an -herpesvirus based on genome architecture (Buckmaster et al., 1988; Camp et al., 
1991).
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Family Subfamily Genus Host















Unassigned Unassigned Birds, Reptiles 
and Mammals
Alloherpesviridae None Ictalurivirus Fish 
Unassigned Fish and 
Amphibians
Malacoherpesviridae None Ostreavirus Oysters
Table 1.1:  Taxonomy and host range of the order Herpesvirales adapted from (Davison et al., 
2009).
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1.1.2 Virus Particle Structure
The structure of a typical herpesvirus particle incorporates a core, icosahedral capsid, 
tegument and envelope as illustrated in figure 1.2.  Mature herpesvirus particles vary in 
size from 120 - 260 nm in size, making them one of the largest mature viral particles.  
The core contains 124-230 kb of linear double-stranded viral DNA arranged in a torus or 
spool (Furlong et al., 1972; Nazerian, 1974).  Herpesvirus capsids consist of a 100-110 
nm diameter icosahedral arrangement of 162 capsomeres consisting of 150 hexons and 
12 pentamers (Haarr and Skulstad, 1994; Nazerian and Burmester, 1968).  The capsid is 
surrounded by an amorphous protein-rich tegument and a lipid envelope containing 
external glycoprotein spikes that vary according to virus species.  The amorphous 
proteinacious tegument between the capsid and envelope contains many pre-synthesized 
proteins used during host cell infection.  The herpesvirus envelope has a trilaminar 
structure typical of phospholipid membranes and is composed of altered host cellular 
membranes containing variable numbers and amounts of glycoproteins depending on the 
viral species.  For a more comprehensive review of viral particle structure see Fields 
Virology (Pellett et al., 2006).     
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Figure 1.2:  Electron micrograph of Varicella Zoster (HHV-3) virus particle illustrating the 
generalized Herpesviridae viral particle structure of an icosahedral capsid containing double 
stranded DNA, amorphous tegument and envelope with glycoprotein spikes.  Photo adapted 
from image taken by Prof. Frank Fenner (John Curtin School of Medical Research, Australian 
National University, Canberra, Australia) downloaded from ICTVdB - The Universal Virus 




The herpesvirus genome encodes between 70-220 genes depending on the individual 
virus.  Genes are often designated by number and according to their location in the 
genome:  for example gene 30 located in the unique long region of the genome reading 
from L to R would be designated as UL30.  Genes encoding products required for viral 
replication and other essential functions are deemed fundamental core genes and are 
conserved in all herpesviruses (Alba et al., 2001; Davison et al., 2002; McGeoch et al., 
2006).  The 44 recognized core genes are listed according to function in table 1.3.  Each 
of the fundamental genes are located within one of 7 core blocks encoding between 2 
and 12 genes whose order and polarity is conserved in all herpesviruses (Alba et al., 
2001; Pellett et al., 2006).  Other genes are also conserved at the subfamily level.  
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Uracil DNA glycosylase UL2 β or γ1, 
non-essential
dUTPase UL50 β, non-essential
Ribonucleotide reductase, large 
subunit
UL39 β, non-essential








DNA polymerase UL30 β, essential
ssDNA binding, ICP8 UL29 β, essential
DNA polymerase processivity 
factor
UL42 β, essential







Terminase/packaging UL15a γ, essential
DNA packaging UL25 γ2, essential
Scaffold protease 
(cleaves to 2 proteins)
UL26 γ, essential
Scaffold UL26.5 γ, essential
Capsid nuclear egress UL31,UL34 γ, essential
Virion UL16 γ, essential
Virion Capsid Major capsid protein UL19 γ, essential





Hexon tips UL35 γ2, non-essential
Virion Tegument Large tegument protein UL36 γ2, essential
Tegument protein UL7 γ1, non-essential
Protein kinase UL13 γ, non-essential





Viron Envelope Glycoprotein B UL27 γ1, essential
Glycoprotein H, VP22 UL22 γ, essential
Glycoprotein L UL1 γ, essential
Glycoprotein M UL10 γ2, non-essential
Glycoprotein N UL49.5 γ2, essential
Other Cell-to-cell fusion UL24 γ1, non-essential
Table 1.3:  Conserved genes in alpha-, beta- and gammaherpesviruses grouped by general 
function HSV homologue and kinetic gene class ( or  genes & whether essential or non-
essential for replication in vitro). Adapted from Fields Virology (Pellett et al., 2006).
10
Genes unique to -herpesviruses include those encoding glycoprotein D, Viral Protein 
16 (VP16) and regulatory genes related to the HSV homologues of ICP0 and ICP4.  In 
-herpesviruses the HSV homologue of the conservedimmediate early gene 4 
(encoding ICP4) plays a key role in the regulation of early lytic gene expression by 
interacting with transcription factors allowing it to function in multiple roles as a 
repressor of viral mRNA synthesis as well as a transactivator (Liu et al., 2010; Pellett et 
al., 2006).  Liu and colleagues reviewed the complex regulatory mechanism in HSV-1 
where the activation of the viral mRNA synthesis cascade in lytic infection is initiated 
by accumulation of the ICP0 immediate early protein and is negatively regulated by
ICP4 (Liu et al., 2010).  Effective gene expression of all  and  genes therefore relies 
on ICP4 but there is some recent evidence that viral micro RNA (miRNA) also plays a 
role in ICP4 regulation (Li et al., 2010; Waidner et al., 2011).  Unique genes to -
herpesvirinae include a block of 14 genes as well as genes associated with US22 and 
highly divergent immediate early genes associated with gene regulation.  Genes 
conserved in -herpesvirinae encode unique proteins necessary for maintaining latency 
in dividing host cells.  
Three additional genes appear to be ancestral to the -herpesvirus HSV-1 but have been 
lost in certain other viral lineages (Davison et al., 2002; McGeoch et al., 2006). The 
origin binding protein (OBP), encoded by the HSV-1 homologue of UL9, is associated 
with DNA replication machinery and is conserved only within -herpesvirinae and the 
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Roseolovirus of-herpesvirinae but not within the rest of the- or -herpesviruses
(Inoue et al., 1994).  The HSV-1 homologues of UL23 (encoding thymidine kinase) and 
UL40 (encoding the small subunit of ribonucleotide reductase) are conserved only in-
herpesvirinae and -herpesvirinae (Davison et al., 2002).  Genes unique to a particular 
species are often associated with latency and transformation, an example being the Meq 
gene in the -herpesvirus MDV (Brown et al., 2009), or immune modulation of the host 
cell, examples being the numerous unique genes in the -herpesvirus KSHV many of 
which demonstrate homology to host cellular immunomodulators (Rezaee et al., 2006).
  
Overall genome arrangement in the herpesviruses can be categorized into six classes 
designated A to F (Pellett et al., 2006) and illustrated in figure 1.4.  Some of these 
classes can exist in more than one isomeric configuration depending on the repeat 
segments of the gene.  Group A, exemplified by Human Herpesvirus 6, contains a left 
and right terminal repeat sequence.  Group B is exemplified by Herpesvirus Saimiri that
has variable numerous repeats of the terminal sequences at both ends.  Group C, 
exemplified by EBV, contains 4 internal repeat domains denoted R1-R4.  Group D,
exemplified by VZV, contains both internal and terminal repeat regions flanked by a 
small unique region.  The short component of Group D can invert relative to the long 
creating two isomers.  Group E, exemplified by MDV, has a more complex arrangement 
with terminal repeat sequences at both ends consisting of n copies of sequence a 
(denoted an) followed by sequence b at one termini and the directly repeated sequence a
followed by sequence c at the opposite termini.  The unique long (UL) and unique short 
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(US) regions of group E are also separated by inverted terminal repeat sequences an’, b’
and c’ (inverted sequences denoted by primes), and thus exist as 4 equimolar isomers 
due to both the long and short components being able to invert.  Group F, exemplified 
by the unassigned -herpesvirus Tupaia Herpesvirus 1 (Bahr and Darai, 2001), contains 
non-identical terminal sequences that are not repeated either directly or inversely.  These 
genome arrangement classifications exist in addition to the subfamily classifications of 
,  and -herpesviruses and are not exclusive to any one subfamily.     
Figure 1.4:  Schematic diagram depicting genomic arrangement of the six different classes of 
Herpesviridae adapted from Fields Virology (Pellett et al., 2006). Unique or quasiunique regions 
are shown in purple and reiterated regions are shown in green.  (LTR denotes Left Terminal 
Repeat, RTR denotes Right Terminal Repeat, R1-R4 denotes internal repeat domains, IR 
denotes internal repeats and TR denoted terminal repeats, UL denotes unique long regions and 
US denotes unique short regions).
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Functions of individual herpesvirus genes can also be classified according to their 
kinetic gene class designating the order of their sequential expression during the 
productive or lytic infection cascade (Pellett et al., 2006) which will be discussed further 
in the following sections. Immediate-early genes () are expressed first in the absence 
of viral protein synthesis and are followed by early genes ().  Lastly the  genes are 
expressed which can be sub-categorized into intermediate-late genes () and true late 
genes ().  It is important to note that these kinetic gene classes are not related to the 
subfamily designations of the same name.  Additionally genes can be classified as 
essential or non-essential to viral replication in vitro. 
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1.1.4 Herpesvirus Life Cycle
The typical herpesvirus life cycle begins with viral entry into the host cell.  
Complementary receptors on the viral envelope and the target host cell membrane 
interact resulting in fusion allowing the viral capsid and tegument proteins to enter the 
host cell cytoplasm.  Viral entry can occur either via fusion of the plasma membrane or 
by endocytosis.  This section will focus mainly on the -herpesviruses as it is beyond 
the scope of this thesis to give a detailed review of the cellular mechanisms operating 
during the life cycle for all herpesviruses.  For a general review of the herpesvirus life 
cycle see Pellet et al. (2006).  
In the -herpesvirus HSV five viral glycoproteins (gB, gC, gD, gH and gL) have been 
shown to be involved with viral entry through membrane fusion (reviewed in Akhtar and 
Shukla, 2009).  Some viral entry can also occur by endocytosis through an alternative  
mechanism (Akhtar and Shukla, 2009).   For membrane fusion gC is considered non-
essential for viral entry although it has been shown to enhance the efficiency of virus
binding (Shukla and Spear, 2001).  Initially, viral gB and gC bind with cellular heparin 
sulphate proteoglycans bringing the two membranes into close apposition.  In HSV gD 
then binds to one of its cellular receptors, such as nectin-1 and -2 and herpesvirus entry 
mediator (HVEM), and undergoes a conformational change allowing it to form a multi-
protein fusion complex with gB, gD, gH and gL (Subramanian and Geraghty, 2007).  
Membrane fusion is then initiated and the nucleocapsid and tegument proteins enter the 
host cell cytoplasm.  The gD cellular receptors bound vary according to host cell type
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(Spear, 2004).  The cellular entry mechanism dependent on gD binding is unique to 
the-herpesviruses as viral entry occurs by other mechanisms such as pH dependent 
conformational changes of fusion proteins in other herpesviruses (Stampfer et al., 2010).  
Considerable research has been done on the more detailed mechanisms of viral entry 
which are beyond the scope of this thesis, but for a review see (Akhtar and Shukla, 
2009).  
Once the tegument proteins and nuclear capsid have gained entry into the host cell
cytoplasm the capsid containing viral DNA is transported to the nucleus where it is 
uncoated in order to initiate viral DNA synthesis. Most herpesviruses encode strong 
enhancers in their DNA which promote the transcription of the early viral genes (Pellett
et al., 2006).  The -herpesviruses are the exception and it is the virion tegument which 
contains essential transactivating proteins, one of the most important being the 
homologue of HSV VP16 encoded by ORF UL48, which promote the expression of 
immediate early viral genes.  
VP16 interacts with the host cell proteins POU domain protein Oct-1 (Oct-1) and 
transcriptional co-activator herpes simplex virus-associated host cell factor 1 (HCF-1) to 
form the VP16 induced complex (VIC) which binds to the TAATGARAT (R = purine) 
sequence present in homologues of the HSV immediate early gene promoters (Preston et 
al., 1988; Thompson et al., 2009; Wilson et al., 1997). HCF-1 is a conserved and 
complex cellular transcriptional co-regulator which interacts with numerous 
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transcription factor molecules to function as a bridge between transcription factors and 
chromatin modulation machinery (Mangone et al., 2010; Narayanan et al., 2005).  In 
HSV infection HCF-1 has been shown to be essential for mediation of immediate early 
viral gene transcription and has been associated with the cellular histone chaperone 
Asf1b, a protein regulating the progression of cellular DNA replication forks via 
chromatin reorganization (Narayanan et al., 2005; Peng et al., 2010).  The coupling of 
Asf1b to HCF-1 has been shown to promote viral DNA replication as well as its well-
described functions as a transactivator (Peng et al., 2010).  Interaction of the trans-
activating cellular protein Oct-1 with VP16 and has been shown to be key to viral 
replication at low but not high multiplicities of viral infection (Kristie and Sharp, 1990;
Nogueira et al., 2004).  The HSV VP16 protein has been well characterised and a 
considerable amount of detail is known on its function and mechanism but is beyond the 
scope of this thesis.  For more detailed reviews see (Pellett et al., 2006; Thompson et al., 
2009).
The viral capsid, containing condensed linear double-stranded DNA, is quickly 
transported from the cytoplasm to the host cell nuclear membrane via the microtubule 
and actin cytoskeleton (Dohner and Sodeik, 2005).  It is important to note that in -
herpesviruses transportation of the viral DNA occurs simultaneously with the tegument 
transactivating proteins, such as VP16, interacting with the host cellular receptors
(Pellett et al., 2006).  When the capsid reaches the nuclear membrane it docks with a 
nuclear pore and the virus is uncoated into the nucleoplasm in a polarized manner
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leaving the empty capsid shell outside the nuclear membrane (Miyamoto and Morgan, 
1971; Newcomb et al., 2009). In -herpesviruses this polarization means that the HSV 
homologue of the 4 gene, which encodes the ICP4 protein, enters the nucleoplasm first 
(Newcomb et al., 2009).  In HSV-1 the cleavage portal protein UL6 has been found to 
correlate with viral DNA release from the capsid suggesting its involvement in allowing 
the capsid to uncoat the viral genome (Newcomb and Brown, 2007).      
Once the viral genome DNA has gained entry into the nucleus, it circularizes and
initiates viral protein synthesis resulting in the remodelling of the host cell nucleus that
enhances viral replication and blocks the host cell immune response.  Immediate early 
genes, such as the genes encoding ICP4, ICP22, ICP27 and ICP0, which contain
promoters responsive to VP-16 are initially induced and expression occurs shortly after 
viral entry (apRhys et al., 1989).  ICP4 is a moderate transactivator of viral mRNA 
synthesis on its own, but when it interacts with ICP0 it becomes a potent transactivator 
of viral mRNA synthesis (Liu et al., 2010).  This interaction of ICP4 with ICP0 as well 
as several other genes is key to overcoming intrinsic cellular resistance to viral 
infections and initiating viral mRNA replication (Gu and Roizman, 2007; Hagglund and 
Roizman, 2004; Hancock et al., 2010).  Kalamvoki and Roizman showed that ICP0 
enhanced viral DNA synthesis and gene expression by playing a key role in the 
disruption of the compartmentalization of the host cell nucleus which is a key 
mechanism for intrinsic cellular defence against viral infections (Kalamvoki and 
Roizman, 2010).  The complex mechanism for compartmentalization disruption 
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involves the recruitment of cellular cyclin D3 by ICP0 to cellular nuclear domain10 
(ND-10) structures, such as ATRX and hDaxx which are vital to maintaining 
compartmentalization of cells (Kalamvoki and Roizman, 2010; Lukashchuk and Everett, 
2010).  The binding of ND-10 structures by cellular cyclin D3 activates cyclin 
dependent kinase 4 which has been associated with reactivation of latent HSV (Schang
et al., 2002).  After nuclear remodelling has been completed gene expression is then able 
to proceed with all viral gene transcription carried out by host RNA Polymerase II 
(Costanzo et al., 1977).
Once initiated, the gene expression sequence during a typical herpesvirus cytolytic 
infection is tightly regulated according to kinetic gene class with immediate early (), 
early (), intermediate (1) or late (2) genes expressed in a well-ordered cascade 
illustrated in figure 1.5. In -herpesviruses immediate early proteins such as ICP4 
encoded by  genes are expressed under the control of pre-synthesized tegument viral 
protein transactivators.  Immediate early proteins in turn promote expression of early 
proteins encoded by genes such as UL29 encoding ICP8.  The immediate early protein 
ICP0 contains multiple domains and plays its role in regulating the switch between 
to gene transcription by binding in the G/C rich C-terminal domain resulting in 
dissociating histone deactylase from the CoREST/REST repressor complex (Gu and 
Roizman, 2007).  ICP4 mediates viral activation and suppression by forming a 
transcriptional complex on the  promoters of various genes allowing the sequential 
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expression of genes (Sampath and Deluca, 2008).  Expression of the 1 and2 genes, 
encoding proteins such as ICP5, gB, gC and gD, are expressed after the  genes and are
enhanced by viral protein synthesis.  A more detailed review of late gene expression can 
be found in (Boehmer and Nimonkar, 2003; Pellett et al., 2006).    
Assembly of the viral particle takes place following viral protein synthesis where the 
nucleocapsid containing double-stranded DNA is assembled within the nucleus and is 
transported to the cytoplasm by primary envelopment at the inner nuclear membrane and 
de-envelopment at the outer nuclear membrane (Kelly et al., 2009).  The inner tegument 
is added in the cytoplasm and the viral particle is transported via kinesin-dependent 
microtubule transport to the Golgi apparatus where the outer tegument is added and 
secondary envelopment takes place.  The enveloped virus is then transported to the cell 
membrane and released by exocytosis.  
Latency occurs when the virus enters a non-replicating suspended state with limited 
gene expression at the beginning of the life cycle as illustrated in figure 1.5.  The latency 
associated transcript (LAT), which overlaps the 0 gene but is transcribed in the 
opposite direction and encodes several spliced RNA species but no proteins, was 
originally regarded as the only viral gene expressed during HSV latency (Pellett et al., 
2006).  miRNAs have since been described mapping to the LAT transcripts in both 
HSV-1 and HSV-2 which silence ICP0 expression (Tang et al., 2009; Umbach et al., 
2008; Umbach et al., 2009; Umbach et al., 2010).  Tang and colleagues also 
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demonstrated the negative regulation of the LAT encoded miRNAs by the ICP4 viral 
transactivator (Tang et al., 2009).  These findings all suggest that miRNA plays a key 
role in the regulation of HSV latency and will be explored further in the next section.  
Figure 1.5:  Schematic diagram showing a simplified herpesvirus lytic and latent life cycle.  
Adapted from a diagram kindly provided by Dr. Robert Dalziel, The Roslin Institute, University of 
Edinburgh, UK
Latency can revert to lytic infection when triggered by stress in the host which is
influenced by modulation of the host immune system (Pellett et al., 2006).  Simplified 
versions of herpesvirus infection stipulate multi-cellular organisms rigidly exist in one of 
three states:  true latency in which all the infected cells are latent,  partial latency in 
which certain infected cells revert to lytic infection producing viral particles either 
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asymptomatically or symptomatically in the host organism, or true lytic infection where
all infected cells are actively producing viral particles and there is shedding of infectious 
virus (Pellett et al., 2006).  It is becoming increasingly apparent that latent infection 
exists in a much more complex and dynamic state than previously thought mediated
principally by host -interferon expression (Carr et al., 2009; Decman et al., 2005).  
Decman and colleagues demonstrated that -interferon expressed by CD8 T cells can 
block HSV-1 reactivation from latency and inhibit ICP0 and gC promoter activity
suggesting a balance between latency and productive infection controlled by the host 
immune system (Decman et al., 2005). This model is consistent with the clinical 
features of herpesvirus reactivation following immunocompromise of the host that
would cause decreased levels of -interferon hence allowing reactivation.  
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1.1.5 Herpesvirus MicroRNAs
  The discovery of integrated developmental genes for non-coding RNA also known as
miRNAs in the soil nematode C. elegans and the pathway for its processing in the cell 
(Lee et al., 1993) led to the discovery of RNA interference as a key regulatory 
mechanism in virtually all metazoan organisms.  Cellular miRNAs play a vital role in 
post-transcriptional gene expression and have been found in a huge array of tissues and 
species encompassing almost every somatic cell in every metazoan eukaryote examined 
as well as viruses most notably herpesviridae (Pfeffer et al., 2004; Sullivan and Ganem, 
2005).  Since their initial discovery the list of known miRNAs continues to expand with 
the current version of the miRbase database (version 16) (http://microrna.sanger.ac.uk/
accessed 28/12/10) containing 15,172 miRNAs, 235 of which are viral miRNAs
(Griffiths-Jones et al., 2008). Herpesviruses account for the vast majority (over 97%) of 
the viral miRNAs described to date.  Sequence analysis has shown a high degree of 
miRNA sequence conservation within viral species but almost no conservation between 
viral species (Walz et al., 2010).   
miRNA precursors can be over 3,000 nucleotides long and are transcribed by RNA 
polymerase II in the nucleus as capped and polyadenylated long primary transcripts
which are both temporally and spatially regulated (Cai et al., 2004).  These are 
processed by the nuclear enzyme Drosha into short hairpin miRNA precursors of ~70 
nucleotides.  These pre-miRNAs are transported by Exportin-5 from the nucleus where 
they are processed by the endoribonuclease enzyme Dicer in the cytoplasm to yield 
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transient ~22 nucleotide RNA duplexes from which the single strands are preferentially 
loaded into the RNA-induced silencing complex (RISC).  The short RNA strands are the 
mature miRNA complex which bind to the 3’ untranslated regions of mRNA (Lee et al., 
1993).  When there is exact pairing between the miRNA and the corresponding mRNA,
then transcript degradation occurs and there is translational gene silencing.  When there 
is imperfect pairing, then there is translational interference of the specific gene without 
transcript degradation (Heidersbach et al., 2006).  Certain miRNAs have also been 
shown to up-regulate translation by binding with other 3’ untranslated region binding 
complexes (Lee et al., 2010a; Vasudevan et al., 2007).
The discovery of viral sequences encoding five miRNA in the herpesvirus EBV
infected Burkett’s Lymphoma cells (Pfeffer et al., 2004) precipitated the discovery that 
viral miRNA could modulate the expression of host genes.  Since this initial discovery 
over 220 herpesvirus miRNAs have been described and miRNAs have been found in 
every herpesvirus examined with the exception of VZV (Boss et al., 2009; Umbach et 
al., 2009).  The  and -herpesviruses miRNAs described to date have been located in 
blocks whereas the -herpesvirus miRNA appears to be more diffuse and associated 
with individual genes (Boss et al., 2009).  Viral miRNAs are conserved in their position 
but not in their sequence, and homology between viral miRNAs exists only in isolated 
cases (Walz et al., 2010).  A review by Grey and colleagues (2008) outlined four general 
mechanisms by which miRNA could affect viral replication:  firstly by viral miRNA
post-transcriptional targeting of viral mRNA expression,  secondly by viral miRNA
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post-transcriptional targeting of cellular mRNA expression, thirdly by host or virus 
miRNA direct cleavage of viral mRNA or fourthly viral miRNA direct cleavage of 
cellular mRNA (Grey et al., 2008).  Numerous examples of the first two mechanisms 
have been documented (Galardi et al., 2007; Tang et al., 2008; Tang et al., 2009; 
Umbach et al., 2008; Yao et al., 2009a), but to date there have been no examples of 
direct cleavage of viral or cellular mRNA by viral miRNA.  The biology of 
herpesviruses facilitates viral miRNA as an effective method for post-transcriptional 
gene targeting which could account for the vast majority of viral miRNAs identified to 
date being herpesviruses.  Nuclear expression in the host cell of the herpesvirus genome 
and its associated miRNAs aids the targeting of mRNA as cleavage of the primary 
miRNA transcript by the nuclear enzyme Drosha into its active form and mRNA
synthesis both take place in the nucleus allowing them to interact (Cullen, 2006).  
Among the -herpesviruses many of the miRNAs in HSV1 and HSV2 have been 
mapped to a region of latency-associated non-coding RNA transcripts (LAT) (Boss et 
al., 2009).  In HSV-1 these LAT miRNAs overlap in an antisense fashion with the lytic 
genes encoding ICP0, ICP4 and ICP34.5 (a viral neurovirulence factor) (Boss et al., 
2009; Liu et al., 2010; Tang et al., 2008; Tang et al., 2009; Umbach et al., 2008).   In 
HSV-1 the LAT acts as a precursor miRNA and its processed miRNAs have been shown 
to down-regulate ICP0 and ICP4 expression (Umbach et al., 2008).  Five miRNAs have 
also been identified in HSV-2 mapping to the LAT located antisense to ICP0 (Umbach
et al., 2009; Umbach et al., 2010).  In both HSV-1 and HSV-2 miRNAs were also found 
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to reduce the expression of the key neurovirulence factor encoded by ICP34.5 and 
therefore may influence the outcome of viral infection in the peripheral nervous system, 
the site of latency (Tang et al., 2008).  Several miRNAs have also been described in 
MDV, HVT and GaHV3 which will be reviewed later.  In summary, herpesvirus
miRNA plays a crucial role in modulating latency and transactivation and appears to be 
conserved within species, but not between different genera suggesting miRNA is under 
strong evolutionary pressure to adapt to the host environment (Boss et al., 2009; 
Gottwein and Cullen, 2008; Walz et al., 2010).
1.2 Marek’s Disease Virus (Gallid Herpesvirus 2)
Marek’s Disease (MD) affects domestic poultry worldwide and is caused by the highly 
contagious cell-associated oncogenic -herpesvirus Gallid Herpesvirus 2, which is also 
known as MDV.   Chickens (Gallus gallus) are the main target species of MD, but it has 
been described in a milder form in other species such as quail, turkeys and geese (Nair et 
al., 2008).  MDV causes rapidly fatal and widespread lymphoproliferative tumours in 
susceptible chickens inflicting large losses on the global poultry industry every year, 
although with the widespread use of a vaccine since the 1970’s the losses are no longer 
as substantial (Calnek and Witter, 1997; Witter and Schat, 2003). Estimates of the cost 
of MDV to the poultry industry have been as high as 2 billion US dollars per year
(Calnek and Witter, 1997; Nair et al., 2008).  
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1.2.1 History
MD was originally described clinically by Joseph Marek, a Hungarian veterinary 
pathologist, in 1907 as a polyneuritis in chickens (Marek, 1907).   The disease did not 
bear his name, though, until almost 40 years after its description when it was 
differentiated from another clinically similar retroviral disease, Avian Leucosis (Davison 
and Nair, 2004).  The causative organism of Marek’s disease, an -herpesvirus, was 
independently isolated in both the UK and USA (Churchill and Biggs, 1967; Nazerian et 
al., 1968).  Around this time MDV evolved from its original form which caused mild 
polyneuropathy to causing aggressive visceral lymphoid T cell tumours with associated 
high mortality (Witter, 1997).  Despite the successful introduction of an attenuated 
vaccine based on the virulent HPRS-16 strain in 1969 (Churchill et al., 1969) MDV 
continued to evolve and multiple strains were identified which could overcome vaccine 
protection (Davison and Nair, 2004).  Several alternate vaccines were developed, 
including the highly effective CVI988 Rispens vaccine strain of MDV (Rispens et al., 
1972a; Rispens et al., 1972b), but these vaccines were not effective against all virulent 
MDV strains. This development led to increased interest and research on new MDV 
control methods and vaccines that will be discussed later in the chapter. 
1.2.2 Taxonomy & Strain Variation
The Marek’s Disease-like viruses are included in the Mardivirus genus that only infects
avian hosts (Table 1.6).  Gallid Herpesvirus 2 or MDV contains all virulent strains as 
well as some attenuated strains such as CVI988 Rispens. Gallid Herpesvirus 3 and 
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Melagrid Herpesvirus 1 are both mildly pathogenic and elicit antigenic cross-reactivity 
to Gallid Herpesvirus 2 which has been exploited in vaccines. The widely used vaccine 
strain Herpesvirus of Turkeys 3 (HVT-3) is a strain of Melagrid Herpesvirus 1 (Davison 
and Nair, 2004).  MDV has been further classified according to strain pathogenicity into 
the categories: mild (m), acute (v), very virulent (vv), and very virulent plus (vv+), each 
representing a substantial increase in pathogenicity measured by the severity of 
symptoms and the ability of the virus to cross the blood brain barrier during lytic 
infection (Osterrieder et al., 2006; Witter, 1997; Witter et al., 2005).  
Some studies refer to an alternate system of classification with Gallid Herpesvirus 2 as 
MDV type 1, Gallid Herpesvirus 3 as MDV type 2 and Melagrid Herpesvirus 1 as 
Herpesvirus of Turkeys (Table 1.6).  These different classifications can cause confusion 
as MDV type 2 and Gallid Herpesvirus 2 have similar names but denote two different 
viruses.  For the purpose of this study Gallid herpesvirus 2 or MDV type 1 will be 
designated as MDV, Gallid herpesvirus 3 will be designated as GaHV3 and Melagrid 








Columbid Herpesvirus 1 Pigeon Herpesvirus
Gallid Herpesvirus 2 Marek’s disease virus 
Type 1
Most Pathogenic strains, but
also includes apathogenic  
CVI988 Rispens vaccine strain
Gallid Herpesvirus 3 Marek’s disease virus 
Type 2
Low pathogenicity or attenuated
strains
Melagrid Herpesvirus 1 Turkey Herpesvirus Low Pathogenicity, includes
HVT3 vaccine strain
Table 1.6:  Taxonomic structure of the Mardivirus genus showing the alternate nomenclature 
equivalents and example strains (Davison et al., 2009).
1.2.3 Genome Structure and Gene Function
The MDV genome consists of  approximately 180,000 base pairs (bp) with a 44% G/C 
composition encoding over 103 functional genes (Tulman et al., 2000).  The genomes of 
several strains of MDV have been completely sequenced (Kingham et al., 2001; Spatz et 
al., 2007a; Spatz et al., 2007b; Spatz and Rue, 2008; Tulman et al., 2000) and with the 
increased availability of high throughput sequencing the genome of many more strains 
should become available in the future.
The overall genome structure of MDV can be categorized as class E and consists of a
Unique Long (UL) and Unique Short (US) region flanked by respective inverted repeat 
sequences designated Internal/Terminal Repeat Short (IRS/TRS) and Internal/Terminal 
Repeat Long (IRL/TRL) (Roizman and Sears, 1996; Spatz and Silva, 2007a).  Most of the 
genes specific to MDV are located in the TRL and IRL regions of the genome.  The UL
and US regions of the genome are generally conserved in arrangement but not sequence
with other -herpesviruses (Davison and Nair, 2004; Li et al., 1994).  The MDV
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genome arrangement is very similar to HSV-1 and -2 and contains an origin of lytic 
replication (Orilyt) located in the IRL and TRL flanking the UL region between the 
phosphoprotein 38 (pp38 or ORF 73.0) and phosphoprotein 14 (pp14 or ORF 75.0) 
genes (Camp et al., 1991; Parcells et al., 2003). The genes adjacent to the Orilyt can be 
grouped into those associated with latency and transformation (Meq, IL8 & pp14) and 
those associated with early lytic infection (pp38, pp24 & BamHI-H encoded protein)
which are expressed in an antisense fashion respective to each other (Parcells et al., 
2003).  Pathogenic MDV contains a number of unique genes many of which are not well 
characterized.  Of the unique genes studied, some of the most notable are the Meq and 
IL-8 genes which have both been associated with oncogenesis (Kingham et al., 2001).  
Genes associated with lytic replication or latency are usually expressed separately, with 
the exception of 23kDa, Meq and RLORF5 which Heidari and colleagues found to be 
expressed in both lytic and latent infections (Heidari et al., 2008; Parcells et al., 2003).  
To date 14 unique viral miRNAs have been found in MDV located in the regions
flanking the Meq oncogene and within the LAT (Burnside et al., 2006; Burnside et al., 
2008; Griffiths-Jones et al., 2008; Morgan et al., 2008; Yao et al., 2009b).  Eighteen
miRNAs in two clusters have been identified in apathogenic GaHV3 and seventeen
miRNAs in HVT but none of these appear to be conserved with MDV (Griffiths-Jones et 
al., 2008; Yao et al., 2009b; Yao et al., 2007).  MDV miRNAs appear highly conserved 
between different strains of the virus despite the identification of sequence variations in
the Meq gene between different MDV strains (Morgan et al., 2008). One of the MDV 
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viral miRNAs described in the region of the Meq gene was mdv1-miR-M4 which has 
homology with the chicken miRNAs miR-155, a cellular miRNA playing a role in the 
function of the immune system (Morgan et al., 2008; Yao et al., 2007).  Yao and 
colleagues demonstrated a decrease of miR-155 coupled with an increase of MDV-
encoded miRNAs in the MDV-transformed cell line MSB-1 compared to normal
lymphocytes which supported evidence for modulation of the host immune response by 
mdv1-miR-M4 viral miRNA (Yao et al., 2009a).  In summary, miRNAs in MDV appear 
to play an important role in the control of latency and pathogenesis through several 
mechanisms but further research is needed to characterise their function.   
1.2.4 Life Cycle & Biology
Electron microscopy of MDV reveals a typical herpesvirus particle consisting of a 95-
100 mcapsid with 162 capsomeres and a 150-170 m enveloped viral 
particle(Nazerian and Burmester, 1968).  The DNA in MDV is wound around a central 
torus or spool shape connecting the two inner poles of the capsid, similar to that 
described for other herpesviruses (Nazerian, 1974).  MDV viral particles are very robust 
and have been documented to survive for up to a year in many environments (Calnek 
and Witter, 1997), making decontamination of an infected poultry house very difficult.
The life cycle of MDV in the chicken, (Davison and Nair, 2004), starts with an infected 
bird shedding mature viral particles from its feather follicle epithelium which mixes with 
feather dander to create an aerosol of dust and viral particles contaminating the 
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surrounding area.  The infectious viral particles are inhaled by uninfected susceptible 
birds and infection occurs when the virus enters pulmonary B cells and to a lesser extent 
macrophages in the air sacs (Baaten et al., 2009).  These cells migrate via the lymphatic 
system to the lymph nodes and bursa of Fabricius where the virus enters a short cytolytic 
phase causing inflammation and lymphocytolysis and viral particles can be detected in 
the lymphatic tissue (Baigent et al., 2005b).  A primary immunosuppression due to the 
depletion of lymphocytes has been documented at this point in the life cycle (Calnek et 
al., 1984).  Initial cytolytic infection occurs in B cells causing inflammation in the 
lymphoid tissue, particularly in the bursa of Fabricius, from 7 days onward and induces 
the activation and subsequent infection of CD4 T cells where the virus establishes a
latent infection (Davison and Nair, 2004). Some CD8 T cells also become infected 
during the initial lytic replication, but CD4 cells prevail as the predominant virus-
infected cells during the subsequent latent infection (Islam et al., 2002; Morimura et al., 
1996).  After the initial 6 to 7 day cytolytic phase the virus switches to latency primarily 
in CD4 T cells with limited expression of viral or tumour antigens even though the viral 
genome persists.  The latently infected T cells are able to migrate to the visceral organs 
and peripheral nerves throughout the body via the bloodstream.  From 14 to 21 days
post-infection the latently infected T cells in the viscera and nerves can undergo 
neoplastic transformation and can proliferate to form gross lymphomas in susceptible 
birds.  These lesions result in the symptoms and eventual mortality of MD.  
A second immunosuppression is a significant feature of MDV infection and occurs in 
late cytolytic infection due to lymphocyte depletion from cytolysis of thymocytes 
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anywhere from day 3 to 35 post infection (Islam et al., 2002).  This immunosuppression 
is most profound in very virulent MDV strains, but has been documented to some extent 
in birds vaccinated with apathogenic HVT-3 (Islam et al., 2002).  From 10 days post-
infection onward, MDV undergoes productive replication in the feather follicle 
epithelium that results in high levels of viral antigen and infectious viral particles.  These 
particles are shed in feather dust throughout the life of an infected bird which continues 
the viral life cycle.  This life cycle is summarized in figure 1.7.
Clinical manifestations of MD can be classified into three major areas:  lymphomas of 
visceral organs, neurological signs and immune suppression.  Mortality resulting from 
widespread lymphomas can occur from 2 weeks post-infection in aggressive MDV 
strains.  In the low pathogenicity strains a polyneuritis, particularly in the sciatic nerves, 
has been noted with the associated ascending paralysis, but mortality is generally low.  
In the most pathogenic strains aggressive lymphoid tumours, eye tumours, 
arthrosclerosis and profound immunosuppression have all been documented (Davison 
and Nair, 2004; Witter, 1997; Witter and Schat, 2003).  In addition to the mortality 
caused by MDV-induced lymphomas it is apparent that the immune suppression caused 
by subclinical MDV also impacts infected birds by causing increased susceptibility to 
other infections such as infectious bursal disease, E.coli and the response to vaccine 
administration for other conditions (Islam et al., 2002).  In summary, the complex life 
cycle of MDV induces cell-mediated immunity in the host that can lead to mortality and 
subclinical immune suppression.
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The rapid formation of aggressive T-cell tumours during MDV lytic infection is one of 
the hallmarks of the disease and is directly linked to mortality and virulence factors.  
Several genes and their encoded proteins as well as both viral and cellular miRNAs have 
been associated with tumourigenesis in MDV.  Uncharacterized genes may also play a 
role in tumourigenesis.    
The RLORF7 gene encodes the polymorphic 339 aa Marek’s EcoRI Q fragment protein, 
hence its designation as Meq.  The MDV genome contains two copies of Meq
transcribed R to L in the TRL and L to R in the IRL regions flanking the unique long 
region of the genome (Spatz et al., 2007b).  Meq overlaps the  RLORF6 gene in the 
same orientation and 23kDa as well as genes encoding two hypothetical proteins MDV 
ORF 5.2 and 5.3 in the opposite orientation as illustrated in figure 1.8, hence the 
designation “Meq loci” describing this cluster of genes (Spatz et al., 2007b).  In addition 
to wild-type Meq several variants, differing in their biological and physical properties, 
have been described to date:  L-Meq (containing a 60 aa insertion between residues 190 
and 191 mainly in attenuated and low pathogenicity strains), S-Meq (containing a 41 aa 
deletion between residues 190 and 191), VS-Meq (containing a 92 aa deletion between 
residues 174 and 175), and Meq (containing only 98 aa from the N-terminal region of 
Meq and a 30 aa frame-shifted distinct C-terminus) (Chang et al., 2002a; Chang et al., 
2002b; Deng et al., 2010; Okada et al., 2007). Meq is considered unique to MDV as no 
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homologues have been found in any other species of herpesvirus (Kingham et al., 2001; 
Lupiani et al., 2004; Petherbridge et al., 2004).  
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Figure 1.8: Diagram of the relative location of the potential target genes located in the IRL region of the MDV genome including the “Meq 
loci” illustrating the overlapping regions of the Meq, RLORF6 and 23kDa genes.  Genes depicted in green are translated from L to R and 
genes depicted in red translated from R to L.  Diagram adapted from the CVI988 Rispens MDV genome (Spatz et al., 2007b) published in 
the GenBank (Benson et al., 2008) graphic interface.
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Meq has been well-characterised and is widely regarded as the major oncoprotein in 
MDV with high expression documented in both MDV induced T cell tumours and MDV 
transformed cell lines (Jones et al., 1992; Osterrieder et al., 2006).  Studies utilizing 
siRNA techniques to analyze the transforming potential of Meq in DF-1 cells transfected 
with a Meq overexpression plasmid demonstrated that Meq alone could act on host cell 
targets to change growth rate and morphology even in the absence of intact MDV (Levy
et al., 2005). Meq has also been shown to maintain latency by blocking apoptosis in 
latently infected T cells and transactivating latent gene expression as well as being 
essential for tumour induction (Lupiani et al., 2004; Parcells et al., 2003).  Studies 
demonstrating that the deletion of the Meq coding region in pathogenic MDV resulted in 
attenuation of the virus while preserving its antigenic properties as a vaccine also 
provided convincing evidence of the association between Meq and oncogenesis (Lee et 
al., 2010b; Silva et al., 2010).  The structure of Meq contains three distinct regions:  a 
DNA-binding domain, a basic region-leucine zipper (bZIP) domain with homology to 
the Jun/Fos family of transcriptional activators, and a proline-rich transactivation 
domain at the carboxy terminus (Anobile et al., 2006; Jones et al., 1992).  As with other 
Jun/Fos proteins the bZIP domain of Meq can form homodimers with itself and 
heterodimers with other cellular proteins such as c-Jun and v-Jun which are transcribing 
factors for activating protein 1 complex (AP-1) playing a key role in regulating normal 
cellular events as well as neoplastic transformation (Hess et al., 2004; Levy et al., 2005).  
In vivo studies have shown that both homodimers and heterodimers of the Meq bZIP 
domain are required for transformation of lymphocytes (Suchodolski et al., 2009).  
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Recombinant virus studies have also shown that homodimerisation of Meq is a 
requirement for MDV virulence (Brown et al., 2009).  Meq also has been shown to 
interact with other non-bZIP cellular proteins regulating the cell cycle such as p53 (a 
tumour suppressor), C-terminal binding protein-1 (a highly conserved cellular 
transcriptional co-repressor regulating cell development, proliferation and apoptosis) and 
heat shock protein 70 (a molecular chaperone protein associated with viral oncogenesis) 
(Brown et al., 2006; Deng et al., 2010; Zhao et al., 2009).  Meq was shown to bind 
directly with the p53 protein resulting in the inhibition of cellular p53-mediated 
transcriptional activity and apoptosis playing a key role in MDV transformation (Deng
et al., 2010).  Tumours caused by very virulent strains of MDV were found to express 
high levels of viral miRNAs, particularly mdv1-miR-M4 associated with the Meq gene, 
despite equivocal levels of Meq transcription suggesting the association of viral miRNA 
with increased pathogenicity (Morgan et al., 2008).  Meq has been the subject of 
intensive research and considerably more detail has been described regarding its 
mechanisms which are beyond the scope of this thesis but for a recent review see (Deng
et al., 2010).  
Subversion of cellular telomerase associated with control of the normal cell cycle by 
viral homologues has been proposed as a mechanism for oncogenesis in several viruses
(Katzenellenbogen et al., 2010; Kaufer et al., 2010).  MDV encodes two copies of a 
viral telomerase RNA subunit (vTR) with an 88% homology to the chicken telomerase 
RNA subunit (chTR) which is thought to play a role in tumourigenesis in MDV (Fragnet
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et al., 2003).  The TR complexes with a protein subunit with reverse transcriptase 
activity (TERT) to form the telomerase ribonucleoprotein complex which compensates 
for the progressive telomere shortening that occurs during mitosis and has been 
implicated in immortalizing cells and tumourigenesis (Artandi, 2006).  More recent 
studies have confirmed the findings of an earlier study (Lounis et al., 2004) showing that 
the promoter for vTR is up to 3-fold more efficient at binding TERT than the chTR 
promoter implying that vTR may compete with chTR for binding of TERT which would 
facilitate the efficient formation of tumours by MDV (Chbab et al., 2010).   
Manipulation of cellular miRNA by oncogenic herpesviruses has also been proposed as 
a mechanism for tumourogenesis.  In a study by Burnside and colleagues deep 
sequencing was used to compare miRNA sequences between MDV-infected and 
uninfected chicken embryo fibroblasts (CEFs) which revealed a cluster on chicken 
chromosome 1 expressing high levels of cellular miR-221 and miR-222 (Burnside et al., 
2008).  Galardi and colleagues also demonstrated increased levels of cellular miRNAs 
miR-221 and miR-222 coupled with a decrease in the cyclin-dependent kinase inhibitor 
of the cell cycle p27kip1 in vitro in aggressive prostate carcinoma cells compared with 
two slow-growing prostate carcinoma cell lines (Galardi et al., 2007).  This down-
regulation of p27kip1 coupled with increased expression of miR-221 and miR-222 
increased proliferation in human prostate carcinoma cells (Galardi et al., 2007), a 
finding which was mirrored in the MDV transformed lymphoblastoid cell line MSB-1 
(Lambeth et al., 2009a) suggesting a similar cellular mechanism.  In separate studies Xu 
40
and colleagues have also demonstrated the consistent down regulation of host cell 
miRNA gga-MiR-26a in chicken lymphocytes transformed by 3 different avian 
oncogenic viruses, including MDV, all with distinct transformation mechanisms 
compared to normal lymphocytes (Xu et al., 2010).  This study also went on to show 
that miR-26a directly targets chicken interleukin 2 (IL-2) which plays a major role in T 
cell development, differentiation and homeostasis by a complex and tightly regulated 
mechanism (Xu et al., 2010).  Disruption of IL-2 has previously been linked with 
leukaemia, autoimmune disease and viral infection, including MDV (Gesbert et al., 
1998; Kaiser et al., 2003).  Additionally miR-26a is down regulated in several human 
cancers suggesting that its mechanism is not unique to MDV (Kota et al., 2009; Visone
et al., 2007).  These findings led to the conclusion that down-regulation of miR-26a in 
MDV and other oncogenic avian viruses can cause an up-regulation of IL-2 leading to 
increased T cell proliferation and contributing to tumourigenesis, but the specific viral 
genes eliciting these changes were not identified (Xu et al., 2010).  
The above interactions all demonstrate that MDV is adept at exploiting complex existing 
host cell miRNA mechanisms controlling cell proliferation and homeostasis to influence 
the development and progression of tumourigenesis during its life cycle.  
1.2.6 Diagnosis of MDV
Diagnosis of pathogenic MDV in the field can often be challenging due to the similarity 
of the clinical signs of MDV with Lymphoid Leukosis.  There is also the ubiquitous 
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presence of attenuated vaccine strains of MDV in most commercial poultry 
environments that can complicate identification of pathogenic MDV strains.  Several 
serological methods for identification of pathogenic MDV can be utilized in conjunction 
with gross pathology for diagnostic investigation of flock outbreaks.  Classical or mild 
MDV infection presents clinically as an ascending paralysis and post-mortem 
examination reveals an oedematous enlargement of the peripheral nerves, often in 
conjunction with small grey lymphomas in the visceral organs (Nair et al., 2008).  Acute 
MDV infection can present clinically as sudden death or paralysis and on post-mortem 
examination the peripheral nerves are grossly enlarged in conjunction with extensive and 
diffuse lymphatomatous involvement of the visceral organs, and occasionally skin and 
eyes.  Atrophy of the thymus (source of T cells) and bursa of Fabricius (source of B
cells) are common post-mortem findings in acute MDV infection due to lymphocyte 
depletion (Nair et al., 2008).
Laboratory confirmation of post-mortem findings is commonly undertaken using a
Polymerase Chain Reaction (PCR) (Becker et al., 1992; Nair et al., 2008; Silva, 1992) or 
a Reverse Transcriptase quantitative Polymerase Chain Reaction (RTqPCR) (Abdul-
Careem et al., 2006; Baigent et al., 2005a; Gimeno et al., 2005; Islam et al., 2006a; 
Islam et al., 2004) both using primers homologous to unique regions of pathogenic 
MDV strains such as the Meq gene.  Feather tips are most often used for MDV diagnosis 
and surveillance as they have a high viral load, are easy to collect, relatively stable and 
require no specialized equipment for sampling (Davison et al., 1986b).  A nested PCR 
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assay can also be used to differentiate between Meq (present in pathogenic MDV) and 
L-Meq (containing a ~180 bp insert in the CVI988 vaccine strain MDV) allowing a
precise differentiation between pathogenic and vaccine strains of MDV (Murata et al., 
2007).   Other methods for MDV detection include agar gel precipitation (Chubb and 
Churchill, 1968) and enzyme-linked immunosorbent assay (ELISA) for MDV antigen
(Davison et al., 1986a; Scholten et al., 1990) and antibody (Cheng et al., 1984).  The 
amount of MDV DNA present in the blood of an infected animal has been found to 
directly correlate to the amount of gross lesions of MDV present at post-mortem and has 
been proposed as a method for early detection and monitoring of MDV infection 
(Gimeno et al., 2008; Islam et al., 2006b; Islam et al., 2002)    
1.2.7 Control of MDV – Vaccination & Viral Vectors
The first vaccine for MDV was developed in 1969 by attenuation by multiple passages 
in tissue culture of the virulent HPRS-16 strain and was subsequently put into 
widespread use (Churchill et al., 1969). The vaccine campaign was successful in 
preventing MDV induced lymphomas, but since the vaccine was a live replicating virus 
vaccinated birds became infected and shed MDV hence it did not produce sterilizing 
immunity (Davison and Nair, 2004).  Despite the success of vaccination, MDV
continued to adapt into more virulent forms that were able to break through vaccine 
protection. A major emergence of vaccine resistance and increased virulence of MDV 
has been documented approximately every 20 years since the 1960’s (Nair, 2005; 
Osterrieder et al., 2006; Witter, 1997).  Other live vaccines introduced to control 
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breakthrough MDV include the apathogenic SB-1 strain of GaHV3 (Schat and Calnek, 
1978a; Schat and Calnek, 1978b), apathogenic strain 3 of HVT (HVT-3) (Witter et al., 
1970; Witter et al., 1976) and the attenuated MDV strain CVI988 (Rispens et al., 1972a; 
Rispens et al., 1972b).  Several bivalent vaccines containing both an apathogenic 
GaHV3 (either strain SB-1 or 301B-1) plus HVT-3 were introduced to give enhanced 
protection as the two strains used together were found to be synergistic (Davison and 
Nair, 2004).  Marek’s disease is currently controlled using a combination of vaccination 
and biosecurity measures in most commercial poultry flocks, but breakthrough cases 
continue to be reported.  Currently the most virulent strains of MDV are only responsive
to the Rispens or CVI988 strain of vaccine (Davison and Nair, 2004).  
All MDV vaccines in current use consist of whole-cell cultures containing live virus
which are individually injected into each bird. Most commercial poultry are vaccinated 
either at day old or in ovo one to two days before hatching with a live whole cell MDV 
vaccine.  These vaccines have a limited shelf life and require a continuous -80ºC cold 
chain for storage from the manufacturer to end user and are stable at room temperature 
for less than one hour once reconstituted.  This poses inherent difficulties in delivering 
effective vaccine protection, particularly in hot climates or where the infrastructure may 
be less developed.  Vaccine misuse rather than failure most likely plays a role in many 
outbreaks, but it is not always immediately apparent when improper handling of the 
vaccine renders it ineffective.  If the current trend of increasing vaccine resistance and 
increased virulence continues then currently available vaccines may not be effective in 
44
protecting from challenge by future strains of MDV, which would have significant
economic and food security implications for the global poultry industry (Witter, 1997).
MDV vaccines, while protective to the bird, do not prevent viral replication and 
shedding.  The implication of this is that vaccinated birds can act as a reservoir of 
infection in densely populated poultry housing, particularly in the broiler sector, 
allowing MDV to develop increased virulence without killing the host during the 
relatively short growing period thus precipitating the emergence of increasingly virulent 
strains (Nair, 2005).  Gandon and colleagues proposed the hypothesis that a partially 
effective vaccine can exert high pressure for evolutionary adaptation towards virulence 
in a wild-type virus resulting in an immunized population able to harbour more virulent 
pathogens than a susceptible population (Gandon et al., 2001).  This hypothesis was 
subsequently proven in models for mouse malaria (Mackinnon and Read, 2004) and 
Bordetella pertusis (Van Boven et al., 2005).   It is tempting to speculate that this could 
be the case in MDV as well, but it is important to note that no study has proven that
vaccination without sterilizing immunity coupled with intensive poultry husbandry fuels
the shift towards increased MDV virulence.  Sterilizing immunity is defined as the 
protection from MDV infection and shedding as well as the symptoms of the disease.  
The technique of incorporating the MDV viral genome into a bacterial artificial 
chromosome (BAC) has assisted the study of MDV in vitro by eliminating the necessity 
of directly working with infectious virus and facilitating manipulation of the viral 
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genome.  To date most sequenced MDV strains have been developed into BACs
(Petherbridge et al., 2004; Petherbridge et al., 2003; Spatz et al., 2007a; Spatz et al., 
2007b).  BAC construction entails cloning the BAC cassette, encoding the bacterial 
replication machinery, into the viral genome necessitating the disruption of a viral gene
at the insertion site.  In MDV the BAC insertion site is in the US2/US3 region of the 
genome that is destroyed (Petherbridge et al., 2004).  MDV BACs can produce lytic 
infections with the inserted bacterial replication genes intact, however a method was 
developed for self-excision of the bacterial replication genes and the subsequent 
restoration of the missing US2 gene to yield reconstituted virus (Zhao et al., 2008).  The 
reconstituted MDV virus produced infections that were greatly increased in 
pathogenicity and replication when compared to the BAC parent strain (Zhao et al., 
2008).  This development is significant as BACs facilitate manipulation of the viral 
genome and making recombinant MDV strains, but the replication kinetics of the
resulting virus in vivo were often poor.  The reconstitution of intact virus from modified 
MDV BACs enables the production of engineered MDV viral vectors and vaccines as 
well as facilitating the archiving of viral strains without the risk of mutagenesis from 
repeated passages in tissue culture.
Using BAC techniques a vaccine coupled with a recombinant viral vector targeting
MDV was developed based on reconstituted virus from a HVT-3 BAC containing an 
insertion expressing shRNA targeting the MDV viral genes gB which plays a key role in 
viral entry and UL29 which plays an essential role in viral DNA replication (Lambeth et 
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al., 2009b).  The recombinant vector acts not only to stimulate immunity against MDV
with the HVT-3 vaccine in the conventional manner, but also protects through the 
shRNA insertions targeting gB and UL29 which would be predicted to reduce MDV 
infection rates and shedding.  Therefore, it would seem that this virus could act both as a 
vaccine and as a viral vector.  Early trials demonstrated protection from MDV challenge 
in vaccinated birds equal to HVT-3 alone coupled with some reduction of MDV 
viraemia in early infection compared with HVT-3 vaccinated birds (Lambeth et al., 
2009b).  
Recombinant MDV vaccines have also been developed from pathogenic strains of MDV 
with the Meq protein coding sequence deleted using BAC techniques which have proved 
to be sufficient to attenuate the virus (Lee et al., 2008; Silva et al., 2010).  Use of the 
Meq deletion recombinant viruses as vaccines showed they protected against virulent 
MDV challenge in susceptible chickens more effectively than the CVI988 Rispens 
vaccine strain, which has long been regarded as the most effective vaccine available
(Lee et al., 2010b; Silva et al., 2010).  Separate trials of a Meq deleted vaccine 
administered to day old chicks gave limited protection from a very virulent strain of 
MDV (rMD5) challenge at 5 and 12 days post-vaccination (Li et al., 2010).  These Meq 
deletion recombinant vaccines show potential over conventional MDV vaccines, but 
they still have the disadvantage of utilizing a live replicating virus vaccine.  Viral 
vectors targeting MDV replication with siRNA (Lambeth et al., 2009b) are a promising 
new development, but they also do not deliver sterilising immunity to MDV in their 
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present form due to their insertion in replicating HVT-3.  Without sterilizing immunity 
to MDV it is likely the cycle of circulating virus in vaccinated birds will continue to fuel 
the shift towards increased virulence.
1.2.8 Control of MDV - Resistance
Genetics undoubtedly play a role in the outcome of MDV infection and several naturally 
occurring haplotypes have been associated with MDV resistance or susceptibility.  Of 
the haplotypes identified to date none are capable of completely preventing MDV 
infection, only of reducing the effects of MDV- induced mortality by varying degrees.  
Resistance to MDV infection has been studied since the 1930’s and has been identified
in several lines of chickens with distinct haplotypes (Bacon et al., 2000; Bumstead and 
Kaufman, 2004; Davison and Nair, 2004; Heifetz et al., 2007).  
Resistance to MDV is undoubtedly a polygenic trait but the chicken major 
histocompatibility complex (MHC) locus has demonstrated the strongest single 
association with MDV resistance or susceptibility.  The MDV resistance and 
susceptibility observed in certain lines of chickens designated B19 and B21 appears to 
be linked to 2 distinct haplotypes located in the 3’-untranslated region of the chicken 
BG1 allele associated with MHC class I (MHC I) expression (Goto et al., 2009; 
Hepkema et al., 1993; Schat et al., 1994).  Comparison of the spleen proteome of the 
MDV-resistant B21 chickens and the susceptible B19 chickens during MDV infection 
undertaken by Thanthrige-Don and colleagues identified differences in protein 
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expression at several time points post-infection (Thanthrige-Don et al., 2010).  Resistant 
B21 chickens showed increased expression in early infection of two predicted products 
of the peroxiredoxin-1 and peroxiredoxin-4 genes encoding components of natural killer 
cell enhancing factor which functions as an antioxidant and is associated with the 
regulation of apoptosis (Han et al., 2005; Thanthrige-Don et al., 2010).  Nitrous oxide
(NO) has been shown to increase the expression of peroxiredoxin-1 (Abbas et al., 2008)
and high levels of NO have been found in B21 chicken tissues (Xing and Schat, 2000)
suggesting a possible mechanism for the observation of increased levels of 
peroxiredoxins.  In the same study susceptible B19 chickens were found to upregulate 
heat shock protein 90 (HSP90) by 4-fold compared to B21 chickens in early infection
(Thanthrige-Don et al., 2010).  HSP90 has been associated with up-regulation of cell 
surface expression of MHC I (Kunisawa and Shastri, 2006) as well as other immune 
functions (Javid et al., 2007; Srivastava, 2002).  In another study MHC I expression 
levels were correlated directly with the MHC-linked MDV susceptibility in B19 and 
B21 chickens.  Susceptible B19 chickens expressed high levels of MHC I and resistant 
B21 chickens expressed low levels of  MHC I (Kaufman and Salomonsen, 1997).  Levy 
and colleagues demonstrated in vitro that pathogenic MDV infection specifically down-
regulated MHC I in CEFs and this effect could be reversed with native chicken 
interferon which increased MHC I expression (Heller et al., 1997; Levy et al., 2003).  
Jarosinski and colleagues went on to show that in MDV infection there is a decrease of 
cellular surface MHC I in response to the homologue of HSV UL49.5 which has also
been shown to cause an MHC I decrease in VZV (Jarosinski et al., 2010).  One proposed
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mechanism for B19 haplotype susceptibility is high levels of MHC I expression 
associated with HSP90 allowing for improved replication kinetics in the infecting virus
(Davison and Nair, 2004).
Other genetic loci have also been implicated in MDV resistance and over 15 quantitative 
trait loci regions have been identified in lines of MDV resistant and susceptible chickens
which may reveal more details of the mechanisms of MDV resistance when studied
(Bumstead and Kaufman, 2004; Davison and Nair, 2004; Heifetz et al., 2007; McElroy 
et al., 2005).  Baaten and colleagues demonstrated in vivo that line 6 MDV-resistant 
chickens, previously associated with decreased early viral replication (Bumstead and 
Kaufman, 2004), had delayed viral replication and  earlier onset of -IFN production 
following respiratory MDV infection compared to susceptible line 7 chickens suggesting 
that early viral replication was important in determining the outcome of MDV infection
(Baaten et al., 2009).  Line 6 and 7 chickens have the same BG1 allele haplotypes, 
unlike lines B19 and B21, suggesting that the differences in MDV resistance are due to a 
different allele (Davison and Nair, 2004).  Although the mechanisms of the naturally 
occurring MDV resistance yield valuable insights into MDV pathogenesis, the existing 
lines of MDV-resistant chickens do not appear to offer sufficient protection against 
lymphoma-induced mortality at present to justify stopping vaccination.  With the 
increasing understanding of the mechanisms of MDV infection and pathogenesis it may 
be possible in the future to engineer lines of MDV resistant chickens carrying small 
interfering RNA (siRNA) sequences targeting selected viral genes.    
50
1.2.9 Introduction to RNA Interference Techniques for Gene Silencing in 
Chickens
RNAi is a term used to describe post-translational suppression of protein expression 
either through miRNA described previously or siRNAs which involves introducing 
synthetic ~22 nucleotide RNA sequences into cells to suppress targeted genes.  
Introduction of long double-stranded RNA (dsRNA) into most non-mammalian cells
results in degradation of the targeted homologous messenger RNA (mRNA) transcripts,
causing a net decrease in gene-specific protein expression and effective sequence-
specific gene silencing (Heidersbach et al., 2006). In mammalian cells, however, 
introduction of long dsRNA activates the innate immune system responsible for 
recognizing the molecular signatures of pathogen-associated molecular patterns 
(PAMPs) which plays a key role in microbial immunity as well as the recognition of self 
and non-self (Heidersbach et al., 2006; Kawai and Akira, 2009; Samuel-Abraham and 
Leonard, 2010).  Innate immune responses produce inflammation through the production 
of cytokines and interferon mediated by phagocytes such as macrophages and dendritic
cells (Kawai and Akira, 2009).  Innate immunity receptors have been grouped into three 
families which are: membrane-bound Toll-like receptors (TLRs), cytoplasmic retinoic 
acid-inducible gene-I-like receptors (RLRs) and nucleotide-binding oligomerisation 
domain-like receptors (NLRs) (Kawai and Akira, 2009; Yokota et al., 2010).  
Additionally a DNA-dependent activator of interferon regulatory factors (DAI) which 
senses DNA has been recently described (Yokota et al., 2010).  The TLRs detect 
PAMPs on the cell membrane or in the lumen of intracellular vesicles while the RLRs 
and NLRs detect intracellular PAMPs (Kawai and Akira, 2009).  RLRs belong to the 
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RNA helicases enzyme family that specifically binds double-stranded RNA in the 
cytoplasm and are key to recognition of viral or exogenous RNA (Yoneyama and Fujita, 
2008).  The activation of the TLR, RLR or NLR signalling pathways trigger a cascade 
resulting in the induction of type 1 interferon and inflammatory cytokines (Yokota et al., 
2010).  An example of these interactions in herpesviruses is the association of immunity 
to HSV-1 with Human Toll-like receptor 3 (TLR-3) dependent induction of -IFN, -
IFN and -IFN (Zhang et al., 2007).  The innate immune response is well studied and a 
great deal more detail on the specific molecular mechanisms are available, but beyond 
the scope of this study.  For reviews see (Kawai and Akira, 2009; Van de Walle et al., 
2008; Yokota et al., 2010).  When exogenous dsRNA is introduced into the mammalian 
cell, the innate immune response triggers a universal gene silencing in the cell and 
apoptosis (Heidersbach et al., 2006; Samuel-Abraham and Leonard, 2010).  This was a 
problem in applying RNAi to mammalian cells until it was demonstrated that short (~21 
bp) dsRNA sequences, rather than the long dsRNA, introduced into cells could 
inactivate specific genes with minimal triggering of the innate immune system (Elbashir 
et al., 2001).  This discovery enabled the use of RNAi based tools to manipulate gene 
expression in mammalian systems that subsequently revolutionized the field of 
functional genomics.  Several methods have been developed to effectively deliver 
siRNA into cells using plasmids, electroporation and lentiviral-based systems (Maurisse 
et al., 2010; Stewart et al., 2003). 
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1.3 Investigation of Selected Uncharacterised MDV Genes
Unique viral genes often have key roles in regulating latency and transformation in 
herpesviruses as each virus adapts to its particular host (Pellett et al., 2006).  MDV 
encodes at least 103 proteins some of which are unique either to MDV or the Mardivirus
genus, and apart from some well-defined examples, such as Meq and pp38, are not well-
characterised (Tulman et al., 2000).   The second portion of this thesis focuses on work 
done to investigate the function of genes in MDV whose function was poorly defined.  
With the exception of US2, a conserved gene in all herpesviruses encoding a tegument 
protein of unknown function, all the genes investigated were unique to the Mardivirus
genus or only to MDV.  The following synopsis consists of a brief background and
literature search for candidate genes.  As many of the genes have been referred to in the 
literature by several different names, attempts have been made to standardize the
designations for each gene.  The nomenclature used to refer to the MDV ORF numbers 
corresponds to the GenBank database (Benson et al., 2008).  Genes that do not have a 
common designation will be referred to by their ORF number.  In order to simplify the 
following gene descriptions genes transcribed from the 5’ termini of the sense strand 
will be designated left to right (L to R) and genes transcribed from the complimentary 
strand will be designated right to left (R to L).  A diagram of the repeat region of the 
MDV genome is illustrated in figure 1.8 and gene information is summarised in table 1.9 

























Table 1.9: Summary of gene information for uncharacterized MDV genes investigated. Genes transcribed on the same strand as 
overlapping genes have no designation and genes transcribed in the opposite orientation designated ‘compliment’.  Note:
*RLORF14 encodes Early 24kDa phosphoprotein, pp24, ** ANTISENSE denotes antisense to ICP4 RNA protein encoding gene, 
***US2 denotes HSV-1 US2-like protein encoding gene.  Table compiled from information contained in GenBank genome of MDV 
strain CVI988 and CU-2 (Benson et al., 2008; Spatz et al., 2007b; Spatz and Rue, 2008).
Designation Unique to 
MDV
MDV ORF Location and 





IRL  (R to L)
TRL (L to R) 
Meq (sense) and
23kDa (compliment), ORF5.2 (compliment), ORF5.3 (compliment) 
23kDa Y 4.0
77.0
IRL  (L to R)
TRL (R to L)
ORF5.2 (sense) and
RLORF6 (compliment), Meq (compliment)
RLORF5a / L1 Y 3.8
78.1
IRL (R to L)




IRL (L to R)
TRL (R to L)
Spliced  gene encoding 14kDa lytic protein A & B (compliment)
MLTI Y 6.5
75.2
IRL (R to L)
TRL (L to R)
Spliced  gene encoding 14kDa lytic protein A (sense)
RLORF12 Y 7.0
74.0
IRL (R to L)
TRL (L to R)
Spliced  gene encoding 14kDa lytic protein A (sense) and LORF1
(sense) in IRL, No overlap in TRL
LORF1  Y 9.0 TRL / UL (R to L) RLORF12 (sense) and
RLORF13 (compliment), RLORF14* (compliment)
LORF3 Y 12.0 UL (L to R) ORF12.8 (sense)and 
ORF11.5 (compliment), ORF 12.4 (compliment)
MNFH Y 49.1 UL (L to R) HSV homologue of UL36 (MDV ORF 49.0) (compliment)
LORF6 Y 49.5 UL (L to R) HSV homologue of UL36 (MDV ORF 49.0) (compliment)
LORF8 Y 57.8 UL (R to L) HSV homologue of cell fusion protein UL45 
(MDV ORF 58.0) (compliment).  
LORF11 Y 72.0 UL (R to L) ORF71.8, ORF72.2, ORF72.4 (all compliment)
LORF12 Y 72.8 UL (R to L) ORF72.6 (compliment)
ANTISENSE** Y 83.0
101.0
IRS (L to R)
TRS (R to L)
4 gene encoding ICP4 (compliment)
US2*** N 91.0 US (R to L) ORF91.5 (compliment)
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1.3.1 The ‘Meq Loci’ Genes
The well-characterised Meq is located in the repeat region of the genome and is unique 
to pathogenic MDV (section 1.2.5).  However, four unique and uncharacterised repeated 
genes (RLORF6, 23kDa, MDV ORF5.2, MDV ORF5.3) are also located in the ‘Meq 
loci’ as shown in figure 1.8.  Two of these genes, RLORF6 (MDV ORF 5.1 & 77.5) and 
23kDa (MDV ORF 4.0 & 77.0) were selected for screening in this study.  Frequent 
deletions and mutations have been identified in Meq (Spatz et al., 2007a; Spatz et al., 
2007b) which usually leads to a corresponding change in the gene sequence and encoded 
protein composition of other ‘Meq loci’ genes.  Screening for MDV-chicken protein 
interactions with a yeast 2-hybrid assay followed up by an in vitro binding assay 
revealed no matches for RLORF6, but the 23kDa ORF (MDV strain Md5) demonstrated 
binding with chicken glycolytic enzyme -enolase (encoded by the cellular ENO1 gene) 
(Niikura et al., 2004).  -enolase is a ubiquitous protein playing an essential part in the 
glycolytic pathway and is found in the cytoplasm of all prokaryotic and eukaryotic cells.  
Subramanian and Miller demonstrated that -enolase RNA (ENO1) contains an 
additional translation initiation site encoding Myc-binding protein 1 (MBP-1) which 
allows two different translation products to be formed from a single α-enolase mRNA
(Subramanian and Miller, 2000). This led to the suggestion that post-translational 
interference with the -enolase mRNA could potentially cause changes in expression of 
both-enolase and MBP-1.  MBP-1 binds to the c-myc promoter which down-regulates 
c-myc expression (Ray and Miller, 1991).  C-myc is a DNA-binding protooncogene 
important for cell growth and differentiation (Marcu et al., 1992) and has been shown to 
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be over-expressed in several malignancies (Cole, 1986).  High levels of ENO1 specific 
antibody have also been described as features of infections and autoimmune diseases
(Terrier et al., 2006).  It is difficult to predict whether these findings have any 
significance, but it is tempting to speculate that 23kDa’s association with the ENO-1 
gene and its proximity to other oncogenic viral genes such as Meq could predict an 
association with tumourigenesis, however there is currently no evidence to support this.
Heidari and colleagues demonstrated that 23kD, along with Meq and RLORF5, were
expressed in both the cytolytic and latent phases of infection (Heidari et al., 2008).  
23kDa has been shown to localise to the nucleus but there was no reference in the 
literature as to where RLORF6 localised or if it was expressed during latent and lytic 
infection.  
1.3.2 Repeat Long Regions of the Genome
Many of the unique genes in MDV are located in the IRL and TRL regions of the genome 
which contain many key genes in addition to Meq that are associated with 
transformation and latency such as pp24, pp38 and IL-8.  There are many unique genes 
in this region which have not been well-characterised.  Five uncharacterised genes from 
this region (RLORF5a, RLORF11, MLTI, RLORF12, and LORF1) were selected for 
these studies and are detailed in figure 1.8 and table 1.9.  
The RLORF5a gene (MDV ORF 3.8 & 78.1), previously designated L1, is unique to 
MDV and encodes a repeated gene product (Jarosinski et al., 2005; Kingham et al., 
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2001).  Schat and colleagues demonstrated that RLORF5a was not necessary for in vitro
or in vivo lytic replication or the establishment of latency in MD lymphoblastoid chicken 
cell lines, but was expressed in latency in their experimental model (Schat et al., 1998).  
Jarosinski and colleagues compared the growth kinetics of the reconstituted virus from a 
RLORF5a deletion mutant MDV strain Rb1b BAC to the parental pRb1b reconstituted 
virus and found no significant changes in vitro or in vivo (Jarosinski et al., 2005).  These 
findings led to the conclusion that RLORF5a did not play any obvious role in 
attenuation of virulent MDV.  Differences in RLORF5a expression during latent 
infection between different cell lines were noted in earlier studies (Schat et al., 1998)
suggesting that RLORF5a expression could vary depending on the stage of the virus life 
cycle.    It was subsequently found that the MDV miRNAs mdv-miR-M1 and -M11 were
embedded within the RLORF5a transcript (Yao et al., 2008).  The significance of these 
findings is unknown but it is tempting to speculate that the role of RLORF5a could be
more complex than previously thought if mdv-miR-M1 and –M11 plays a role in gene 
regulation, however there is no supporting evidence at this time.  RLORF5a was 
included in this study because no studies had been done examining the effect of removal 
of the gene product using siRNA on a non-producer MDV lymphoblastic cell line.  It 
was hypothesized that the removal of the RLORF5a gene product from an established 
non-producer MDV cell line and analysis for phenotypic changes would help confirm 
whether RLORF5a had any measurable effect in latent infections.
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Niikura and colleagues screened for MDV-chicken protein interactions as described 
previously in RLORF11 (MDV ORF 6.4 & 75.4), RLORF12 (MDV ORF 7.0 & 74.0)
and LORF1 (MDV ORF 9.0).  Interactions were only found between RLORF12 and 23p 
growth- related transcriptionally-controlled tumour protein (TCTP) encoded by the 
chicken gene TPT1 (Niikura et al., 2004).  TCTP is a highly conserved protein with a 
housekeeping function that has been identified in multiple tissues in virtually all 
eukaryotic organisms and has been associated with many vital cellular functions 
(Bommer and Thiele, 2004).  Studies have shown TCTP over-expression inhibits Na, K-
ATPase cell plasma membrane activity in a dose-dependent manner (Jung et al., 2004).  
The Na K-ATPase membrane protein plays a vital role in the cell maintaining the 
homeostasis of cells.  TCTP over-expression has been linked with smooth muscle 
vasoconstriction leading to systemic hypertension (Kim et al., 2008) and with formation 
of cataracts in mice and in human lens cells in vitro (Kim et al., 2009). Cataracts have 
been described as a feature in the pathology of highly virulent MDV infection (Dukes 
and Pettit, 1983; Pandiri et al., 2008).  It is tempting to speculate as to whether the 
pathology of some of the more acute symptoms of MDV such as cataracts and brain 
oedema seen in virulent and very virulent+ strains could be associated with changes to 
TCP0 function and the subsequent disruption of Na/K balance in the cell, but currently 
there is no evidence to support this.  
Sequence differences between attenuated and pathogenic virus strains were used as one
indicator of the suitability of a unique gene for study.  MLTI (ORF6.5 & 75.2), first 
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described in the CVI988 strain of MDV (Spatz et al., 2007b), encodes a 328 aa gene
product in the attenuated CVI988 Rispens strain of MDV, but only a 64 aa gene product 
in pathogenic strains of MDV. Sequencing of the strain CVI988 MDV genome revealed 
that RLORF12 encoded a truncated 64 aa protein for one of the repeats (ORF74.0) 
relative to the oncogenic strains containing a 115 aa protein in both repeated sequences
(Spatz et al., 2007b).  Even though LORF1 was not a repeated gene it was included in 
this section as its position overlaps the TRL and UL region.  No sequence variation 
between strains was identified in the LORF1 or RLORF11 genes (Spatz et al., 2007b). 
No functional information, other than the gene description detailed in table 1.9, was 
available for the RLORF11, MLTI and LORF1 genes.
1.3.3 Other Regions of the Genome
Several other genes of interest (LORF3, LORF11, MNFH, ANTISENSE, US2, LORF6, 
LORF8 and LORF12) were located in regions of the genome out with those described 
above and identified for inclusion in this study.
  
LORF3 (MDV ORF 12.0) is located in the UL region of the MDV genome which is 
associated with conserved HSV-1 homologues encoding intermediate and late genes
such as the genes encoding the homologue of HSV-1 UL1-like protein and HSV-1 UL2-
like protein adjacent to LORF3.  A LORF3 homologue of unknown function has been 
described in Duck Enteritis Virus, an unassigned -herpesvirus affecting waterfowl (Li 
et al., 2009; Liu et al., 2009), but not in other avian -herpesviruses outside the 
59
Mardivirus genera such as Gallid Herpesvirus-1 or Psittacid Herpesvirus 1 (Thureen and 
Keeler, 2006).  The functions of LORF3 as well as the three genes overlapping LORF3
(figure 1.8 and table 1.9) have not been described (Spatz et al., 2007b).   
LORF11 (MDV ORF 72.0) is located in the UL region adjacent to the gene encoding 
pp38 which is associated with latency and tumourigenesis (Spatz et al., 2007b).  
Homologous genes to LORF11 have been identified only in strain HPRS-24 GaHV3 and 
serotype 3 HVT and BLAST searches of LORF11 showed matches only within the 
genus Mardiviruses (Lee et al., 2007).  Lee and colleagues generated a LORF 11 
deletion mutant MDV virus based on the pathogenic Md5 strain (designated rMd5
LORF11).  Similar growth characteristics in vitro were found when comparing lytic 
infection by pathogenic rMd5 virus to deletion mutant virus rMd5LORF11 in primary 
duck embryo fibroblasts in vitro (Lee et al., 2007).  In vivo experiments comparing 
viraemia levels between chickens infected with rMd5 MDV and rMd5LORF11 
demonstrated a 10 to 100 fold reduction (p<0.01) in viraemia levels in MDV-susceptible 
chickens (Lee et al., 2007).  These findings suggest that LORF11 may be a virulence 
factor of MDV in vivo.  Although no differences were found between rMd5LORF11 
and rMd5 infection in vitro there have been no studies examining the effect of post-
transcriptional targeting of RLORF11 in a non-producer MDV infected cell line that
would clarify whether the LORF11 gene product had a role in latency in vitro. LORF11 
was selected for this study because it was unique to MDV-like viruses and appeared to 
be associated with MDV virulence factors.
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MNFH (MDV ORF 49.1) was first described as a predicted protein in the CVI988 strain 
of MDV (Spatz et al., 2007b). It encodes a 93-94 aa gene product in the virulent MDV 
strains Md5, Md11 and GA but due to a mutation causing a stop codon it only encodes a 
34 aa gene product in the attenuated CVI988 strain of MDV (Spatz et al., 2007b).  The 
mutation, causing a stop codon in MNFH, was silent in the UL36 gene and apparently 
only affected the MNFH gene (Spatz et al., 2007b).  MNFH was deemed a good 
candidate for study because the truncated gene product was found only in attenuated 
MDV strains and because relatively little was known about its function and expression.
The ANTISENSE gene (ORF 83.0 & 101.0) encodes two RNA transcripts (15 kb and 
1.32 kb) which are strongly expressed in vitro in latent MDV transformed chicken 
lymphoblasts (Li et al., 1994).  The 4 gene encoding ICP4 overlaps some of the 
ANTISENSE gene and is transcribed on opposite strands (table 1.9).  As ICP4 is 
expressed only during lytic infection these findings imply that ANTISENSE may be
expressed during latency when ICP4 would not be expressed and may be spliced as two 
RNA transcripts were identified.  ANTISENSE was selected for study because of its 
association with selective expression during latency.  
The US2 gene (MDV ORF 91.0) located in the unique short (Us) region of the genome 
is conserved in all -herpesvirus genomes and a homologue has been described in the 
HSV-2 genome (Jiang et al., 1998).  US2 is a tegument protein with an unknown 
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function (Kelly et al., 2009; Pellett et al., 2006; Spatz et al., 2007b).  The US region in 
-herpesviruses has been shown to encode a number of glycoprotein gene products that 
appear to be linked with determination of pathogenesis and virus-cell interaction 
(Brunovskis and Velicer, 1995).  Excision of US2 in a deletion mutant virus did not 
appear to affect oncogenicity or the establishment and maintenance of latency (Parcells
et al., 1995) but deletion of US2 in conjunction with UL13 protein kinase and gC was 
linked to failure of horizontal transmission in chickens infected with strain Rb1b MDV 
(Jarosinski et al., 2007).  These findings led to the conclusion that US2 was conserved 
and present in latent and lytic infections, but non-essential for infection and latency 
(Parcells et al., 1995).  There have been no studies, however, analyzing at the effect of 
targeting US2 using siRNA in transformed lymphoblasts to assess whether it plays a role 
in maintenance of latency.  
LORF6 (MDV ORF 49.5), LORF8 (MDV ORF 57.8) and LORF12 (MDV ORF 72.8) 
are all unique genes to MDV and are located in the repeat long region of the genome.  
The function of all three of these genes is unknown.  Screening of LORF12 for MDV-
chicken protein interactions as previously described revealed no matches (Niikura et al., 
2004).  
        
1.4 Project Aims  
This project intended to explore the molecular control mechanisms operating in latent 
MDV infections by studying selected uncharacterized MDV genes in order to identify 
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those affecting phenotype in MDV-transformed latent cell lines using siRNA techniques.  
The intention was to further characterise any genes that affected phenotype and 
determine whether they play a role in the maintenance of latency or transformation in 
MDV infected cells.  Genes were selected for investigation based on a number of criteria 
that will be discussed further in chapter 3.  
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Chapter 2 – Materials and Methods
2.1 Molecular Techniques
2.1.1 Restriction Endonuclease Digestion
Restriction digests were performed on plasmids and purified deoxyribonucleic acid 
(DNA) using restriction enzymes according to manufacturer’s instructions.  All digests 
were carried out in a 37ºC water bath for 1 to 6 hours.
2.1.2 DNA Isolation & Purification
Preparation of DNA from animal cell samples was, unless otherwise indicated, 
performed using a commercially available kit (DNeasy Kit, Qiagen).  Cells were lysed
with sodium dodecyl sulfate (SDS) followed by treatment with protease K which 
degraded protein contaminants and nucleases.  The DNA in the cell lysate was then 
bound to a silica gel membrane, washed in two steps and eluted in water or low salt 
buffer such as TE Buffer (section 2.1.10).  After purification all DNA samples were 
stored at either 4ºC for short-term or at -20ºC for long-term storage in TE Buffer or EB 
Buffer (section 2.10.1).  All DNA samples were checked for concentration and purity 
after isolation (section 2.1.15).  Samples that were deemed too dilute for their intended 
purpose were concentrated using ethanol precipitation (section 2.1.6) before use.  
2.1.3 RNA Isolation & Purification
Cells intended for ribonucleic acid (RNA) extraction were harvested and washed in 
sterile phosphate buffered saline (SPBS) and frozen immediately at -80ºC in SPBS or 
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RNALater solution (Ambion, Invitrogen) until RNA was extracted.  Preparation of 
purified RNA from cell samples was, unless otherwise indicated, performed using a
commercially available kit (RNeasy Kit, Qiagen) that utilized the selective binding of 
RNA to a silica gel membrane in the presence of a high salt buffer followed by washing 
and eluting the bound RNA.  All RNA samples were eluted in RNase-free water and 
stored at -80ºC and thawed slowly on ice before use.  All RNA samples were checked 
for concentration and purity with a low volume spectrophotometer (section 2.1.15).  
Samples were also analyzed using electrophoresis in a 2% agarose gel containing 0.8 
g/ml ethidium bromide (Thermo Fisher Scientific) (section 2.1.13) to assess purity 
before further treatment.  To decrease the likelihood of RNase contamination of 
samples, all RNA work was carried out using gloves, disposable RNase-free lab ware, 
RNase-free reagents and work surfaces were treated with RNase decontamination 
solution (RNaseZap, Ambion, Invitrogen) before use. 
2.1.4 DNaseI Treatment of RNA Samples
Residual viral DNA contamination was removed from RNA samples by digestion with 
DNaseI.  Samples were treated with 2.4U DNaseI (Ambion, Invitrogen) or 3U Turbo 
DNaseI (Ambion, Invitrogen) per reaction (<10g RNA/reaction) and incubated for 30 
minutes at 37ºC.  This process was repeated 4 times (total of 12U/reaction for 120 
minutes) to ensure complete removal of viral DNA after early experiments experienced 
problems with residual contaminating viral DNA in samples following shorter DNaseI
treatment.  The DNaseI was inactivated, according to manufacturer instructions, either 
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with DNaseI inactivation reagent (Ambion, Invitrogen) or by phenol/chloroform 
extraction (section 2.1.7).   DNaseI treatment of RNA samples was always performed 
before further treatment.  To ensure that viral DNA had been completely removed, a 
polymerase chain reaction (PCR) was performed as described in section 2.1.10 using 
primers specific for Meq (Forward primer TGACCCTTGGACTGCTTACC and reverse 
primer GAGCAATGTGGAGCGTTAGG) and the DNaseI treated RNA as a template.  
No bands would be seen if the treatment had removed all viral DNA. 
2.1.5 Synthesis of First Strand cDNA from RNA
Complementary DNA (cDNA) was prepared from DNaseI treated RNA using reverse 
transcriptase according to standard manufacturer’s instructions using either Stratascript 
5.0 Multi-Temp Reverse Transcriptase (Stratagene) or AffinityScript Multiple 
Temperature cDNA Synthesis Kit (Stratagene) using sequence specific primers.  Once 
synthesized the cDNA was used for either PCR or RTqPCR assays (sections 2.1.8 and 
2.1.17).  Samples were immediately stored at -80ºC after synthesis and kept on ice at all 
times while setting up further experiments.
2.1.6 Concentration of DNA Samples
Dilute DNA samples were concentrated either by using the QIAEX II kit (Qiagen) using 
standard manufacturer instructions or by ethanol acetate precipitation.  Ethanol acetate 
precipitation was performed by adding 1/10 volume 3M sodium acetate pH 5.2 and 3
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volumes of 100% ethanol in a 1.5 ml microcentrifuge tube.  Samples were then 
centrifuged at 13,000 x g for 10 minutes and the supernate removed after pelleting the 
DNA.   The DNA pellet was washed with 70% ethanol, the supernate removed again and 
the DNA pellet allowed to air dry for 10 to 15 minutes before resuspending in an 
appropriate volume of either EB or TE buffer (section 2.10.1).
  
2.1.7 Purification of RNA by Phenol: Chloroform Extraction
Phenol chloroform extraction was performed by combining an equal volume of a 
blended mix of phenol (49.5%), chloroform (49.5%) and isoamyl alcohol pH 8 (1%) 
(Fluka Chemicals, Sigma-Aldrich) with a 1/10 volume of 3M pH 5.2 sodium acetate and
the RNA sample in the fume hood.  The sample was mixed then centrifuged for 10 
minutes at 13,000 x g at 4ºC.  The top (aqueous) layer containing the RNA was removed 
and placed into a fresh microfuge tube.  An equal volume of chloroform and isoamyl 
alcohol 24:1 mix was added in the fume hood.  The sample was then thoroughly mixed 
and centrifuged for 10 minutes at 13,000 x g at 4ºC.  The top (aqueous) layer was 
removed again, placed into a fresh microfuge tube, and mixed with 3 volumes of 100% 
ethanol.  After inverting the tube briefly to mix, the sample was then placed in a -80ºC 
freezer.  Once frozen, the sample was removed from the freezer and centrifuged for 20 
minutes at 13,000 x g at 4ºC in a microfuge tube after which the supernate was decanted.  
The RNA pellet was washed with an equal volume of 70% ethanol and centrifuged again 
at 13,000 x g at 4ºC for 10 minutes. The supernate was carefully removed and the RNA 
pellet was then air-dried on ice for a maximum of 5 minutes before resuspending in an 
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appropriate volume of RNase-free water.    This protocol was adapted from standard 
laboratory protocol.  The purified RNA sample was assessed for concentration with a 
low volume spectrophotometer and 2% agarose gel electrophoresis to assess for purity
(sections 2.1.13 and 2.1.15).
2.1.8 Polymerase Chain Reaction (PCR)
PCR was carried out using either recombinant Taq DNA polymerase (Invitrogen) for 
non-proofreading reactions or Native Pfu DNA polymerase (Stratagene) for reactions to 
be sequenced.  Forward and reverse primers were used at a concentration of 1-2 pmol 
per reaction. The amount of template used for each reaction was 20-30 nmol per 
reaction.  Both DNA polymerases were used according to standard manufacturer’s 
instructions.  DNA polymerase was added after the initial denaturing period of 5 minutes 
at 95ºC (‘hot start’ program).  The program used for each cycle was as follows:  95ºC for 
45 seconds, 55-62ºC for 45 seconds and 72ºC for 2 minutes.  The number of cycles per 
reaction was 30-40 followed by a 5-10 minute cooling down period.  All reactions were 
set up in a dedicated room using equipment and clothing used only for setting up PCR 
reactions.  PCR reactions not used immediately were stored either at 4ºC or at -20 º C.   
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2.1.9 Reverse Transcriptase Quantitative PCR (RTqPCR)
cDNA (section 2.1.5) was diluted to 20-40 pMol/l in RNase-free water and prepared in 
triplicate for RTqPCR using either Meq or Chicken -actin primer sets as detailed in 
tables 2.1 and 2.2.  A standard curve of known concentrations of a Meq or Chicken -
actin plasmid was also prepared to quantify samples. The plasmids used for the standard 
curves were  made centrally in our laboratory by amplifying a target sequence 
approximately 50 base pairs upstream and downstream of the detection primers (see 
table 2.1 and 2.2) for either Meq (Meq forward = TACAGTC CCGCTGACGA TCCG 
and Meq reverse = GACCGTAGACTGAGTATCCG) or chicken-actin (ChActin 
forward = GGGTGTGATGGTTGGTATGG and ChActin reverse = 
AAGAAAGATGGCTGGAAGAGG)  The PCR product from these primers was then 
cloned into TOPO pcDNA3.1 plasmid (Invitrogen) for Meq and TOPO PCR 4 plasmid 
(Invitrogen) for Chicken -actin, sequenced for accuracy, linearised, purified and its 
concentration established so that copy number could be calculated for preparing the 
respective standard curves for each experiment. The total reaction size used was 20 l 
that consisted of 5 l of diluted cDNA sample and 15 l of a master mix containing all 
other components of the reaction which are detailed in tables 2.1 and 2.2.  Depending on 
the concentration of the original RNA, the cDNA used was between 0.5-1.5g per 
reaction.  RTqPCR of all samples in each experiment were run at the same time and with 
the same batch of master mix to reduce variation resulting from pipetting variation and 
variable reverse transcriptase activity.  Equal amounts of RNA as determined by a low 
volume spectrophotometer were used to make cDNA, however the samples were not re-
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normalized at the cDNA stage, leaving a small potential for error should the cDNA 
reactions vary in their efficiency.  A 72-well thermocycler was used to process samples 
(Rotor-Gene, Corbett Research, model 080316).   The software used for running the 
thermocycler was Rotor-Gene 6 (Version 6.1, Build 71).  Cycle settings were as follows:  
hold temperature 95ºC for 15 minutes followed by 45 cycles of 95ºC x 20 seconds, 60ºC 
(Meq) or 62ºC (chicken -actin) x 20 seconds and 72ºC x 20 seconds.  A second hold of 
95ºC x 20 seconds was then performed followed by a melt curve from 60ºC to 95ºC 
rising by 0.4ºC each step.  There was a wait of 20 seconds after the first step of the melt 
curve and then a pause of 1 second between steps.
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(amounts in l) Per Reaction
10x PCR Reaction Buffer with 2.0 mM MgCl2 (Roche) 2.0
dNTPs 5 mM (Roche) 0.4
SYBR Green I Stock (Made by adding 5 l SYBR
Green reference solution (Bio Gene Ltd), 45 l DMSO 
and 4950 l DEPC-treated water)
0.7
Taq DNA Polymerase 5U/l (Roche) 0.15
Forward Primer 3,200 nM
5’ – TGA CCC TTG GAC TGC TTA CC – 3’
2.5
Reverse Primer 4,000 nM
5’ – GAG CAATGT GGA GCG TTA GG – 3’
2.5
MgCl2 25 mM (Roche) 1.6
DEPC-treated Water 5.1
Table 2.1:  RTqPCR master mix for chicken -actin (4.0mM Magnesium Chloride, 400nM 
forward primer, 500 nM reverse primer final concentrations and 62ºC anneal) for 15l master 
mix and 5l sample per reaction. 
(amounts in l) Per Reaction
10x PCR Reaction Buffer with 2.0 mM MgCl2 (Roche) 2.0
dNTPs 5 mM (Roche) 0.4
SYBR Green I Stock 0.7
Taq DNA Polymerase 5U/l (Invitrogen) 0.15
Forward Primer 2,400 nM
5’ – GAA TCC CAA AGC CAA TCG – 3’
2.5
Reverse Primer 1,600 nM
5’ – CCC AGA GTC AAG CAC AAT CC – 3’
2.5
MgCl2 25 mM (Roche) 0.4
DEPC-treated Water 6.3
Table 2.2:  RTqPCR master mix for Meq (2.5 mM MgCl2, 300nM forward primer, 200 nM reverse 
primer final concentrations and 60ºC anneal) for 15l master mix and 5l sample per reaction. 
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2.1.10 Normalization of cDNA Samples
A single control normalization error using the 75th percentile of housekeeping gene 
chicken -actin was calculated for each sample using a formula described in 
(Vandesompele et al., 2002).  This was done to allow more effective comparison of
levels of gene expression between samples correcting for multiple factors such as 
transfection variation, differential RNA degradation and variable efficiency of the 
reverse transcription reaction.  Normalization of RTqPCR data consisted of comparing 
two runs, one with the primers specific for the gene of interest and another with primers 
specific for the housekeeping gene chicken -actin.  Meq was expected to vary 
according to experimental treatment. Chicken -actin was not expected to vary with the 
experimental groups as it should be expressed at consistent levels for all cells, thus 
making it a suitable housekeeping gene (Suzuki et al., 2000; Yin et al., 2011).  
2.1.11 Purification of PCR Products
Contaminant primer, nucleotides, polymerase or salts were removed from PCR reactions 
using the QIAquick PCR Purification Kit (Qiagen) according to standard manufacturer 
instructions.
   
2.1.12 Agarose Gel Electrophoresis
1 to 2% (w/v) Agarose was prepared by mixing either 1 or 2g of LE agarose (SeaKem) 
per 100ml of TAE buffer (section 2.10.3) in a heat-resistant glass jar and heating in a 
microwave until completely dissolved.  The mixture was then allowed to cool slightly 
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and 3 l of Ethidium Bromide stock solution 10 mg/ml (Thermo Fisher Scientific) was
added and mixed thoroughly.  The mixture was then poured into a block mould and 
combs for placement of the nucleic acid samples were positioned.  Once cooled, the 
combs were removed and the gel block was placed into an electrophoresis tank filled 
with 1X TAE buffer with the sample wells situated at the negative pole of the tank.  
Nucleic acid samples were loaded into the wells combined with loading buffer (section 
2.10.3) at a ratio of approximately 1:5.  Current was then applied at the rate of 40-70mA 
(55-100V) for 30-90 minutes until the visible Orange G dye in the loading buffer had 
migrated to the bottom of the gel.  After running, gels were visualized using long 
wavelength UV light and photographed.  2-log DNA ladder (New England Biolabs) or 
1kb DNA ladder (New England Biolabs) was used to determine nucleic acid size on all 
agarose gels according to manufacturer instructions.    
2.1.13 DNA Extraction from Agarose Gels
Purification of DNA fragments from agarose gels was performed by identifying the band 
of interest from the gel using long wavelength UV light.  The band was then carefully 
cut from the agarose gel with a surgical scalpel and DNA purified using the QIAquick 
Gel Extraction Kit or QIAEX II Agarose Gel Extraction Kit (Qiagen) according to 
standard manufacturer instructions.  
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2.1.14 Quantification of Nucleic Acid by Spectrophotometry
Nucleic acid samples were checked for concentration and purity after isolation with a 
Nanodrop ND-1000 low volume spectrophotometer measuring 220nm to 750nm 
wavelength and version 3.7.1 software (Thermo Fisher Scientific).  The key ratios used 
to assess purity of nucleic acids was the 260/280 absorbance as an indicator of 
contaminants and the 260/230 absorbance as an indicator of both contaminants and co-
products.
2.1.15 Sequencing of DNA
Sequencing of plasmids was performed by Mr. Ian Bennett in the University of 
Edinburgh Molecular Pathology Unit using a Licor 4000L Sequencer and an Epicenter 
Sequitherm Excel tm II Licor DNA Sequencing Kit (Li-Cor Biosciences).  Sequencing 
directly from PCR products was performed using a Big Dye Terminator Cycle v 3.1 
(Applied Biosystems, Invitrogen) PCR reaction in our lab using the following protocol 
adapted from The Gene Pool website 
(www.wiki.ed.ac.uk/display/GenePool/Sequencing+Reactions, accessed 15/4/2008) 
which is detailed in tables 2.3 and 2.4.  The subsequent PCR product was then 
sequenced using an ABI3730 sequencer (Applied Biosystems, Invitrogen) by The Gene 
Pool, University of Edinburgh School for Biological Sciences Sequencing Service, UK.  
The resulting sequence was analyzed using Vector NTI version 10 & 11 software 
(Invitrogen) to combine, align and overlay individual sequences to form longer 
sequences (2000-3000 bp).
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Big Dye Terminator Cycle PCR Reaction l
5x Sequencing Buffer (Applied Biosystems, Invitrogen) 2.0 
Double distilled H2O 4.7
Primer (10M) 0.3 
Big Dye Terminator Cycle (Applied Biosystems, Invitrogen) 1.0 
DNA Template 2.0 





Table 2.4:  PCR program for Big Dye Terminator Cycle (Applied Biosystems, Invitrogen)   
Reactions were carried out for 25 cycles. 
2.2 Bacterial Techniques
2.2.1 Bacterial Culture
Bacterial growth was carried out using either LB broth or LB agar plates (Merck)
(section 2.10.4) as the culture medium in either a 37ºC still air incubator or a 37ºC 
shaking incubator rotating at 250 rpm.  Commercially available chemically competent 
E.coli cells were stored at -80ºC until use (Invitrogen or Stratagene).  Tubes of cells 
were thawed slowly on ice before cloning.  Transformed E.coli cells intended for short-
term storage (less than 5 days) were stored at 4ºC.
2.2.2 Transformation of Chemically Competent E. coli
Plasmids were transformed into commercially prepared chemically competent E.coli
(One Shot TOP10 & Stbl3 chemically competent E.coli, Invitrogen and Sure & Sure2 
Supercompetent cells, Stratagene) according to standard manufacturer’s instructions. 
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2.2.3 Plasmid DNA Isolation from Bacteria (Small-Scale)
Small-scale preparation of DNA from bacterial cells was performed using the 
commercially available QIAquick Miniprep Kit (Qiagen) according to standard 
manufacturer instructions.  All DNA samples were stored at either 4ºC for short-term or 
-20ºC for long-term storage in EB buffer (section 2.10.1). 
2.2.4 Plasmid DNA Isolation from Bacteria (Large-Scale)
Large-scale preparation of DNA from bacterial cells was performed using the 
commercially available Endo-Free Maxiprep kit (Qiagen) or PureLink HiPure Plasmid 
Maxiprep Kit (Invitrogen) according to standard manufacturer instructions.  All DNA 
samples were stored at either 4ºC for short-term or -20ºC for long-term storage in TE 
Buffer (section 2.10.1). 
2.2.5 Marek’s Disease Virus Bacterial Artificial Chromosome Preparation
Marek’s Disease Virus Bacterial Artificial Chromosomes (MDV BAC) were originally 
obtained from Dr. Venugopal Nair’s Laboratory at the Institute for Animal Health in 
Compton, UK.  The MDV BAC was prepared in Dr. Nair’s lab for use in transfection 
experiments by inserting the MDV genome into E.coli (Petherbridge et al., 2003).  A 
glycerol aliquot (section 2.2.6) of starter colony was continuously maintained at -80ºC
for use in our experiments.  The MDV BAC transformed E.coli were streaked on a LB 
agar plate containing Chloramphenicol (15g/ml) and grown at 37ºC overnight.  One 
colony was picked and placed in 10 ml of LB broth containing Chloramphenicol 
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(15g/ml) and placed in a shaking incubator at 37ºC and 250 rpm until an optical density 
of 0.6 was reached (usually 6-8 hours).  This starter colony was then placed on ice 
overnight.  The following day 2 x 250 ml LB broth containing Chloramphenicol 
(15g/ml) were placed in 2 x 1 litre Erlenmeyer flasks and seeded with 5 ml starter 
culture each.  The flasks were then placed in a shaking incubator at 37ºC and 250 rpm 
until an optical density of 0.6 was reached (4-6 hours).  Cultures were transferred to 2 x 
250 ml sterile centrifuge bottles and centrifuged at 4000-5000 x g for 10 minutes.  
Supernate was then decanted and discarded leaving the bacterial cell pellets, which were 
stored at -20ºC overnight if required.  A standard commercial kit was used to recover the 
MDV BAC from the bacterial cells according to manufacturer’s instructions (Phase Prep 
BAC DNA Kit Midi Scale Preparation, Sigma-Aldrich or Large-Scale DNA Construct 
Kit, Qiagen).  The bacteria cell pellets were resuspended and subjected to a modified 
alkaline-SDS lysis procedure with RNase contained in the initial resuspension solution.  
Afterwards the lysate was centrifuged at 15,000 x g for 30 minutes to remove cellular 
debris from the sample.  The cleared lysate was removed and nucleic acids precipitated 
by the addition of isopropanol.  Another centrifugation at >15,000g was performed to 
pellet the DNA after which the supernate was discarded and the pellet was washed with 
ethanol and air dried before eluting in TE buffer (section 2.10.1).  Residual RNA was 
then removed from the DNA by a short digestion at 60ºC with an RNase cocktail 
(Sigma-Aldrich or Qiagen).  A sodium acetate buffer solution (Sigma-Aldrich or 
Qiagen) was added before endotoxins and impurities were removed with a single 
temperature-mediated extraction and phase separation.  Finally, the BAC DNA was 
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precipitated from solution with isopropanol and washed with ethanol before air-drying 
the pelleted product.  The pelleted product was dissolved in 200 to 300 l elution buffer
(Sigma-Aldrich or Qiagen) and stored at 4ºC or -20ºC for later use.
2.2.6 Preparation of Bacterial Stocks for Long Term Storage
Bacterial stocks were prepared for long-term storage at -80ºC by picking a fresh colony 
from an overnight LB agar plate and placing it in 2-5 ml of sterile LB broth with 
antibiotics and incubating it at 37ºC and 250 rpm in a shaking incubator for 6-10 hours.  
0.85 ml of the subsequent culture was combined with 0.15 ml of sterile glycerol and 
mixed thoroughly by pipetting up and down in a screw top microcentrifuge tube.  The 
microcentrifuge tube was then labelled and stored long term at -80ºC.  Once frozen, 
samples could be obtained from the master stock by scraping a small amount of frozen 
sample with a sterile wire loop, spread on a fresh agar plate, and incubated overnight at 
37 º C.
2.3 Protein Blots
The following protein blotting protocol was adapted from standard lab protocol used in 
our lab and Molecular Cloning 3rd edition (Sambrook and Russell, 2001).
2.3.1 Protein Electrophoresis
CEF or RPL-1 cell pellets were harvested following experimental treatment by 
immediately washing twice with SPBS and centrifuging at 480 x g at room temperature 
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for 5 minutes to pellet cells and then pouring off the supernate.  Following the washes all 
SPBS was removed and 200-500 l of Western Blot Lysis Buffer (section 2.10.2) was 
added.  The sample was then placed in a screw-top microcentrifuge tube, mixed using a 
vortex mixer and stored at -80ºC until use.   Just prior to electrophoresis the samples 
were placed in a boiling water bath for 3-5 minutes.  8.5 cm x 7 cm plates with 7.5mm 
spacers (Bio-rad Laboratories) were cleaned and assembled in a Mini Protean-3 Cell and 
Electrophoresis Module Assembly (Bio-rad Laboratories).  A 12% Acrylamide resolving 
gel (section 2.10.2) was poured to the level of the base of the combs immediately after 
the addition of 10% ammonium persulphate and N, N, N’, N’ 
Tetramethylethylenediamine (TEMED).  After pouring the gel was overlaid by 200 l of 
H2O saturated methyl butanol.  Once the gel had polymerized (approximately 5-15 
minutes) the saturated butanol was removed and the top of the gel was rinsed with either 
H2O or Tris-Glycine SDS Buffer (Severn Biotech).  After rinsing, a stacking gel (section 
2.10.2) was prepared and poured on top of the resolving gel and the sample combs were 
set in place.  The stacking gel was allowed to polymerise for an additional 5-15 minutes.  
The gels were then assembled in the Bio-rad vertical gel tank and the tank was filled 
with Tris-Glycine SDS Buffer (Severn Biotech).  The combs were removed and the 
wells rinsed with Tris-Glycine SDS Buffer (Severn Biotech) before placing 10-20l of 
each sample per well using a 1 ml glass syringe (Hamilton).  10 l of Broad Protein 
Marker (Bio-rad Laboratories) or Pre-stained Protein Marker, Broad Range (7-175 kDa) 
(New England Biolabs) was also placed in the far left lane as an aid to identifying target 
protein bands.  Current was applied to the gel at approximately 70 mAmps (150 V) until
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the blue dye front had reached the bottom of the gel (approximately 1 hour).  Gels were 
then either stained with Coomassie stain for 30 minutes followed by de-stain overnight 
(section 2.10.2) or the proteins were transferred to a nitrocellulose membrane for further 
analysis (section 2.3.2). 
  
2.3.2 Transfer of Protein to Nitrocellulose Membranes
Following protein electrophoresis the separated proteins were transferred to a 
nitrocellulose membrane.  A piece of Hybond C nitrocellulose membrane (Amersham 
Biosciences) was cut to the size of the resolving gel (approximately 9 x 6 cm) along with 
6 pieces of slightly larger chromatography paper and these were all soaked briefly in 
transfer buffer (section 2.10.2) prior to transfer.  The semidry electroblotter was then 
prepared by placing 3 sheets of moistened chromatography paper in the centre of the bed 
followed by the nitrocellulose membrane and the polyacrylamide gel.  The remaining 3 
sheets of chromatography paper were placed on top and lightly rolled with the edge of a 
plastic pipette to remove any residual air bubbles that might interfere with contact 
between the sheets.  The cathode assembly was then placed on top and secured before 
current was applied at 110 mA for 60 minutes.  Following transfer the nitrocellulose 
membrane was carefully removed and the chromatography paper and polyacrylamide 
gel discarded.    The nitrocellulose membrane was first rinsed with PBS + 0.1% (v/v) 
Polyoxyethylenesorbitan Monolaurate (TWEEN 20, Sigma-Aldrich) and then washed 
gently on a 20-50 rpm rocking table for 30 minutes in Blocking Buffer (section 2.10.2).  
The nitrocellulose membrane was later sealed into a plastic envelope with 5-10ml of 
80
fresh blocking buffer and stored flat at -20ºC until immunological detection of protein 
blots the following day.
2.3.3 Immunological Detection of Protein Blots
For detection of the Meq protein, nitrocellulose membranes were thawed from frozen to 
room temperature slowly and incubated in fresh blocking buffer for 20-30 minutes on a 
rocking table at 20-50 rpm.  The primary antibody Meq Monoclonal Mouse Anti-Meq 
FD7 (Kindly provided by Dr. Venugopal Nair’s group at the Institute for Animal Health, 
Compton, UK) was diluted 1:150 in blocking buffer and incubated with the 
nitrocellulose membrane fully covered for 60 minutes on a rocking table at 20-50 rpm.  
After incubation the membrane was washed in PBS + 0.1 % TWEEN 20 for 3 washes of 
5 minutes each on a rocking table at 20-50 rpm.  After the washes were complete the 
secondary antibody, Polyclonal Rabbit Anti-mouse Immunoglobulins HRP (Dako 
Cytomation) was made up at a 1:1000 dilution in Blocking Buffer (section 2.10.2).  5-10 
ml of secondary antibody was incubated with the nitrocellulose membrane at room 
temperature on a rocking table at 20-50 rpm for 60 minutes.  After incubation the 
membrane was again washed in PBS + 0.1 % TWEEN 20 for 3 washes of 5 minutes 
each on a rocking table at 20-50 rpm.  After the final wash the proteins were visualized 
using Chemiglow West Substrate (Alpha Innotech) according to standard manufacturer 
instructions.  After incubating the nitrocellulose membrane for 1-2 minutes with a 1:1 
mixture of the luminol/enhancer solution and stable peroxide solution the membrane was 
photographed using the Fluorchem HD2 Imaging System (Alpha Innotech).  A light 
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photograph was also taken to visualize the protein marker.   After photographing several 
different exposures over a period of up to 30 minutes the nitrocellulose membrane was 
discarded once the chemiluminescence reaction had faded.
2.4  Tissue Culture and Virus Growth Techniques
2.4.1 Growth of Established Cell Lines
Unless otherwise indicated all cell culture was performed under aseptic conditions in a 
Class II containment cabinet.  All cell lines unless otherwise noted were stored in liquid 
nitrogen for long-term storage and thawed for use.  Unless otherwise noted all cells were 
grown in either 6-well dishes (9.6 cm2/well, Nunclon, Thermo Fisher Scientific) or 
tissue culture flasks (25 cm2, 75 cm2, 150 cm2 Nunclon, Thermo Fisher Scientific or BD 
Falcon, BD Biosciences).  Unless otherwise noted all tissue culture protocols were 
adapted from standard laboratory protocols.
2.4.2 Preparation of Cell Lines for Liquid Nitrogen Storage
Healthy cells in log phase growth were suspended in a known volume of media (usually 
10 ml) and counted using a haemocytometer.  Once counted the cells were centrifuged at 
480 x g at room temperature for 5 minutes to pellet cells and the media poured off.  The 
amount of freezing media added to give a concentration of 2-5 x 106 cells/ml was 
calculated and freezing media (90% Foetal Calf Serum (FCS) (Sera Laboratories 
International) and 10% DMSO mix) was combined with the cells and gently inverted to 
mix.  1 ml of the cell mixture was then added to each cryotube (Nunclon, Thermo Fisher 
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Scientific or BD Falcon, BD Biosciences) which was then placed in a -80ºC freezer for 
24-72 hours before moving on dry ice to the appropriate liquid nitrogen freezer for long-
term storage.
2.4.3 Growing Cell Lines from Liquid Nitrogen Frozen Stocks
Once removed from liquid nitrogen cells were thawed immediately and quickly in a 
37ºC water bath.  When thawed the osmotic pressure was equilibrated by adding a few 
drops of pre-warmed media before transferring to a universal tube containing 20ml of 
pre-warmed cell culture media.  The cells were then centrifuged at 480 x g at room 
temperature for 5 minutes to pellet cells and then the media was poured off. The cell 
pellet was subsequently resuspended in 5-10 ml of fresh media and moved to a T25 flask 
using a pipette.  Cells were then incubated overnight either at 38.5ºC for avian lines or 
37ºC for mammalian lines in a 5% CO2 humidified incubator.  The next day cells were 
checked for growth and contamination.  Once cells were growing well they were split 
and moved up to the next sized flask. 
2.4.4 Counting Cells Using Haemocytometer
Cells to be counted were diluted 1:1 with 0.4% Trypan Blue stain and mixed thoroughly 
with a pipette before loading 50-100 l into the haemocytometer by allowing the 
chamber to fill by capillary action, taking care not to flood the chamber.  A 
haemocytometer chamber divided into 25 smaller squares having an area of 1mm2 total 
was used.  When the cover slip was loaded to form newton rings the depth of the 
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chamber was 0.1mm making the volume of each large square 0.1mm3 or 0.0001ml.  
Total live cells in the 25 squares were counted and the number of cells/ml calculated 
using the following formula:  Counted cells x dilution factor of 2 x 104.  For each cell 
count determination at least 2 chambers were counted and the average was taken of the 
chamber readings. 
2.4.5 Transformed Chicken Lymphocyte Cells
Three different suspension transformed chicken lymphocyte cell lines were used:  RPL-
1, Rb1b T Cells and MSB-1.  The original cell stocks were all obtained from Dr. 
Venugopal Nair’s group at the Institute for Animal Health, Compton, UK and 
maintained in liquid nitrogen until use.  RPL-1 cells are a non-producing chicken T cell 
lymphoblastoid cell line transformed by MDV strain JM (Nazerian et al., 1976).  MSB-1 
cells were developed from a chicken T cell line transformed by MDV (Akiyama and 
Kato, 1974). The Rb1b T cells had been isolated from an MDV infected chicken T cell 
line by Dr. Nair’s group.  Growing conditions for all 3 cell lines were the same.  The 
media used was RPMI (Gibco, Invitrogen) supplemented with 10% (v/v) FCS (Sera 
Laboratories International), 10% (v/v) tryptose phosphate broth (Gibco, Invitrogen), 100 
mM sodium pyruvate (Gibco, Invitrogen) and 10 U/ml penicillin/streptomycin (Gibco, 
Invitrogen) (section 2.10.5).  The incubation conditions were 38.5ºC and 5% CO2.  
Seeding density was around 1 x 104/cm2 in a tissue culture flask.  
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2.4.6 Chicken Embryo Fibroblasts
CEFs were prepared by incubating eggs obtained from The Roslin Institute’s laying 
flock for ten days under standard commercial conditions.  At day ten the eggs were 
transferred to the laboratory and prepared for harvesting aseptically in a tissue culture 
cabinet.  The eggs were cracked at the air space and embryos were immediately and 
humanely euthanized by severing the head.  Limb buds and internal organs were then 
removed and the embryo was washed twice in SPBS (section 2.10.5).  The embryo was 
then placed in an Erlenmeyer flask containing 20ml of 0.05% trypsin
ethylenediaminetetraacetic acid (EDTA) solution (Gibco, Invitrogen) and incubated at 
38ºC for 10 minutes with occasional mixing.  At the end of incubation the trypsin 
solution was removed using a 10 ml pipette and placed in a universal vial with 1 ml FCS 
(Sera Laboratories International) to neutralize the trypsin.  This process was repeated 
five times.  The first wash was discarded as it contains a high proportion of blood and 
damaged cells.  The tissue remaining after five washes was also discarded.  The cells 
were then centrifuged at 480 x g for five minutes and the trypsin solution was discarded.  
The cell pellets were then combined and resuspended in 10 ml of CEF standard Media 
199 (Gibco, Invitrogen) with 5% added FCS (Sera Laboratories International) (section 
2.10.5).  The cell suspension was then diluted 1:10 and counted with a haemocytometer.  
Once the cell density was known then six-well dishes were seeded at a density to give 
3.5x105 cells/9.6 cm2 well in 2 ml of CEF growth Media 199 (Gibco, Invitrogen) with 
5% added FCS.  This was the density that was found to reliably grow to 80-85% 
confluence when incubated at 38.5ºC and 5% CO2 in humidified air for 24-36 hours.  
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CEF were grown in M199 medium (Gibco, Invitrogen) supplemented with either 5% 
(v/v) for growth or 2% (v/v) for maintenance FCS (section 2.10.5).  This protocol was 
adapted from standard lab procedures developed by Dr. Venugopal Nair’s group at the 
Institute for Animal Health in Compton, UK.
2.5 In vitro Experiments
2.5.1 Transfection of CEFs using Lipofectamine
One day prior to transfection 3.5 x 105 aseptically prepared CEF cells were seeded into 
one well of a six-well dish and grown overnight at 38.5ºC and 5% CO2 in humidified air.  
The following day the cells were approximately 80% confluent and ready for 
transfection.  For each well 1-2 g of DNA to be transfected was brought to a total 
volume of 100 l with serum-free media (Optimem, Gibco, Invitrogen).  In a separate 
tube 5 l of Lipofectamine (Invitrogen) was combined with 100 l serum-free media 
and incubated at room temperature for 5 minutes to allow complexes to form.  The 
contents of the tubes were then combined and incubated for 20 minutes at room 
temperature.  During incubation the media in the CEF wells was changed to 0.8 ml 
serum-free media.  After incubation the DNA/Lipofectamine mixtures were added to the 
appropriate wells and incubated for three to four hours at 38ºC and 5% CO2 in 
humidified air.  The media was then changed to 2 ml CEF media M199 with 5% FCS 
and incubated at 38ºC and 5% CO2 in humidified air overnight.  The following morning 
the media was changed to CEF media M199 with 2% FCS and incubated for an 
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additional two to three days.  At three to four days post-transfection cells were harvested 
for analysis at 90-100% confluence. 
2.5.2 Transfection of CEFs using Electroporation
CEF cells which had been either freshly prepared or thawed from liquid nitrogen were
grown for 24-48 hours in standard tissue culture conditions (section 2.4.10).  
Immediately prior to electroporation cells were treated with 0.05% trypsin EDTA 
solution (Gibco, Invitrogen) to detach cells from the growing surface and counted using 
a haemocytometer (section 2.2.4).  An average of two counts was taken for calculating 
cell numbers.  Once counted the CEF cells were aliquoted to give 3.5 x 106 cells per 
single transfection or 1.05 x 107 cells per triplicate experiment and centrifuged at 100 x 
g for 10 minutes at room temperature.   After centrifugation media was carefully and 
completely drained.  27mer siRNA oligonucleotides (Stealth siRNA, Invitrogen) were 
diluted with 500ul RNase-Free water (Invitrogen) to give a 40nM working stock which 
was flash frozen on dry ice and stored at -80ºC for later use.  Before transfection 1.4 ml 
of fresh, antibiotic-free CEF growth media was placed in each well of a 6-well plate 
(Nunclon, Thermo Fisher Scientific) and stored in a 38.5ºC/5% CO2 incubator until 
required.  500l of fresh antibiotic-free CEF growth media was also placed in a 1.2ml 
microcentrifuge tube and placed in a 38.5ºC/5% CO2 incubator until needed.  After 
centrifugation 300l Nucleofector Fibroblast Solution (Amaxa, Lonza) was added to 
each triplicate cell pellet along with 300pMol Stealth siRNA (100pMol/Reaction).  Cells 
were then mixed briefly and gently to resuspend cell pellets and then 100l per 
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transfection was pipetted into a cuvette.  The cuvette was then placed into a 
Nucleofector II electroporation unit (Amaxa, Lonza) and treated using program T-016.  
Immediately after transfection a disposable plastic pipette was used to gently suck up 
500l media of pre-warmed media which was then added into the cuvette.  The media 
and cell mixture was then gently removed and added to 1.4 ml pre-warmed media in the 
6-well dish.  Total volume at this point was 2 ml containing approximately 3.5 x 106
cells.  Cells were then incubated for 24 hours at 38.5ºC and 5% CO2. This protocol was 
adapted from standard manufacturer’s protocol from Amaxa (Lonza) and Invitrogen.
2.5.3  Transfection of RPL-1 and Rb1b T cells using Electroporation
Original stocks of RPL-1 and Rb1b T cells (section 2.4.5) obtained from Dr. Venugopal 
Nair’s lab at the Institute of Animal Health, Compton, UK were frozen in aliquots 
(section 2.4.2 and 2.4.3) when growing well in log phase growth.  For each experiment a 
fresh aliquot of cells was thawed and passaged 7-10 times.  The seeding density for each 
passage was approximately 3 to 3.5 x 105/ml of media in a T75 flask with 20 ml of 
media supplemented with penicillin/streptomycin.  Cells were then grown in a T150 
flask for the final passage (in 40ml media supplemented with penicillin/ streptomycin) 
and harvested between 5 x 105 to 1 x 106 cell density per ml with >90% live viable cells 
of cell total.  Stock Stealth siRNA oligonucleotides (27mers) (Invitrogen) were prepared 
as previously described (section 2.5.2).  For the RPL-1 and Rb1b T cells a transfection 
indicator SiGLO Red (Dharmacon, Thermo Fisher Scientific) was also used in the 
experiments.  SiGLO Red 50l stock solutions were prepared by diluting with SPBS and 
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frozen at -20ºC in aliquots until use.  RPL-1 and Rb1b T cells were counted and 
prepared for electroporation as described for CEF cells in section 2.5.2.   After 
centrifugation  300l Nucleofector Solution V (Amaxa, Lonza) was added to each 
triplicate cell pellet along with 300pmol Stealth siRNA (100pmol/Reaction) and SiGLO 
Red at 500nM overall concentration (3-6 l of 50M stock per triplicate).  
Electroporation of cells was done as described for CEF in section 2.5.2 except that cells 
were treated with program A-033.  After transfection cells were incubated as described 
for CEF in section 2.5.2.  Total volume per well after transfection was 2 ml containing 
approximately 3.5 x 106 cells.  Cells were then incubated for 24 hours at 38.5ºC and 5% 
CO2.  50l aliquots of cells were removed for counting as described in section 2.4.4 at 
24, 48, 72, 96 and 120 hours post-transfection.  At 24 hours a 100l aliquot of cells from 
each transfection was removed for determination of transfection efficiency.  This was
done by making a wet mount slide with the cell suspension on a glass slide and placing a 
cover slip over the sample.  Four 20x fields were photographed and counted both under 
bright field and ultraviolet light with a red filter.  A percentage determination of 
transfection efficiency was then made on the basis of a cumulative average of the 4
random fields.  Depending on growth cells were split every 24 hours during the 
experiment into an appropriate volume to ensure an average density of 3.5 x 105 cells/ml
to 1 x 106 cells per ml after the aliquots were removed.  An additional aliquot of cells 
from each transfection of no more than 20% of total starting cell volume was removed at 
48, 72 and 96 hours for RNA extraction as described in section 2.1.3.  All cell samples 
taken for RNA were placed immediately on wet ice and processed as quickly as 
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possible.  This protocol was adapted from manufacturer’s protocol from Amaxa (Lonza), 
Invitrogen and Dharmacon (Thermo Fisher Scientific).
2.6 Dual Reporter Luciferase Assays
Dual-Luciferase® Reporter Assay System (DLR) (Promega) was used to measure the 
response of an N-terminal fusion reporter plasmid containing a gene of interest 
transfected into CEF cells.  The use of two luciferase plasmids, one based on the firefly 
reporter (Photinus pyralis) and a renilla plasmid (Renilla reniformis) allow a correction 
factor for variable transfection efficiency and transcription activity.   The DLR assays 
were performed as follows: 
CEF cells were prepared using standard methods (section 2.4.10) and passaged for 24-36 
hours in 5% growth media (section 2.10.5) before being frozen and stored in liquid 
nitrogen in approximately 5 x 106 cell aliquots.  24 hours before starting the experiment 
CEF cells were thawed and counted as detailed in section 2.4.3.  Cells were then 
aliquoted into a 6-well plate (35mm diameter) with 3.5 x 105 cells per dish.  Cells were 
passaged in 5% growth media without antibiotics in a 38.5/5% CO2 incubator until 
reaching 50-60% confluence around 24 hours post-thawing.  Reporter plasmid 
transfection was carried out as follows:  100l Optimem serum-free media (Gibco, 
Invitrogen) and 5l Lipofectamine (Invitrogen) per well were gently mixed in 1.5 ml 
microcentrifuge tube and incubated for 5 minutes at room temperature (~25ºC) to form 
complexes.  In a separate microcentrifuge tube DNA and siRNA to be transfected were 
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mixed gently with Optimem (Gibco, Invitrogen) to form a total volume of 100l 
containing 100pmol stealth siRNA (Invitrogen) and 0.8 to 1.6 g of N-terminal fusion 
reporter plasmid DNA.  While the Optimem solutions were incubating, the cell culture 
media from each experimental well was removed and replaced with 0.8 ml 
Optimem/well and placed back in the 37ºC/5% CO2 incubator.  After incubation the 
dilute DNA/siRNA complex was gently mixed with the dilute Lipofectamine and 
incubated a further 20 minutes at room temperature.  After incubation 0.2ml of the 
Lipofectamine complex was added to each corresponding well and incubated at 38.5ºC / 
5% CO2 for 5-8 hours.  At end of the incubation media was changed to 2ml/well 5% 
CEF growth media and incubated at 38.5ºC / 5% CO2 to 24 hours post-transfection.  At 
24 hours media was changed to 2% CEF maintenance media with antibiotics and 
incubated at 38.5ºC / 5% CO2 to 48 hours at 38.5C / 5% CO2.  Cells were harvested at 
80-90% confluence at approximately 48 hours.   At 48 hours cell lysates were prepared 
using passive lysis buffer and scraping using a plastic pipette according to standard 
manufacturer instructions.  If required, cell lysates were occasionally stored for up to 1 
month at -80°C in a microcentrifuge tube before carrying out the DLR assay.  
Luminescence readings were performed according to manufacturer instructions using a 
Glomax 20/20 Luminometer (Promega).
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2.7  Confocal Laser Microscopy Techniques
2.7.1 Suspension Cell Lines
Suspension Rb1b T cells were transfected with plasmids as described in section 2.5.3 and 
grown at 38ºC and 5% CO2 for 24 or 48h.  Cells were harvested by placing an aliquot of 
approximately 3.5 x 106cells in a microcentrifuge tube and pelleted using a centrifuge at 
3000 x g for 3 minutes.  The supernate was removed and 1 ml of SPBS was added.  The 
cells were mixed gently then pelleted again using a microcentrifuge (3000 x g for 3 min). 
Supernate was removed and 500l of 4% (w/v) paraformaldehyde solution was added.  
Samples were placed on a rotating wheel at 10 rpm to gently mix for 10 minutes at room 
temperature.  After fixing cells were pelleted and washed in SPBS as described above.  
Cells were resuspended in 100l of SPBS and dropped on to a lysine-coated microscope 
slide (Polysine, VWR International) and air-dried.   Once dry the cells were fixed a second 
time on the microscope slide by dropping 200l of 4%  (w/v) paraformaldehyde on to the 
slide and incubating them at room temperature for 10 minutes.  Slides were washed in 
SPBS for 3 minutes after incubation.  Before staining, cells were permeabilised by 
incubation with 300l SPBS containing 0.25% (v/v) Triton X-100 (t-
Octylphenoxypolyethoxyethanol, Sigma-Aldrich) for 5 minutes at room temperature 
followed by a wash with SPBS as described above.  Cells were counter-stained for nuclear 
DNA by incubating with 200l of SPBS with 1% (w/v) bovine serum albumen, 10g/ml 
RNaseA (Invitrogen) and TO-PRO-3 iodide (Molecular Probes®, Invitrogen diluted 
1:1,000 to 1M) at room temperature in the dark for 15 minutes.   Cells were then gently 
rinsed with SPBS as described above.  Cells were then air-dried and mounted with cover 
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slips using VectaShield Hard Mount Mounting Medium (Vector Labs) or Mowiol 
Mounting Medium with DABCO (Sigma-Aldrich) (section 2.10.2) and sealed with nail 
varnish.  Slides were stored in the dark at room temperature for the first 24 hours to allow 
the mounting medium to harden and then at 4ºC.  Slides were examined using a Leica 
Confocal Laser Scanning Microscope at either 63x or 100x power at the Impact Imaging 
Facility, University of Edinburgh with the assistance of Mrs. Trudi Gillespie.  Images were 
analyzed using both the Zeiss LSM Image Browser and the Carl Zeiss AxioVision Version 
4.6 software.  Protocol was adapted from standard protocols used in our lab.  
2.7.2 Adherent Cell Lines
CEFs (either freshly prepared or frozen) were transfected  with 0.5 to 2.0 g plasmids 
either using Lipofectamine (Invitrogen) (section 2.5.1)  or electroporation (section 2.5.2) 
and grown at 38ºC and 5% CO2 for 24 to 48h in 2 ml CEF 2% maintenance media on 
sterile plain glass cover slips placed in a 6-well dish.  Cells were harvested by removing 
the media and rinsing twice with 2 ml of SPBS.    After rinsing all excess SPBS was 
drained and discarded.  After the supernate was removed 1.5 ml of 4% 
paraformaldehyde solution was added.  Slides were incubated for 10 minutes at room 
temperature.  After fixing cells were washed in SPBS as described above.  Excess SPBS 
was removed and cover slips were air-dried.  Before staining cells were permeabilised 
by incubation with 500ul SPBS containing 0.25% (v/v) Triton X-100 for 5 minutes at 
room temperature followed by a wash with SPBS as described above.  Cells were 
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counter-stained for nuclear DNA, mounted and examined as previously described for 
suspension cells (section 2.7.1).  
2.8 Statistical Analysis
Data was subjected to statistical analysis using the MiniTab software program version 
15.1.1.0 .  Dr. Darren Shaw (University of Edinburgh, Royal (Dick) School for 
Veterinary Studies) kindly assisted me in analyzing the data.
2.9 Recipes
2.9.1 Commonly Used Solutions
Phosphate Buffered Saline Solution 






pH adjusted to 7.2 with HCl or NaOH 
H2O to 10 litres
Mowiol Mount Amount
Mowiol 4-88 2.4 g
Glycerol 6.0 g
Distilled H2O 6.0 ml
0.2M Tris, pH 8.5 12.0 ml
1,4-diazabicyclo-[2.2.2]octane (DABCO, Sigma-Aldrich)* 2.5% (w/v)
*1, 4-diazabicyclo-[2.2.2] octane (DABCO, Sigma) added as an anti-fade reagent prior to use.  
Aliquots of 1 ml were stored at -20ºC in screw top tubes.  Protocol adapted from our laboratory 
protocol and (Sambrook and Russell, 2001). 
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4% Paraformaldehyde Solution Amount
Paraformaldehyde 4.0 g 
Distilled H2O 50.0 ml
1M NaOH 1.0 ml
10X PBS 10.0 ml
pH adjusted to 7.4 using HCl and final volume brought to 100 ml with 
H2O
Aliquots of 10ml were stored at-20ºC before use.  Protocol adapted from (Sambrook and 
Russell, 2001).
TE Buffer (Supplied in Qiagen Kits) Amount
Tris, pH 8.0 10mM
EDTA 1 mM
EB Buffer (Supplied in Qiagen Kits) Amount
Tris-Cl, pH 8.5 10mM
2.9.2 Protein Electrophoresis
Western Blot Lysis Buffer Amount
SDS 10% Solution 4.0 ml
Glycerol 4.0 ml
0.125M Tris HCl pH 6.8 2.5 ml
Bromophenol Blue 1-2 grains
H2O 8.5 ml
2-Mercaptoethanol 1.0 ml
Aliquot into 1ml screw top tubes and store at -20ºC for up to 6 months
Ammonium Persulfate (10% w/v) Amount
Ammonium Persulfate (Sigma) 1g
H2O To 10 ml
Store at 4ºC for up to 7 days
12% Polyacrylamide Resolving Gel Amount
H2O 3.3 ml
30% Acrylamide/Bis-Acrylamide (Sigma) 4.0 ml
1.5M Tris-HCl pH8.8 2.5 ml
10% SDS 100 l




30% Polyacrylamide Mix 830 l
1.0M Tris-HCl pH6.8 630 l
10% SDS 50 l




Coomassie Blue R250 2.5g
Methanol 500 ml
Acetic Acid 50 ml
H2O To 1 litre
Stain dissolved in methanol and added to acetic acid and water and passed through filter    
paper before use to remove any debris.
Destaining Solution (for 1 litre) Amount
Acetic Acid (10% v/v) 100ml
Methanol (20% v/v) 200ml
H2O 700ml




H2O to 2 litres
Semi-Dry Transfer Buffer 1X Amount
25mM Tris Base (w/v) 1.5g
150mM Glycine (w/v) 5.6g
Methanol 10% (v/v) 50 ml
H2O To 500 ml
Blocking Buffer Amount
Skimmed Milk Powder (5% w/v) 5g
PBS + 0.1% v/v TWEEN 20 100 ml
2.9.3 Nucleic Acid Electrophoresis
Tris-Acetate EDTA (TAE) Running Buffer Amount
Tris, pH 8.0 10mM
EDTA 1 mM
5 x Loading Buffer (Prepared centrally in our laboratory) Amount
Ficoll dissolved in TAE buffer 15 ml
Saturated solution of Orange G 0.25 ml
H2O To 100 ml
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2.9.4 Bacterial Media
Luria-Bertani (LB) Broth (Marek) 






Luria-Bertani (LB) Agar Plates Amount
LB Broth (as above) 500 ml
Agar 7.5 g
Mixture was autoclaved and cooled to approximately 60ºC before adding antibiotic and     
pouring aseptically into plates.  Plates were stored at 4ºC in the dark for up to 14 days.
2.9.5 Tissue Culture Media
Transformed Chicken Lymphoblastic Cell Media Amount
RPMI 1640 Media (Gibco, Invitrogen) 500 ml
Tryptose Phosphate Broth (Gibco, Invitrogen) 50 ml
Sodium Pyruvate 100 mM (Gibco, Invitrogen) 5 ml
FCS 50 ml
Penicillin/Streptomycin 10U/ml (Gibco, Invitrogen) 5 ml
Seeded at 1 x 104 cells/flask cm2 
CEF Media (5% Growth/ 2% Maintenance) Amount
M199 Media (Gibco, Invitrogen) 500 ml
Tryptose Phosphate Broth (Gibco, Invitrogen) 50 ml
7% Sodium Bicarbonate Solution (Sigma-Aldrich) 13.5 ml
FCS 25 ml (growth)/
10 ml maintenance)
Penicillin/Streptomycin 10U/ml (Gibco, Invitrogen) 5 ml
Seeded 6-Well Dish at 3.5 x 105 cells/dish
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Chapter 3 – siRNA Studies of Selected MDV Genes
Results
3.1 Project Objectives
The objective for this portion of the study was to identify uncharacterised MDV genes
expressed during latent infection.  Following identification of such genes siRNA 
techniques were used to investigate their function.  Post-transcriptional targeting using a 
25-mer siRNA oligonucleotide was used to remove the gene product from persistently 
MDV-infected chicken lymphoblastic cells in vitro.  The cells were then screened for 
any phenotypic changes when the gene product was removed.  Cell growth rate was used 
as the primary phenotypic indicator.    
3.2 Selection of Genes for Study
The sequencing of the CVI988 (Rispens) vaccine strain of MDV (Spatz et al., 2007b)
made it possible to compare the sequence of an attenuated strain with that of pathogenic
strains such as Md5 (Tulman et al., 2000), Rb1b (Spatz et al., 2007a) and GA (Lee et al., 
2000).  Multiple differences between the MDV strains have been identified, and some of 
these differences, particularly in Meq, have been extensively studied (Kingham et al., 
2001; Spatz and Silva, 2007b).  However, there were many other genes that had not been 
fully characterised which became the selection pool for this study.  All candidate genes 
were subjected to a literature search to assess prior knowledge (chapter 1) and a protein 
motif scan to identify any recognized similarities between the protein sequence and known 
protein motifs using the CVI988 Rispens strain MDV genome (GenBank DQ530348.1) 
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and the “Prosite MyHits” online database (Pagni et al., 2007) and a prediction of 
transmembrane protein regions generated by the ExPASy TMPred software based on the 
TMbase online database (Hofmann and Stoffel, 1993).  Proteins with a predicted motif or 
potential transmembrane region were preferred over proteins without a recognizable motif.  
Fifteen MDV ORFs were selected for characterization based on the criteria of predicted 
protein motifs/ transmembrane regions and not being extensively characterised in the 
literature at the time of selection and are listed in table 3.1.  Some of the candidate genes 
(RLORF5a, 23kDa, RLORF6, MLTI, RLORF12, MNFH, LORF12 and ANTISENSE)
contained strain differences in the number of codons present which are illustrated in table
3.1 (Spatz et al., 2007a; Spatz et al., 2007b; Spatz and Silva, 2007b).  In the case of 
23kDa, RLORF6, MLTI, RLORF12 and MNFH these differences in codon length were 
observed between the attenuated CVI988 strain and one or more of the pathogenic strains 
of MDV which could potentially play a role in determining virulence.  Table 3.2 contains a 
summary of the results of the protein motif scanning and transmembrane region prediction
























































































































































































































LORF1 9.0 13,785 14,786 333 333 333 333 333 NI
LORF3 12.0 18,276 19,430 384 384 384 398 384 NI
MNFH 49.1 80,737 80,872 34 93 93 94 94 NI
LORF6 49.5 88,510 88,977 155 155 155 155 155 NI
LORF8 57.8 104,760 105,386 208 208 208 208 208 NI
LORF11 72.0 123,905 126,616 903 903 903 903 903 NI





















US2 91.0 158,593 159,405 270 270 270 270 270 NI
Table 3.1:  Comparison between the 15 selected ORFs in the CVI988 (Rispens) vaccine strain 
and pathogenic strains as adapted from (Spatz et al., 2007a; Spatz et al., 2007b; Spatz and 
Silva, 2007b) (GenBank DQ530348.1, EF523390.1 and DQ534539.1).  NP denotes not present




















4 P (weak match), 
1 G (weak match),
0 M
0 A
None None 1 Ankyrin repeat (weak 





5 P (weak match)
2 G (weak match)
7 M (weak match)
4 A (weak match)
None None 3 FMRFamide related 
peptide family (weak 
match), 1 NUMOD3 motif 




10 P (weak match)
1 G (weak match)
2 M (weak match)
0 A
None 1 Proline-Rich 
Region (strong match) & 




2 P (weak match)
2 G (weak match)





None 1 Microbodies C-terminal 
targeting signal (weak 






7 G (weak match)
7 M (weak match)
0 A
None 7 None identified
RLORF12
(repeat)
5 P (weak match)
2 G (weak match)
1 M (weak match)
0 A
None 1 None identified
LORF1 8 P (weak match)
2 G (weak match)





2 Serine-rich region (weak 
match)
LORF3 17 P (weak match)
3 G (weak match)
2 M (weak match)




2 2 DUF1509 protein of 
unknown function (strong 
match), 1 Protein 
prenyltransferases 
subunit repeat profile 
(weak match), Arginine 
and Proline-rich regions.




Truncated protein in 
CVI988 strain, but not 
pathogenic strains.
LORF6 2 P (weak match)
0 G
2 M (weak match)
0 A

















LORF8 1 P (weak match)
2 G (weak match)






LORF11 31 P (weak match)
2 G (weak match)
4 M (weak match)
0 A
None 1 2 Major Vault Protein 
repeat profile (weak 
match)
LORF12 4 P (weak match)
2 G (weak match)
1 M (weak match)
0 A
None 1 None identified
ANTISENSE
(repeat)
5 P (weak match)
0 G
3 M (weak match)
0 A
None None None identified
US2 4 P (weak match)
0 G
3 M (weak match)
0 A
None 1 Strong match for US2 
family proteins found in 
other herpesviruses
Table 3.2:  Summary of the protein motif scanning results of the 15 selected MDV genes using 
the CVI988 Rispens strain genome (GenBank DQ530348.1) and the online databases TMPred 
and Prosite Motif Scan (Hofmann and Stoffel, 1993; Pagni et al., 2007).   
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3.3 PCR Screening for Expression in Latency
PCR primers specific for each of the 15 candidate genes were designed using 
WebPrimer software (GenScript) and sourced from a commercial supplier 
(Eurofins/MWG).  Primers for each ORF were between 18-22 nucleotides and are 
outlined in table 3.3.  A BLAST search against the chicken genome (Wallis et al., 2004)
for each primer was undertaken to make sure that there was no homology with the 
chicken genome that might cross-react in the PCR reactions.  Conventional PCR (section 
2.1.8) was then used to determine expression of the selected ORFs in several chicken 
cell culture models as shown in table 3.3.  DNA from the CVI988 strain MDV BAC 
(Petherbridge et al., 2003) was used as a template to optimize the PCR reactions, 
ascertain functionality of the primer sets and act as a positive control.  Primer sets were 
designed using the CVI988 strain of MDV (GenBank DQ530348.1) and checked for 
predicted function with the Primer3 (http://frodo.wi.mit.edu/primer3, accessed 2/7/2007) 
(Rozen and Skaletsky, 2000) and WebPrimer (http://www.yeastgenome.org/cgi-
bin/web-primer, accessed 27/6/2007) software packages as detailed in table 3.4.  
Homologous sequences to all the PCR primers were present in the Rb1b strain MDV 
genome (GenBank EF523390.1), so the primer sets were expected to work in DNA or 
cDNA isolated from Rb1b MDV Infected CEFs and Rb1b T cells.  The IRL region of 
JM/102W strain MDV (GenBank DQ534539.1) (Spatz and Silva, 2007b), which was the 
partial sequence of a clone of the prototype strain JM MDV found in RPL-1 cells, also 
confirmed homologous regions corresponding to the primer sets of the Meq, RLORF6, 
23kDa, MLTI, LORF1, RLORF11, RLORF12 and RLORF5a genes.  The context of the 
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selected ORFs within the genome is also illustrated in figures 3.5a-e.  Of the 15 genes 
examined it is important to note that RLORF6, 23kDa, MLTI, RLORF12, LORF1 and 
LORF3 had some degree of overlap with 1-2 other ORFs on the same strand which have 
been detailed previously in table 1.9.
DNA Sequence Strain MDV Model
MDV BAC DNA Rb1b 
(US2 inactive)
Positive Control
Rb1b MDV Infected CEF 
cDNA
Rb1b Lytic Infection Model
Rb1b T cell Line cDNA Rb1b Reactivating Latent Infection Model
(Latent Model 1)
RPL-1 Cell Line cDNA JM Non-Reactivating Latent Infection Model
(Latent Model 2)
Table 3.3:  Experimental groups for determination of expression in a latent and lytic MDV 
infection utilizing PCR
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MDV ORF Forward Primer Position in
MDV CVI988
Genome



































LORF3 ATTTCACCCACCTGATGACC 18518-18537 GGGAATGTTACGATGAGACG (18742-18761) 244










US2 GTCCCAGACACTTTGATTGC 158918-158937 CAGGATGTTCCACAGAATGG (159073-159092) 175
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MDV ORF Forward Primer Position in
MDV CVI988
Genome


















































MNFH ATGAACTTTCACTGGTCGG 80768-80786 GTGATCCGATTGATGAAACC (80844-80863) 57
LORF6 AAGCGAACAGAGTCCAGACG 88734-88753 CAGCAGTGGAGCTTATGTCG (88902-88921) 188








Table 3.4:  Primers used for PCR to amplify the corresponding MDV gene in screening for expression during latency.  Nomenclature of the 
ORFs based on MDV strain CVI988 (Spatz et al., 2007b) and stated 5’ to 3’ unless in parentheses which denotes 3’ to 5’. (*pol-1_for &     
pol-1_rev designed by Dr. Jeanette Webb; **MeqForQPCR, MeqRevQPCR, designed by Dr. Bernadette Dutia)
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Figure 3.5a: Overview of CVI988 Rispens genome (GenBank DQ530348.1) and 3 regions of interest containing the ORFs investigated in 
this study as outlined in table 3.1.  TRL = Terminal Repeat Long region, IRL = Internal Repeat Long region, IRS = Internal Repeat Short 






Figure 3.5b: Expanded Region A from figure 3.5a of MDV CVI988 genome showing genes of interest in the terminal repeat long and 
unique long region of the genome.  Genes of interest in this region are shaded in yellow.  MDV003.8 = L1, MDV004 = 23 kDa, MDV005 = 
Meq, MDV005.1 = RLORF6, MDV006.4 = RLORF11, MDV006.5 = MLTI, MDV007 = RLORF12, MDV009 = LORF1 and MDV0012 = LORF3.  
Diagram adapted from graphics interface of the NCBI GenBank database.
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Figure 3.5c: Expanded Region B from figure 3.5a of MDV CVI988 genome showing genes of interest in the unique long region of the 
genome.  Genes of interest in this region are shaded in yellow.  MDV049.1 = MNFH, MDV049.5 = LORF6, MDV057.8 = LORF8.  Diagram 
adapted from graphics interface of the NCBI GenBank database.
MDV 49.1
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Figure 3.5d: Expanded Region C from figure 3.5a of MDV CVI988 genome showing genes of interest in the internal repeat long and 
internal repeat short region of the genome.  Genes of interest in this region are shaded in yellow. MDV072 = LORF11, MDV072.8 = 
LORF12.  Diagram adapted from graphics interface of the NCBI GenBank database. 
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Figure 3.5e:  Expanded Region C from figure 3.5a of MDV CVI988 genome showing genes of interest in the internal repeat short and 
unique short region of the genome.  Genes of interest in this region are shaded in yellow.  MDV083 = ANTISENSE and MDV091 = US2.  
Diagram adapted from graphics interface of the NCBI GenBank database.
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In all PCRs 60-180 ng of template DNA or a 1:10 dilution of cDNA made from equal 
amounts of RNA was used and the conditions were: 50-57ºC annealing temperature run 
for 30 cycles as detailed in section 2.1.8.  The MDV BAC DNA contained the entire 
genome of the CVI988 strain except for US2 which had been deleted during the process 
of BAC construction and therefore the PCR would not be expected to work when using 
the MDV CVI988 BAC control DNA as a template (Petherbridge et al., 2003).  The 
CVI988 strain MDV was selected for a control as the complete genome had been 
published and a BAC was available from Dr. Venugopal Nair’s Laboratory at the 
Institute for Animal Health, Compton, UK.  To mimic a productive infection cDNA was 
prepared as detailed in section 2.1.5 from RNA isolated from Rb1b MDV infected 
CEFs.  This model for lytic infection was predicted to express all genes in a productive 
MDV infection.   
The first latent MDV model used (latent model 1) was Rb1b T cells which were derived 
from MDV strain Rb1b-infected lymphoblastic chicken tumours and kindly provided by 
Dr. Venugopal Nair at the Institute for Animal Health, Compton, UK.  To test that these 
cells were truly latent, cDNA was prepared from purified Rb1b T cell mRNA (section 
2.1.5) and used as a template in a PCR using primers specific for DNA polymerase.  Dr. 
Jeanette Webb, Centre for Infectious Disease, University of Edinburgh kindly provided a 
proven primer set for DNA polymerase (table 3.4).  DNA polymerase would not be 
expressed in latent MDV infections (Pellett et al., 2006) and therefore should not be 
expressed in a true latent cell line model.  The Rb1b T cells had been predicted to 
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express only genes that were expressed during latency, however some background 
expression of DNA polymerase was observed in PCRs which suggested a low level of 
productive infection in the cell line (table 3.6).  The latent model 1 was subsequently 
replaced with a non-productive MDV cell line RPL-1 (designated latent model 2) which 
was also obtained from Dr. Venugopal Nair at the Institute for Animal Health, Compton, 
UK.  
RPL-1 cells were derived from immortalized JMV MDV-infected chicken lymphoblastic 
tumours and while MDV viral sequences could be isolated from these cells they were a 
non-producer of virus (Nazerian et al., 1976; Stephens et al., 1976).  Previous studies 
had also used RPL-1 cells as a latent infection model (Koptidesova et al., 1995).  The 
virulent prototype JM strain in RPL-1 cells was originally isolated from a lymphomatous 
ovarian suspension of chicken cells isolated from a flock in Massachusetts, USA 
suffering from multiple cases of neurolymphomatosis and was the first MDV strain 
successfully used for experimental reproduction of the neural and visceral forms of MD 
(Sevoian et al., 1962).  When the PCR analysis was repeated for DNA polymerase using 
cDNA prepared from purified RPL-1 mRNA as a template there was no apparent
expression of DNA polymerase (figure 3.7).  Based on this evidence the decision was 
made to use the RPL-1 cells as the true latent infection model in the siRNA studies 





























270 + ND Inconclusive -
Meq 100 + + + +
23 kDa 240 Inconclusive Inconclusive Inconclusive Inconclusive
RLORF6 151 + + + +
LORF1 191 + + + +
LORF3 244 + + + +
LORF11 230 + + + +
LORF12 152 + + + +
ANTISENSE 180 + + + +
US2 175 - + - +
MLTI 110 Inconclusive Inconclusive Inconclusive Inconclusive
RLORF11 157 + + + +
RLORF12 229 + - Inconclusive Inconclusive
MNFH 57 + + + -
LORF6 188 + + + -
LORF8 163 + + + -
RLORF5a
or L1
248 + + + -
Table 3.6:  Summary table showing MDV genes selected for study showing expression in a 
latent (RPL-1) cell line, a reactivating cell line (Rb1b T cells), a lytic infection (Rb1b Infected 
CEF) and a control (MDV BAC CVI988).   ND = Not Done.  Genes shaded in blue were
located in the ‘Meq Loci’.  Genes shaded in pink were expressed in latency.  Genes shaded 
in yellow were not expressed in latency.
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Figure 3.7:  2% agarose gel showing comparison between latent and lytic expression of Meq, 
LORF6 and DNA polymerase.  Figure Key:  Lane 1 shows the Positive control (strain CVI988 
MDV BAC DNA), Lane 2 shows lytic infection (cDNA Rb1b Infected CEF), Lane 3 shows latent 
infection model 1 (cDNA Histopaque-treated Rb1b T cells) and Lane 4 shows latent infection 
model 2 (cDNA RPL-1).  DNA polymerase shows only 2 lanes:  Positive control (strain CVI988 
MDV BAC) and latent infection model 2 (cDNA RPL-1).  Ladder used was 2-log DNA Ladder (0.1-
10 kb) (New England Biolabs).
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Meq expression was used as a positive control in the selection of cell models and 
optimizing the PCR reactions as it would be expressed in both latent and productive 
MDV infections (Brown et al., 2006).  Dr. Bernadette Dutia from The Roslin Institute, 
University of Edinburgh, UK kindly provided a proven primer set for Meq which was 
described in table 3.4.  PCRs using the Meq primer set and templates of MDV BAC 
DNA, Rb1b infected CEF cDNA, Rb1b T cell cDNA and RPL-1 cDNA all yielded a 
band signifying expression as expected on a 2% agarose gel (figure 3.7).  Table 3.6
contains a summary of all the findings of the PCR studies and the individual 
comparative 2% agarose gels of the PCR products (section 2.1.13) are detailed in figures 
3.7 to 3.12.  Analysis of the agarose gels demonstrated the presence of clear bands of the 
expected size in PCRs performed with RPL-1 cDNA (latent model 2) as a template for 
the following genes:  23kDa, RLORF6, LORF1, LORF3, LORF11, LORF12, 
ANTISENSE, US2 and RLORF11.  Based on these findings it was concluded that these 
genes were all expressed in latency.  The ORF for both the 23kDa and RLORF6 
significantly overlap Meq, however, so it was possible that the PCR primers may not 
have been able to accurately predict expression during latency due to the presence of 
Meq which is also expressed in latency (Brown et al., 2006).  MLTI did not yield any 
distinct bands (figure 3.10), only a faint multiple banding pattern on all templates except 
the CVI988 MDV BAC which could be from an ineffective primer set or possibly
attributed to the repeating nature and small size of the target protein which made 
selection of primers expected to yield a single distinct band nearly impossible.  The 
presence of a multiple banding pattern for MLTI was interpreted as inconclusive.  The 
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results for expression of RLORF12 (figure 3.8) were not clear despite several rounds of 
optimizing the PCR.  It was concluded that RLORF12 was probably expressed at a low 
level in latency based on the faint agarose gel band present in the latent model 2 lane 
compared to the strong band in the CVI988 MDV BAC positive control lane (indicating 
that the primers were effective).  It was not possible to determine why no agarose gel 
bands for RLORF12 were seen in the lytic or reactivating latent model (latent model 1) 
as the RLORF12 primer sets were homologous to the Rb1b strain MDV found in these 
cell lines.  The decision was made that despite the indeterminate results RLORF12 and 
MLTI would be included in the next phase of the project.  No evidence of expression in 
latent model 2 was found for LORF6, LORF8, L1 or the hypothetical protein MNFH so 
no further studies were carried out on these genes. 
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Figure 3.8:  2% agarose gel showing comparison between latent and lytic expression of MNFH 
(Primer MNFH), LORF 11 (Primer LORF11), RLORF12 (Primer RLORF12).  Figure Key:  Lane 1 
shows the Positive control (MDV BAC DNA), Lane 2 shows lytic infection (cDNA Rb1b Infected 
CEF), Lane 3 shows latent infection model 1 (cDNA Histopaque-treated Rb1b T cells) & Lane 4 
shows latent infection model 2 (cDNA RPL-1).  Ladder used was 2-log DNA Ladder (0.1-10 kb).
Figure 3.9:  2% agarose gel showing comparison between latent and lytic expression of
LORF12 (Primer LORF12), LORF1 (Primer LORF1), 23kDa (Primer 23kDa).  Figure Key:  Lane 
1 shows the Positive control (MDV BAC DNA), Lane 2 shows lytic infection (cDNA Rb1b Infected 
CEF), Lane 3 shows latent infection model 1 (cDNA Histopaque-treated Rb1b T cells) and Lane 
4 shows latent infection model 2 (cDNA RPL-1).  Ladder used was 2-log DNA Ladder (0.1-10 
kb).
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Figure 3.10:  2% agarose gel showing comparison between latent and lytic expression of US2 
(Primer US2), RLORF5a or L1 (Primer L1), and MLTI (Primer MLTI).  Figure Key:  Lane 1 shows 
the Positive control (MDV BAC DNA), Lane 2 shows lytic infection (cDNA Rb1b Infected CEF), 
Lane 3 shows latent infection model 1 (cDNA Histopaque-treated Rb1b T cells) and Lane 4 
shows latent infection model 2 (cDNA RPL-1).  DNA polymerase shows only 2 lanes:  Positive 
control (MDV BAC) and latent infection model 2 (cDNA RPL-1).  Ladder used was 2-log DNA 
Ladder (0.1-10 kb).
Figure 3.11:  2% agarose gel showing comparison between latent and lytic expression of
LORF8 (Primer LORF8), RLORF6 (Primer RLORF6), ANTISENSE (Primer ANTISENSE).  
Figure Key:  Lane 1 shows the Positive control (MDV BAC DNA), Lane 2 shows lytic infection 
(cDNA Rb1b Infected CEF), Lane 3 shows latent infection model 1 (cDNA Histopaque-treated 
Rb1b T cells) and Lane 4 shows latent infection model 2 (cDNA RPL-1).  Ladder used was 2-log 
DNA Ladder (0.1-10 kb).
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Figure 3.12:  2% agarose gel showing comparison between latent and lytic expression of
LORF3 (Primer LORF3) and RLORF11 (Primer RLORF11).  Figure Key:  Lane 1 shows the 
Positive control (MDV BAC DNA), Lane 2 shows lytic infection (cDNA Rb1b Infected CEF), Lane 
3 shows latent infection model 1 (cDNA Histopaque-treated Rb1b T cells) and Lane 4 shows 
latent infection model 2 (cDNA RPL-1).  Ladder used was 2-log DNA Ladder (0.1-10 kb).
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3.4 Sequencing of Genes of Interest in MDV JM Strain
Once the initial screening of the 15 ORFs had been completed (section 3.3) the potential 
targets were narrowed down from 15 to the 11 expressed in latent model 2:  LORF1, 
LORF3, LORF11, LORF12, ANTISENSE, US2, MLTI, RLORF11, RLORF12, 23kDa 
and RLORF6.  These genes were selected for siRNA knockdown studies using RPL-1 
cells which were persistently infected with the JM strain of MDV (Nazerian et al., 
1976).  The complete sequence of  strain JM MDV was not available at the time of this
study, but a partial sequence of strain JM/102W IR Long region (Spatz and Silva, 
2007b) was available that encompassed the RLORF6, RLORF11, RLORF12, 23kDa and 
MLTI ORFs.  
The JM strain of MDV was used extensively in early studies of MDV (Calnek et al., 
1984; Churchill and Biggs, 1967; Churchill et al., 1969; Dukes and Pettit, 1983; 
Nazerian et al., 1968; Witter and Burmester, 1967; Witter et al., 1980) and many clones 
of the prototype strain were used in the different labs working on MDV in the 1960’s
and 1970’s.  The MDV strain JM/102-W was a clone of the prototype strain JM virus 
and was used to develop the JMV non-productively infected transplantable tumour
(Stephens et al., 1976) which was subsequently used to develop the RPL-1 cell line 
(Nazerian et al., 1976).  Based on these early studies it was determined that the JM strain 
described in (Sevoian et al., 1962) and the JM/102W strain of MDV (Stephens et al., 
1976) were most likely homologous as they were clones of the same virus.  The decision 
was made to use the published sequence of MDV strain JM/102W (Spatz and Silva, 
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2007b) for designing the siRNA oligonucleotides used for the in vitro studies in section 
4.5 in RPL-1 cells.
The LORF 1, LORF 3, LORF 11, LORF 12, ANTISENSE and US2 ORFs were not 
covered in the published JM/102W sequence.  In order to correctly design the siRNA 
oligonucleotides specific for RPL-1 cells the sequence of LORF1, LORF3, LORF11, 
LORF12, ANTISENSE and US2 was determined as illustrated in figure 3.13.  
Sequencing primers were selected using the Rispens (CVI988) MDV genome (Spatz et 
al., 2007b) (GenBank DQ530348.1) and were located outside the published beginning 
and end of each ORF.  The online databases WebPrimer 
(http://www.yeastgenome.org/cgi-bin/web-primer, accessed 27/8/07) and Primer3 
(http://frodo.wi.mit.edu/primer3, accessed 27/8/07) were used to assist the primer 
selection process.  A forward and reverse sequencing reaction was done (section 2.1.16) 
using walking primers to ensure complete coverage of the gene to be sequenced.  The 
sequences were then aligned using the align function in the Vector NTI v.10-11 software 
package (Invitrogen) to give a minimum of three overlapping sequences for each ORF.  
Each PCR sequenced between 200 and 600 bp so multiple primers were required in the 
longer ORFs to ensure complete and overlapping coverage.  Sequencing primers used
and their position in the CVI988 genome are detailed in table 3.14.    
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Figure 3.13:  Experimental flowchart for siRNA transfection studies.
MDV ORF Primer 
Designation
Primer Sequence Position in MDV 
CVI988 Strain
LORF1 LORF1 5’ to 3’ CGTTCGCACCAGAGTCC 13744-13760
(128683-128699)
LORF1 3’ to 5’ TGGCAAACCACGACTACC (14794-14811)
LORF1 REV#2 TAGGAGTAGACTGACACG (14938-14955)
LORF3 LORF3 5’ to 3’ GGTCTTGCTGCTGAATGC 18258-18275
LORF3 3’ to 5’ CCCATAACAATACGTGAAGG (19511-19530)
LORF11 LORF11 5’ to 3’ ATTGTATCATCGTATGTGGG 123850-123869
LORF11 3’to 5’ CCTTGATGTGGTTTGACG (126678-126695)
LORF11 FOR#2 CTGCGATACTGTATATTATG 125079-125098
LORF11 REV#2 ATTTGGCATATCTTCGCTC (126036-126054)
LORF12 LORF12 5’ to 3’ CACAAGCGAGAAAGGAGC 126748-126765









US2 US2 5’ to 3’ TAGCAAGTAGGTCTGTCG 158567-158584
US2 3’ to 5’ AAAGATTATTGGTGGAGGTG (159409-159428)
Table 3.14:  Primers used for sequencing reactions of LORF1, LORF3, LORF11, LORF12, 
ANTISENSE and US2.  Sequences are shown 5’ to 3’ direction. 
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Completed nucleotide and protein sequences for LORF3, LORF11, LORF12, 
ANTISENSE and US2 of the MDV JM strain aligned with the attenuated MDV CVI988 
(Spatz et al., 2007b) and highly pathogenic MDV Rb1b strain (Spatz et al., 2007a) are 
detailed in Appendix 1.  It was not possible to sequence the JM strain LORF1 gene due 
to difficulties in selecting specific primers for the sequencing reactions.  This could have 
been due to multiple regions of partial homology in the LORF1 gene with other regions 
of the CVI988 genome which would lead to primers binding non-specifically in the 
sequencing reactions.  After multiple unsuccessful attempts to sequence the LORF1 
gene the decision was made to abandon sequencing it and use the Rb1b genome to 
design the siRNA oligonucleotides.  
The sequencing of strain JM MDV genes LORF3, LORF12 and ANTISENSE showed 
100% homology for MDV strains CVI988 and Rb1b.  Analysis of the JM strain MDV 
LORF11 sequence revealed 4 different one bp substitutions between the CVI988 strain 
resulting in three aa substitutions in the final gene product.  The aa substitutions between 
MDV LORF11 strain JM and CVI988 were:  A to V at position 57, T to A at position 
302 and P to L at position 780 which were detailed in Appendix 1.  Comparison of 
strains JM and Rb1b MDV LORF11 showed 100% homology.   Sequenced JM strain 
MDV US2 compared to strain CVI988 revealed 100% homology, but a G to A one bp 
substitution at position 159,005 was identified in the Rb1b strain resulting in an A to V 
aa substitution at position 51. 
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The MDV JM strain LORF1 was not sequenced so the siRNA oligonucleotides were 
designed based on the MDV strain Rb1b (GenBank EF523390.1) and the gene 
knockdown studies were performed with Rb1b T Cells rather than RPL-1 cells which 
ensured that the siRNA targets selected would be present in the genome utilized.  The 
completed strain JM MDV sequences were used to design siRNA 25-mer duplex oligo-
ribonucleotides for gene knockdown studies which will be discussed in the next section. 
3.5 Knockdown of Viral Gene Expression using siRNA
Two 25-mer siRNA oligonucleotides were designed for each target gene using BLOCK-
IT TM RNAi Designer software (Invitrogen) and either the JM/102 genome (Spatz and 
Silva, 2007b) or the JM strain sequence described previously for each of the selected 
ORFs expressed in latency (table 3.15).  The only exception to this was the LORF1 gene 
which used the Rb1b genome (Spatz et al., 2007a) (GenBank EF523390) as there were 
technical problems in sequencing the JM strain as described in the previous section. The 
25-mer siRNA oligonucleotides were sourced from a commercial supplier (StealthTM
siRNA, Invitrogen).  The experimental groups for all the in vitro studies were the two 
25-mer siRNA oligonucleotide for each target gene which were both compared to a 
control siRNA sequence (SilencerTM Negative Control siRNA #2, Ambion, Invitrogen) 
which was a non-targeting siRNA oligonucleotide that had been validated to have 
minimal effects on gene expression profiles by the manufacturer.  Each experimental 
group was transfected in triplicate for each experimental run to give three repetitions for 
each group.  The siRNA oligonucleotides and a transfection indicator (siGloRed, 
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Dharmacon, Thermo Fisher Scientific) were transfected into RPL-1 cells as described in 
section 2.5.3.  The only exception to this design was the LORF1 siRNA oligonucleotides 
which were transfected into Rb1b T cells instead of RPL-1 cells in order to match the 
MDV strain used to design the siRNA.  Transfection efficiency was determined at 24 
hours (section 2.5.3), cell counts were taken at 24, 48, 72, 96 and 120 hours post-
transfection (section 2.4.4) and cell samples were taken for RNA isolation at 48, 72, 96 
and 120 hours post-transfection (section 2.1.3).  Transfection efficiencies calculated at 
24 hours varied from 8.5 to 65.1% with an overall mean of 36.7%.  All cell samples for 
RNA extraction were archived in RNALater solution and stored at -80ºC for possible 
analysis with RTqPCR at a later date.  Due to the timescale and budget constraints 
siRNA studies for RLORF11, US2, 23kDa and LORF12 were not performed. 
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Table 3.15:  siRNA oligonucleotides used for gene knockdown studies in RPL-1 cells. MDV 











LORF1 siRNA Rb1b LORF1 101 Rb1b (14662-14686)C CAGGAACUUG
GAUCUUUGUA
CCUUU
siRNA Rb1b LORF1 644 Rb1b (14119-14143)C CCGAGAGGG
UCAAACUAUG
UUAUAA
LORF3 siRNA JM LORF3 9 JM 18284-18308 CGGAGGAGG
AACUAUUGCA
UUAAUA
siRNA JM LORF3 217 JM 18492-18516 CGGAAAUGUU
UAGAUUGGU
GCUGCG
LORF11 siRNA JM LORF11 388 JM (126205-126229)C CCAUGGUCAU
UAUUGGGAAG
GAUAA





siRNA JM ANTISENSE 44 JM (168845-168869)C UGUUUGCAG
CGAGACGCCU
UGAUAA
siRNA JM ANTISENSE 268 JM (168621-168645)C CCUCCCAUGC
UAGACCACAA
GAUGU
MLTI siRNA JM MLTI 7 JM/
102W
16 Repeats, 





siRNA JM MLTI 86 JM/
102W
16 Repeats































CONTROL Silencer Negative Control 
siRNA #2 (Ambion, 
Invitrogen)
None n/a Not Available
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Cell growth data was averaged for the 3 transfection repetitions and plotted for each 24 
hour time point in the study with error bars equivalent to 1 standard error for LORF1, 
LORF3, LORF11, ANTISENSE, MLTI, RLORF12 and RLORF6 (figures 3.16-3.22).  
Analysis of the cell growth data showed a non-parametric distribution for LORF1, 
LORF3, LORF11, ANTISENSE, MLTI and RLORF12 and a normal distribution for 
RLORF6 (p=<0.005 at 72 and 96 hours).  Statistical analysis of the cell growth data was 
performed using a Mann-Whitney test for all non-parametric data sets (LORF1, LORF3, 
LORF11, ANTISENSE, MLTI and RLORF12) or a general linear model ANOVA for 
normally distributed data (RLORF6) using MiniTab15 software as described in section 
2.8.  The criterion for statistical significance was a 95% confidence interval (p-value 
<0.05).  Statistical findings and 24 hour transfection efficiencies were summarized at the 
bottom of figures 3.16 - 3.22 for each gene screened.  The p-values for LORF1, LORF3, 
LORF11, ANTISENSE, MLTI and RLORF12 were all greater than 0.05 which did not 
meet the criteria for significance.  Based on this analysis it was concluded that no 
significant differences existed in vitro between LORF1, LORF3, LORF11, 
ANTISENSE, MLTI or RLORF12 siRNA transfected RPL-1 cells and the siRNA 
negative control transfected RPL-1 cells.  Due to timescale and budget constraints no 
follow-up studies for these genes were planned.  
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siRNA Rb1b LORF1 101 Mann-Whitney 0.9362 1.0000 22.55%
siRNA Rb1b LORF1 644 Mann-Whitney 0.8102 0.4712 19.78%
siRNA Control N/A N/A N/A 20.88%
Figure 3.16a:  LORF1 cell growth data for first repetition of experiment in Rb1b T cells showing 
error bars equivalent to 1 standard error.  Note the higher rate of cell growth compared to other 
siRNA experiments in this section.  The Mann-Whitney test for significance incorporated all data 
points in the first and second repetitions and each experimental siRNA oligonucleotide was 
compared to the siRNA Control oligonucleotide.  Transfection rates were determined as 
discussed in section 2.5.3 and calculated as an average value based on the first repetition only.  
N/A denotes not applicable.
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Figure 3.16b:  LORF1 cell growth data for second repetition of experiment in Rb1b T cells 
showing error bars equivalent to 1 standard error.  Note the difference in y-axis scale compared 













siRNA JM LORF3 9 Mann-Whitney 0.0809 1.0000 32.55%
siRNA JM LORF3 217 Mann-Whitney 0.3827 0.1904 47.00%
siRNA Control N/A N/A N/A 40.52%
Figure 3.17:  LORF3 cell growth data for first repetition of experiment in RPL-1 cells showing 
error bars equivalent to 1 standard error.  Note the higher rate of cell growth reflected by the y-
axis scale compared to other siRNA experiments in this section.  The Mann-Whitney test for 
significance compared each experimental siRNA oligonucleotide to the siRNA Control 
oligonucleotide. Transfection rates were determined as discussed in section 2.5.3 and calculated 
as an average value.  N/A denotes not applicable.
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siRNA JM LORF11 388 Mann-Whitney 0.8728 0.7488 24.95%
siRNA JM LORF11 1087 Mann-Whitney 0.9362 1.0000 29.12%
siRNA Control N/A N/A N/A 27.33%
Figure 3.18a:  LORF11 cell growth data for first repetition of experiment in RPL-1 cells showing 
error bars equivalent to 1 standard error.  The Mann-Whitney test for significance compared 
each experimental siRNA oligonucleotide to the siRNA Control oligonucleotide for all data points. 
Transfection rates were determined as discussed in section 2.5.3 and calculated as an average 
value based on the first repetition only.  N/A denotes not applicable.
132
Figure 3.18b:  LORF11 cell growth data for second repetition of experiment in RPL-1 cells 
showing error bars equivalent to 1 standard error.
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siRNA JM ANTISENSE 44 Mann-Whitney 0.1904 0.1904 33.81%
siRNA JM ANTISENSE 268 Mann-Whitney 0.6625 0.0809 34.71%
siRNA Control N/A N/A N/A 40.52%
Figure 3.19:  ANTISENSE cell growth data for first repetition of experiment in RPL-1 cells 
showing error bars equivalent to 1 standard error.  Note the higher rate of cell growth reflected 
by the y-axis scale compared to other siRNA experiments in this section.  The Mann-Whitney 
test for significance compared each experimental siRNA oligonucleotide to the siRNA Control 
oligonucleotide. Transfection rates were determined as discussed in section 2.5.3 and calculated 













siRNA JM MLTI 7 Mann-Whitney 0.1489 0.3865 46.27%
siRNA JM MLTI 86 Mann-Whitney 1.0000 0.3865 40.80%
siRNA Control N/A N/A N/A 40.27%
Figure 3.20:  MLTI cell growth data for first repetition of experiment in RPL-1 cells showing error 
bars equivalent to 1 standard error.  The Mann-Whitney test for significance compared each 
experimental siRNA oligonucleotide to the siRNA Control oligonucleotide. Transfection rates 
were determined as discussed in section 2.5.3 and calculated as an average value.  N/A 
denotes not applicable.
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siRNA JM RLORF12 69 Mann-Whitney 0.4113 0.5228 55.42%
siRNA JM RLORF12 186 Mann-Whitney 1.0000 1.0000 49.88%
siRNA Control N/A N/A N/A 40.27%
Figure 3.21a:  RLORF12 cell growth data for first repetition of experiment in RPL-1 cells 
showing error bars equivalent to 1 standard error.  The Mann-Whitney test for significance 
compared each experimental siRNA oligonucleotide to the siRNA Control oligonucleotide for all 
data points in both replications. Transfection rates were determined as discussed in section 
2.5.3 and calculated as an average value for both repetitions.  N/A denotes not applicable.
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Figure 3.21b:  RLORF12 cell growth data for second repetition of experiment in RPL-1 cells 
showing error bars equivalent to 1 standard error.  Note the relatively higher rate of cell growth 
reflected by the higher y-axis scale.
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siRNA RLORF6 JM 524 ANOVA 0.7265 0.4777 33.92%
siRNA RLORF6 JM 626 ANOVA 0.0094 0.4134 21.35%
siRNA Control N/A N/A N/A 31.29%
Figure 3.22a:  RLORF6 cell growth data for first repetition of experiment in RPL-1 cells showing 
error bars equivalent to 1 standard error.  The general linear model ANOVA test for significance 
compared the experimental siRNA oligonucleotides to the siRNA Control oligonucleotide for all 
three repetitions and adjusted the p-value to take into account the replicate effect observed. 
Transfection rates were determined as discussed in section 2.5.3 and calculated as an average 
value.  N/A denotes not applicable.
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Figure 3.22b:  RLORF6 cell growth data for second repetition of experiment showing error bars 
equivalent to 1 standard error.  Note the relatively higher rate of cell growth reflected by the y-
axis scale.
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Figure 3.22c:  RLORF6 cell growth data for third repetition of experiment showing error bars 
equivalent to 1 standard error.
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Figure 3.22d:  RLORF6 cell growth data statistical analysis of 3 repetitions of experiment at 72 
hours.  Note the marked replicate effect existing between the three trial repetitions.
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The residual graphs comparing the RLORF6 siRNA 524 and siRNA 626 to the negative 
control siRNA (figure 3.22d) showed a relatively normal distribution despite there being 
a marked replicate effect.  To correct for the observed replicate effect and because the 
data was normally distributed statistical analysis was carried out using a general linear 
model ANOVA to analyze the raw cell growth data from the repetitions of the 
comparisons between the RLORF6 siRNA 524 and siRNA 626 with the negative control 
siRNA (figure 3.22d).  When the ANOVA was performed on the 72 hour post-
transfection data and adjusted for the replicate effect with pair wise comparisons the 
adjusted p-value for siRNA JM RLORF6 524 was 0.7265 and siRNA JM RLORF6 626 
was 0.0094.  The same calculations were also performed with the 96 hour post-
transfection data and no significant differences were identified (p>>0.05, figure 3.22a) 
Based on these calculations it was concluded that RPL-1 cells transfected with the 
oligonucleotide siRNA JM RLORF6 626 led to a significantly higher cell growth rate 
than the siRNA control oligonucleotide at 72 hours post-transfection, but not at 96 hours 
post-transfection.  It was also concluded that a significant increase in RPL-1 cell growth 
rate was not seen for siRNA JM RLORF6 524 transfected cells over siRNA control at 72 
or 96 hours post-transfection.  
Some of the reasons for these observations could be due to the low number of replicates 
as the experiment was only repeated twice for the RLORF6 siRNA524 rather than the 
three times for the RLORF6 siRNA626.  Other reasons for the lack of significant 
differences could have been related to variable efficiencies of the siRNA 
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oligonucleotides selected or variable cell transfection rates which will be discussed later 
in the chapter.  Based on the significantly higher cell growth rate observed in siRNA JM 
RLORF6 626 transfected RPL-1 cells, follow-up studies utilizing RTqPCR, confocal 
microscopy and protein blotting were carried out for RLORF6 which will be detailed in 
the following chapter.  
3.6 Summary
This study analyzed several uncharacterised genes in MDV for expression in latency.  
Genes found to be expressed in latency were targeted with post-transcriptional siRNA 
knock down in a latent model MDV transformed cell line using growth rate as an 
indicator of changed phenotype.  Fifteen uncharacterised MDV ORFs were screened 
using PCR for expression in latency in the non-producer MDV-transformed cell line 
RPL-1:  RLORF5a (L1), 23kDa, RLORF6, RLORF11, MLTI, RLORF12, LORF1, 
LORF3, MNFH, LORF6, LORF8, LORF11, LORF12, ANTISENSE and US2.  Eleven 
of these ORFs were found to be expressed in latency:  23kDa, RLORF6, RLORF11, 
MLTI, RLORF12, LORF1, LORF3, LORF11, LORF12, ANTISENSE and US2.  25-
mer siRNA oligonucleotides were designed to target seven of these ORFs for gene 
knockdown studies in RPL-1 and Rb1b T cells:  LORF1, LORF3, LORF11, RLORF6, 
RLORF12, ANTISENSE and MLTI.  The non-producer MDV transformed chicken 
lymphoblast cell line RPL-1 was used as the latent model for the siRNA transfection 
studies and was persistently infected with the JM strain of MDV (Nazerian et al., 1976).
The complete sequence of the JM strain was not available, however the JM/102W strain 
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was a clone of the prototype JM strain, and the IRL region sequence was available 
(Spatz and Silva, 2007b).  This sequence was used to design the RLORF6, RLORF11, 
MLTI and RLORF12 25-mer siRNA oligonucleotides to use in the transfection studies.   
The sequences of JM strain MDV LORF3, LORF11, LORF12, ANTISENSE and US2 
were sequenced from a template of DNA purified from RPL-1 cells (sections 2.1.2 & 
2.1.16).  Sequencing of strain JM MDV LORF1 was unsuccessful due to homologous 
regions in the MDV genome causing non-specific binding of the primers, and the 
decision was made to utilize the published Rb1b genome (Spatz et al., 2007a) to design 
the siRNA and transfect it into Rb1b T cells for siRNA in vitro studies.   Two siRNA 
oligonucleotides targeting each individual gene product and a negative control siRNA 
were transfected in triplicate into MDV-transformed chicken lymphoblasts along with a 
transfection indicator (RPL-1 cells for all but LORF1 which used Rb1b T cells) which 
allowed the study of what the effect of gene product removal had on phenotype in vitro.   
There were no significant differences in cell growth with post-transcriptional siRNA 
knockdown identified in any of the genes at the 95% confidence interval except for 
siRNA JM RLORF6 626 where there was an increase in cell growth over the siRNA 
control at 72 hours with an adjusted p-value of 0.0094 (Figure 3.22d).  As this result was 
significant and the same trends were seen during 3 repetitions of the experiment the 
decision was made to validate these results and further characterize the RLORF6 gene 
which will be discussed in chapter 4.
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Discussion
3.7  Overview & Introduction
There are at least 113 unique ORFs in the MDV genome.  To date barely a third have 
been well-characterised in the literature.  This project intended to examine some of the 
less-studied ORFs in MDV and find out if they were expressed in latency and look at 
what effect post-transcriptional siRNA knock down would have in a latent MDV 
transformed cell line using growth rate as an indicator of changed phenotype.  It was 
hypothesized that more regulatory functions were operating in latent MDV infection 
than those controlled by the well-studied genes such as vIL-8, Meq, pp38 and pp24 as 
the complexity of MDV infection was likely to be controlled by many gene interactions 
rather than the relatively few that had been studied to date.  Proteomic comparisons 
between MDV infected and mock-infected chicken cells revealed large numbers of 
chicken proteins unique to the MDV infected group.  Following MDV infection an over 
20-fold greater number of proteins were found to be expressed or changed in the host 
chicken cell, particularly among phosphorylated proteins, than there were present in the 
MDV genome (Ramaroson et al., 2008).  This would suggest that many of the genes in 
MDV play multiple roles and interact with multiple target molecules.  Many of these 
interactions may not be apparent in vitro however, as many target molecules may play a 
role in complex processes such as immune regulation in the infected animal.  With such 
a large number of potential gene targets the decision was reached that there was a 
reasonable likelihood that knockdown of some genes could produce phenotypic 
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differences that would be apparent in vitro.  Screening for gene interactions in vivo is a 
very difficult and expensive process which is why in vitro studies such as the ones used 
in this project can be useful to obtain information about some phenotypic changes 
produced by the absence of a gene product.  The hypothesis was that any genes 
producing a measurable phenotypic change in vitro would have changed the protein 
interactions within the cell and therefore may act as a regulatory gene that should be 
further characterised. 
3.8  Selection of Genes for Study
Because of the timescale and scope of the project only a limited number of genes could be 
studied.  The decision was made to focus mainly on the TRL and IRL regions of the 
genome as they contain many genes unique to MDV which would be most likely to be 
associated with latency and transformation.  Of particular interest were the uncharacterised
genes in the region of the origin of replication as many genes surrounding this region are 
unique to MDV and have been implicated in latency, transformation and early lytic 
replication (Parcells et al., 2003).  An initial literature search was undertaken on selected 
candidate genes as discussed in chapter 1.  These selected genes were then subjected to 
further analysis to identify possible target molecules or functions.  The motif scans in table
3.2 outlined multiple matches with the potential to affect regulatory functions in each of 
the selected genes.  The “Prosite MyHits” online database (Pagni et al., 2007) used for the 
protein motif scans utilized a series of algorithms to determine the probability of 
sequences corresponding with recognized protein motifs.  The matches produced could 
146
either be true positives that were genuinely homologous to recognized patterns or false 
positives which attributed the observed similarity to chance.  The algorithm categorized 
these matches as strong, which was defined as being very unlikely to be due to a false 
positive result, and weak which required further biological evidence for definitive proof of 
function.  These definitions were used to describe the results shown in table 3.2.  Most of 
the results noted in table 3.2 were weak matches, so it is important to note that before any 
final conclusions could be made further biological evidence would be needed.  Of 
particular note was the prevalence of various phosphorylation site motifs found for many 
functions such as casein kinase II phosphorylation, cAMP- and cGMP-dependent protein 
kinase phosphorylation, protein kinase C phosphorylation and tyrosine kinase 
phosphorylation in every gene analyzed with the exception of MLTI.  Protein kinases are a 
large class of enzymes that modify other proteins by phosphorylation which can change 
the function of the target protein (Lehninger et al., 1993).  Proteomic comparisons between 
MDV infected and uninfected chicken cells (Ramaroson et al., 2008) have shown that 
there was a marked increase in phosphorylated proteins in the MDV-infected group over 
the uninfected group.  This led to the hypothesis that genes containing multiple predicted 
phosphorylation sites could potentially play a role in regulation of MDV infection and 
would be appropriate targets for the study.  MLTI was interesting in that it contained a 
repeating motif encompassing seven predicted transmembrane regions as well as 7
corresponding mystroylation and N-glycosylation sites in strain CVI988 MDV (8 
transmembrane regions and 13 mystroylation and N-glycosylation sites in strain Rb1b 
MDV), all of which could be consistent with a transmembrane receptor molecule.  The 
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undescribed MNFH (ORF49.1) was also interesting as in virulent strains it encodes a 93-
94 aa protein, but in the attenuated CVI988 strain it was truncated to a 34 aa protein due to 
a point mutation (Spatz et al., 2007b).  The MNFH protein was, however, not included in 
the published CVI988 genome (GenBank DQ530348.1) or any of the other pathogenic 
strains discussed in the article (Spatz et al., 2007b) and reconstruction of the aa sequence 
for a protein motif scan based on the published reference point of 80737-80872 bp was 
unsuccessful as the start and stop codons were not able to be determined from the 
information given.  Even though there was no protein motif information the decision was 
made to include MNFH in the study based on the apparent sequence differences between 
the virulent and attenuated MDV strains.  Many of the genes that were analyzed for protein 
motifs showed an additional variety of weak matches which could be consistent with 
functional proteins such as: Microbodies C-terminal targeting signal (a motif associated 
with retention signals for protein sorting, often in the endoplasmic reticulum), DUF1509 (a 
protein of unknown function found in MDV-like viruses), Ankyrin repeats (a common 
protein-protein interaction motif), Major Vault Protein repeat profiles (a novel component 
of multi-subunit structures that may act as scaffolds for proteins involved in signal 
transduction) and FMRFamide related peptide family (which has been associated with 
neurosecretory cells).  Although most of the protein motifs were weak matches the 
decision was made that it was possible that the proposed uncharacterised target genes 
could be functional proteins and therefore appropriate for inclusion in the study.        
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3.9  PCR Screening for Expression in Latency   
LORF6 has been shown to down-regulate MHC I in host cells which is thought to be a 
key step in immune evasion during MDV infection (Jarosinski et al., 2010).  This 
finding suggested that LORF6 would most likely be expressed with the early genes 
during MDV infection and the study hypothesized that it may also operate during 
latency and reactivation.  However, we could find no evidence of expression of 
RLORF6 in RPL-1 cells and therefore it seems that it may not function in this way in the 
latent model RPL-1 cells.  MNFH, RLORF5a/L1 and LORF8 were also not found to be 
expressed in latent RPL-1 cells, but as limited information on their function was 
available no hypothesis could be formed on the possible significance of these findings. 
It is important to note that there was some overlap on the same strand with other ORFs 
for MLTI, RLORF 12, LORF1 and LORF3 (table 1.9) which could have interfered with 
PCR based methods of quantification and affected PCR based screening assays.
All of the remaining genes screened appeared to be expressed at some level in RPL-1 
cell cDNA indicating that the gene products were expressed during latency, but again no 
hypothesis could be formed regarding the significance of these findings due to the 
limited information available for these genes.
3.10 Sequencing of Genes of Interest in JM Strain MDV
The attenuated CVI988 MDV genome was used for the sequencing reaction primer 
selection as the JM/102W strain MDV IRL contained many similarities.  Both strains 
contained a 177 bp insertion in the Meq gene region and a 10 bp deletion in the 
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RLORF12 gene which were not found in comparisons of JM/102W with more 
pathogenic strains such as Rb1b (Spatz et al., 2008; Spatz and Silva, 2007b).  Based on 
these observations the decision was made that the likelihood of strains CVI988 and JM 
being homologous for the selected primer sequences was greater than the likelihood of
homology with one of the more pathogenic strains (Spatz et al., 2007a).  
A comparison of the sequenced strain JM MDV with attenuated CVI988 and pathogenic 
Rb1b strains revealed 100% homology for the LORF3, LORF12 and ANTISENSE 
genes.  This indicated that these genes were probably conserved between strains of 
MDV.  In any future follow-up studies it would be possible to use the siRNA 
oligonucleotides designed for JM strain MDV for post-transcriptional gene product 
targeting in other cell lines based on the Rb1b or CVI988 strains of MDV.  Comparison 
of the strain JM MDV LORF11 and US2 sequences were found to be homologous with 
strain Rb1b MDV.  Analysis of strain JM attenuated strain CVI988 MDV LORF11 
revealed 4 one bp substitutions resulting in 3 aa substitutions.  Comparisons of the strain 
JM and CVI988 MDV US2 sequences revealed a one bp substitution resulting in a one
aa substitution.    
In LORF11 the first aa substitution was alanine to valine at position 57 which both carry 
no charge and are hydrophobic (hydrophobicity index +1.0 and +2.3 respectively) 
(Lehninger et al., 1993).  This probably would not change the orientation of a 
membrane-bound protein, however, as both aa were hydrophobic.  The second 
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substitution identified was threonine to alanine at position 302 which represents a 
change from a hydrogen-bonding hydrophilic molecule to a non- hydrogen bonding 
hydrophobic molecule (Lehninger et al., 1993) which could potentially change the 
affinity of a molecule to water and interfere with the orientation of a membrane-bound 
protein.  Comparison of protein motif scans of the sequenced strain JM and CVI988 
MDV LORF11 revealed the loss of one casein kinase II phosphorylation site motif at aa
position 302 due to this mutation which could impact protein function.  The third 
substitution was proline to leucine at position 780 which denotes a change from a rigid 
hydrophilic aa to a strongly hydrophobic aa with less steric hindrance (hydrophobicity 
index -1.6 and +3.8 respectively) (Lehninger et al., 1993).  This substitution had the 
potential to change the shape and orientation of the LORF11 protein at this site.  As the 
exact structure and function of LORF11 was not fully known at the time of this study it 
can only be speculated as to whether these aa substitutions and the loss of a casein 
kinase II phosphorylation site had any bearing on attenuation in the CVI988 strain.
Comparison of US2 sequence between MDV JM & Rb1b strains and CVI988 strain 
identified one aa substitution of alanine to valine at position 51.  This substitution 
represents a substitution of a mildly hydrophobic aa for a strongly hydrophobic one
(hydrophobicity index +1.8 and +4.2 respectively) (Lehninger et al., 1993).  As the 
fundamental properties of the CVI988 substituted aa were not substantially different 
from the original aa there were probably no changes between the gene product targets of 
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strain CVI988 US2 and strain JM or Rb1b MDV US2.  Comparison of protein motif 
scans of the US2 gene of JM and CVI988 strains also revealed no differences.  
3.11 Knockdown of Viral Gene Expression Using siRNA
The lack of significant changes in cell growth rate following post-transcriptional gene 
targeting of LORF1, LORF3, LORF11, RLORF12, ANTISENSE and MLTI was 
disappointing and could indicate that these genes did not play a role in determining cell 
proliferation.  However, the lack of phenotypic changes seen for in vitro post-
transcriptional targeting could have been due to extraneous factors such as the effects 
produced by gene product knockdown not effecting cell proliferation or that the siRNA 
oligonucleotides used were not effective in knocking down their target.  Transfection 
efficiency also could have played a role in the lack of observed changes in cell growth.   
Transfection rates achieved for MDV transformed chicken lymphoblasts using the 
Nucleofector II transfection system (Amaxa, Lonza) had been reported to be in the 
region of 20-30% with 99% viability by the manufacturer’s online database 
(http://www.lonzabio.com/no_cache/meta/cell-database/cell-details/cell/1149, accessed 
4/10/10) which was somewhat lower than the overall average of 36.71% +/- 14.04% 
calculated in this study.  Variations in transfection rates observed during the study 
appeared to be more dependent on the replicate rather than the transfected siRNA 
oligonucleotide group which indicated that the source of variation was probably not due 
to cytotoxic effects produced by particular siRNA oligonucleotides.  It is tempting to 
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speculate that this could have had an influence on the replicate effect observed in the 
RLORF6 cell growth data, but further studies would be needed for confirmation.  
Transfection rates as high as 75% with an 80% viability have been documented in EBV 
transformed lymphocytes using the Nucleofector transfection system which is regarded 
as one of the most reliable and reproducible methods available for transfecting 
lymphoblastic cell lines (Maurisse et al., 2010).  Reported transfection efficiency and 
viability can vary a great deal between apparently similar cell lines, however, so these 
efficiencies would probably not be reproducible in RPL-1 cells.  Optimization of another 
MDV transformed chicken lymphoblastic cell line, MSB-1, undertaken in our lab by Dr. 
Jeanette Webb, showed a transfection rate of 67% efficiency with a 50% viability using 
Nucleofector program X-001.  These rates could not be reproduced on this program with 
RPL-1 cells transfected with siRNA however so a separate optimization was carried out 
which is detailed in Appendix 3.  After optimizing the RPL-1 cells in our lab as detailed 
in section 2.5.3 the most efficient program identified was A-033 using solution V which 
produced an efficiency of 35.7% and 18.3% viability using the pmaxGFP reporter 
plasmid (Amaxa, Lonza).  These results raised the possibility that the transfection 
efficiency was too low for any effects of siRNA post-transcriptional gene knockdown in 
the transfected cells to be detected in mixed populations with untransfected cells.  A 
second attempt to optimize transfection of RPL-1 cells, undertaken after the siRNA 
transfection studies had been completed, identified another program A-30 that produced 
a 26.8% efficiency and a 96.6% viability which may be useful for increasing transfection 
153
efficiency in future siRNA studies in RPL-1 cells.  The poor transfection and viability 
rates of the RPL-1 cells coupled with the other factors identified above make the finding 
of an increased growth rate in siRNA JM RLORF6 626 transfected cells despite these 
conflicting factors remarkable. 
    
The overlapping nature of RLORF6 and Meq on the L to R strand and 23kDa on the 
complimentary strand makes targeting and measuring expressed levels of one gene 
without measuring or affecting the others very difficult-hence the name ‘Meq loci’.  
Because of the extensive gene overlap in this location conventional PCR and RTqPCR 
were of limited use in assessing gene knockdown as primers specific for one gene would 
also be specific for the overlapping genes and it would not be possible to determine 
relative levels of individual transcripts.  An antibody specific to Meq was kindly made 
available by Dr. Venugopal Nair (Institute of Animal Health, Compton, UK), but no 
antibodies were available specific to 23KdA or RLORF6.  The Meq antibody was used 
for protein immunoblots in some of the follow up studies which will be discussed in 
chapter 4, but relative levels of these 3 genes could not be accurately determined with 
the tools available in the study.  
The results showing an increased RPL-1 cell growth rate following siRNA JM RLORF6 
626 transfection were particularly interesting because post-transcriptional targeting of 
Meq in MDV transformed cell lines had been shown to result in cell death as Meq is 
necessary for the maintenance of latency (Brown et al., 2006).  Therefore any post-
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transcriptional targeting of Meq inadvertently produced by siRNA JM RLORF6 
oligonucleotides would be expected to cause cell death rather than the observed increase 
in cell growth.  Clarification is needed as to why post-transcriptional targeting of 
RLORF6 in these experiments produced a significant increase in cell growth despite the 
substantial background factors of poor transfection rates, poor cell viability and potential 
siRNA cross targeting of Meq.  Future siRNA studies of RLORF6 need to address these 
issues of low cell transfection efficiency and viability in order to decrease the potential 
for error due to the transfection process which would depict a more accurate picture of 
the role that RLORF6 plays in latent MDV infection.  
3.12 Conclusions
Targeting of RLORF6 in the RPL-1 cell line appeared to have a measurable effect on 
RPL-1 cell growth in at least one of the siRNA oligonucleotides used in the transfection 
studies despite complicating factors such as mixed cell populations and poor transfection 
rates.  This unanticipated finding raised several questions such as what was the host cell 
target of RLORF6 in latent and lytic MDV infections and does RLORF6 interact directly 
or indirectly with Meq in latent MDV infections?  Before these questions could be 
addressed though studies should be done to confirm the observed RLORF6 siRNA cell 
growth results were genuine preferably in a 90-100% transfected cell population and to 
ascertain that the RLORF6 siRNA used was both effective and specific against its 
intended target.  Cell lines other than RPL-1, such as Rb1b T cells, could be trialled in 
future studies in an attempt to increase cell transfection rates as they appear to vary 
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substantially between different cell lines.  If higher transfection rates and increased 
viability could be achieved it may be possible to sort transfected and untransfected cell 
populations using methods such as fluorescence activated cell sorting. This approach 
was not tried in the current studies as the observation was made that RPL-1 cells did not 
grow well at low densities and it would not be possible to isolate sufficient numbers of 
cells without multiple replications which were not possible in the timescale of the study.  
Most of the uncharacterised gene product targets in the host cell were still unknown at 
the time of this study, but given the large number of protein changes in the chicken 
genome relative to the number of MDV genes following MDV infection (Ramaroson et 
al., 2008) it is very likely that most MDV genes have multiple targets and functions.   It 
is possible that some of the genes studied that did not produce any measurable 
phenotypic changes when targeted in vitro would effect phenotypic changes when 
targeted in vivo.  Unfortunately in vivo experiments for the uncharacterised genes in this 
study and determination of the molecular targets of RLORF6 were beyond the timescale 
and budget of the current project.
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Chapter 4 – Characterization of MDV RLORF6
Results
4.1 Project Objectives
The objective of the work undertaken in this section was to confirm that the siRNA JM 
RLORF6 oligonucleotides used in the experiments outlined in chapter 3 selectively 
targeted RLORF6.  This was done in two phases:  Firstly performing a dual-reporter 
luciferase assay using the RLORF6 Luc firefly luciferase fusion plasmid co-transfected 
with the pRL-SV40 Renilla luciferase plasmid to confirm that the siRNA RLORF6 
oligonucleotides effectively targeted RLORF6 and secondly using protein 
immunoblotting and gene-specific RTqPCR to confirm that Meq was not co-targeted by 
siRNA RLORF6 JM 524 and 626.  A secondary objective was to determine the 
localization of RLORF6 in the MDV infected cell.  This was undertaken with 
transfection experiments with the pEGFP RLORF6 and pDSRed Meq fusion plasmids 
and analysis using confocal laser microscopy.  
4.2 Determination of siRNA Knockdown of RLORF6 
A key assumption in interpreting the cell growth data in chapter 3 was that the siRNA 
oligonucleotides used were effectively knocking down expression of their target gene.  If 
the oligonucleotides had not effectively targeted their intended gene product then any 
observations regarding their effect on cell growth would be invalid.  In order to validate 
this assumption a dual reporter luciferase assay was used to confirm the effectiveness of 
siRNA JM RLORF6 524 and 626 in reducing post-transcriptional expression of 
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RLORF6.  An N-terminal firefly luciferase fusion plasmid based on the pGL3 plasmid 
vector (Promega) and encoding the MDV strain CVI988 RLORF6 gene (designated 
RLORF6 Luc) was kindly provided by Ola Ali Hassanin (Division of Pathway 
Medicine, University of Edinburgh, UK) for use in the assay.  The pRL-SV40 Renilla
luciferase control reporter vector (Promega) encoded the Renilla luciferase gene and was 
used as the Renilla control plasmid in the assay.  The pGL3 plasmid (Promega) encoded 
the firefly luciferase gene and was used as the luciferase control plasmid.  The full 
protocol used for the dual reporter luciferase assay was detailed previously in section 2.6 




Non-Transfected Control (NTC) Luciferase Background control
RLORF6 Luc + Renilla SV40 RLORF6 Luc w/ no siRNA
RLORF6 Luc + Renilla SV40 + siRNA RLORF6 524 RLORF6 Luc w/ siRNA 
RLORF6 524
RLORF6 Luc + Renilla SV40 + siRNA RLORF6 626 RLORF6 Luc w/ siRNA 
RLORF6 626
RLORF6 Luc + Renilla SV40 + siRNA Control RLORF6 Luc w/ siRNA Control
pGL3 + Renilla SV40 Luciferase Control w/ no siRNA
pGL3 + Renilla SV40 + siRNA RLORF6 524 Luciferase Control w/ siRNA 
RLORF6 524
pGL3 + Renilla SV40 + siRNA RLORF6 626 Luciferase Control w/ siRNA 
RLORF6 626
pGL3 + Renilla SV40 + siRNA Control Luciferase Control w/ siRNA Control
Figure 4.1:  Schematic diagram of dual reporter Luciferase assay experimental design.
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Non-transfected control (NTC) samples were used to calculate a correction factor for 
background luminescence from instrumentation and sample tubes for each data point.  
Readings for both firefly luciferase and Renilla luminescence were taken for each 
sample.  The siRNA JM RLORF6 oligonucleotides 524 and 626 were expected to target 
and degrade the RLORF6 Luc fusion protein which would result in reduced firefly 
luciferase luminescence in treated samples.  Firefly luciferase readings were used as a 
measure of siRNA targeting of RLORF6.  Renilla luciferase produced a luminescence 
distinct from firefly luciferase and was expected to be expressed at a constant rate in co-
transfected cells as siRNA JM RLORF6 oligonucleotides were not designed to target the 
pRL-SV40 plasmid.  Any observed variation in Renilla luciferase luminescence would 
therefore be due to variations in transfection rate.  The Renilla luciferase luminescence 
was used to calculate a correction factor for the firefly luciferase reading to adjust for 
variations in transfection rate which was designated the adjusted luminescence.  The 
primary aim of this experiment was to compare the adjusted luminescence produced in 
CEF cells by co-transfecting with one of the following: siRNA JM RLORF6 524, 
siRNA JM RLORF6 626, siRNA Control or no siRNA and both the RLORF6 Luc and 
pRL-SV40 plasmids.  If the siRNA JM RLORF6 oligonucleotides effectively targeted 
RLORF6 then a reduction in luminescence would occur only in siRNA JM RLORF6 
treated samples and not in siRNA Control or no siRNA samples.  Two control 
experiments were incorporated into the experimental design to determine correction 
factors for the luminescence readings produced by extraneous factors not related to 
siRNA targeting of RLORF6.  The first experimental control was a comparison of 
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samples transfected with RLORF6 Luc and pRL-SV40 (Renilla) with samples 
transfected with siRNA Control, RLORF6 Luc and pRL-SV40 (Renilla) which 
determined the change in measured luminescence produced by transfection with non-
targeting siRNA.  The second control was to duplicate the experiment substituting the 
pGL3 plasmid which encoded only firefly luciferase for the RLORF6 Luc plasmid 
which encoded both firefly luciferase and RLORF6.  This was undertaken to determine 
whether there was any reduction of luminescence attributable to non-specific targeting 
by siRNA JM RLORF6 oligonucleotides.  The effect of siRNA transfection on 
luminescence was determined by comparing cells transfected with siRNA Control 
oligonucleotide and cells transfected only with DNA plasmid.  Non-specific targeting of 
firefly luciferase by siRNA JM RLORF6 would be expected to reduce luminescence in 
the duplicate experiment transfected with pGL3 which did not encode any MDV viral 
genes.  Three repetitions of each experimental group were prepared and the adjusted 
luminescence readings were summarized in figure 4.2.
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Figure 4.2: Averaged results of the dual-reporter luciferase assay for RLORF6.  Percentages 
shown are the reduction of adjusted luminescence compared with samples treated with siRNA 
Control.  
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The results of this experiment (figure 4.2) showed an 89% reduction of adjusted 
luminescence in cells treated with siRNA JM RLORF6 524 over siRNA Control #2.  A 
76% reduction was measured for siRNA JM RLORF6 626.  In CEFs transfected with 
pGL3 instead of RLORF6 Luc there was a non-specific reduction in luminescence of 
32% for siRNA JM RLORF6 524 and a 22% for siRNA JM RLORF6 626.  This was 
compared to the higher percentage of luminescence reduction seen in the RLORF6 Luc 
experiment and the overall targeting efficiency of siRNA JM RLORF6 524 was 
calculated to be 57% and JM RLORF6 626 was 54%.  Percentages were used for this 
comparison rather than absolute luminescence as the overall amount of luminescence 
produced by the pGL3 plasmid was considerably higher than RLORF6 Luc so a direct 
comparison would not accurately represent the differences between the 2 groups. 
4.3 Effect of RLORF6 Knockdown on Meq Expression
Due to the extensive overlap on the same strand of the predicted Meq and RLORF6 
mRNAs (figure 4.3) it was possible that siRNA designed to target RLORF6 could also 
inadvertently target Meq.  If this was correct then the siRNA RLORF6 cell growth study 
data described in chapter 3 would be difficult to interpret as there would be no way to 
determine which gene had affected cell growth.  Two experiments were designed to 
investigate this hypothesis by comparing the levels of Meq gene expression and protein 
in RPL-1 cells transfected with siRNA oligonucleotides targeting either RLORF6 or a 
non-targeting control.  If no significant variations in Meq gene expression or protein 
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synthesis were found then this would be supporting evidence that siRNA JM RLORF6 
oligonucleotides 524 and 626 did not co-target Meq. 
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Figure 4.3: Depiction of the “Meq Loci” in the TRL region of MDV strain CVI988 (GenBank DQ534539.1) showing in the context in the 
genome of the location of the Meq gene specific primer (depicted by GS and shaded lavender, bp 5286-5301), siRNA RLORF6 JM 
oligonucleotides 524 (depicted as 1, bp 5391-5415) and 626 (depicted as 2, bp 5289-5313) which are both shaded in blue and the region 
amplified by the RTMeq primer set (shaded pink, bp 5911-6013).  Arrows indicate the direction of transcription.  Overlapping regions of the 
Meq gene and the RLORF6 gene are clearly visible.  Homologous regions to those shown above were identified in the IRL region of MDV 
strain JM/102W (GenBank DQ534539.1).  Diagram was adapted from GenBank online material accessed 11/9/10 (Benson et al., 2008).  
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4.3.1 RTqPCR Studies Utilizing a Directional cDNA Template for 
Determination of Meq Expression Levels
PCR and RTqPCR assays were used to analyze whether there was any variation in 
expression of Meq using a cDNA template made with a directional primer specific to the 
RLORF6 predicted mRNA (designated directional primer).  No suitable primers could 
be identified in the region that did not overlap the Meq predicted mRNA as well so the 
directional primer was selected in the extreme 3’ region of the Meq/RLORF6 genes as 
close as possible to the non-overlapping RLORF6 region using the JM/102W strain 
MDV IRL sequence (Spatz and Silva, 2007b).  The primer (5’-CGA ATA CAA GGA 
ATC C-3’) which overlapped the Meq/RLORF6 coding regions by approximately 80 bp 
was chosen with the assistance of Dr. Robert Dalziel (The Roslin Institute, University of 
Edinburgh, UK).  Figure 4.3 shows the relative location in the MDV genome of the 
directional primer (homologous region in MDV strain CVI988 shaded yellow) and the 
region of the genome amplified by the Meq primer set (described in table 3.4 and shaded 
red).  The PCR product amplified by the Meq primer set was located approximately 700 
bp upstream from the directional primer and would only produce a full length 102 bp 
PCR product for the Meq and MDV ORF 05.2 genes.  Since the directional cDNA 
template contained only the Meq and RLORF6 genes then only Meq would be amplified 
in a PCR or RTqPCR assay.  The RLORF6 gene would not be expected to produce a 
PCR product as there would only be one primer site present in the RLORF6 gene rather 
than the forward and reverse primer site required for a full-length PCR product.  
Therefore the Meq/RLORF6 specific directional cDNA (designated directional cDNA) 
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used as a template in a PCR or RTqPCR using the Meq primer set would be specific for 
Meq only.
To obtain the RNA samples used to synthesize the directional cDNA RPL-1 cells were 
transfected in triplicate (section 2.5.3) either with siRNA RLORF6 JM 524, siRNA 
RLORF6 JM 626 or siRNA Control #2 (Ambion, Invitrogen) as part of the third 
repetition of the cell growth studies in RPL-1 cells previously described in section 3.5.  
Cell counts were carried out (section 2.4.4) at 24, 48 and 72 hours post-transfection and 
showed an increase in cell growth of the siRNA JM RLORF6 transfected cells over the 
siRNA Control transfected cells which was illustrated previously in figure 3.21a.  RNA 
was extracted (section 2.1.3) from cells harvested at 48 and 72 hours post-transfection 
and used as a template to prepare the directional cDNA as follows:  100 ng of directional 
primer was used for each AffinityScript Multiple Temperature cDNA Synthesis Kit 
reaction (Stratagene) in the place of oligo (dT) primers used in non-specific cDNA 
reactions.  The full protocol for synthesis of first strand cDNA was described previously 
in section 2.1.5.    The resulting directional cDNA was then used as a template in two 
PCR assays (section 2.1.8), using primer sets specific for either RLORF11 or Meq 
described previously in figure 3.4.  The RLORF11 primer set was selected as it had been 
shown to be effective in previous PCR assays (figure 3.11) and the region of the MDV 
genome amplified was approximately 5.3 kb downstream from the Meq and RLORF6 
genes and was not expected to be represented in the directional cDNA template.  The 
conditions used for the PCR reactions were as follows: 2 ng of template, 30 pg of each 
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primer, 57ºC annealing temperature and 40 cycles as described in section 2.1.8.  A 
higher number of PCR cycles were selected than the standard 25-30 as the aim of these 
reactions were to demonstrate the presence of a PCR product and the high cycle number 
would maximize amplification.  The resulting PCR products were analyzed using a 2% 
agarose gel (section 2.1.13).  The results confirm that the cDNA was specific to 
Meq/RLORF6 as an approximately 100 bp band was seen for all the Meq primer 
samples (figure 4.4a) and no bands were present for the RLORF11 primer samples 
(figure 4.4b).  
To extend the PCR findings RTqPCR was undertaken as described in section 2.1.10 
utilizing the directional cDNA samples as templates and the Meq primer set (table 2.2 
and figure 4.4) to more accurately determine the variation in Meq expression.  A second 
RTqPCR assay was also performed using primers specific for chicken -actin (table 2.1) 
and the results were normalized against the 75th percentile of the housekeeping gene as 
described in section 2.1.10 to correct for RNA and cDNA variations.  The normalized 
results were statistically analyzed using a Mann-Whitney test for non-parametric data as 
described in section 2.8 and the p-values are shown in figures 4.5a and 4.5b.  None of 
the results were deemed to be statistically significant as all of the p-values were greater 
than 0.05 which represents the 95% confidence interval criteria for significance.  Meq 
expression at 72 hours was notably lower than at 48 hours in all the experimental 
groups, but as the variability between the replicates was high no conclusions could be 
drawn as to the significance of these findings.  
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Figure 4.4a:  PCR results for Meq/RLORF6 specific cDNA using Meq primer set and analyzed 
on a 2% agarose gel.  Bands at approximately 100 bp were identified for every sample which 
indicated Meq amplification.  Ladder used was 2-log DNA ladder (New England Biolabs).
Figure 4.4b:  PCR results for Meq/RLORF6 specific cDNA using RLORF11 primer set and 
analyzed on a 2% agarose gel.  No bands were identified indicating no amplification of 
RLORF11.  Ladder used was 2-log DNA ladder (New England Biolabs).
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Figure 4.5a:  RTqPCR data from gene-specific Meq/RLORF6 cDNA at 48 hours.  Raw data was 
normalized against the 75th percentile of the housekeeping gene Chicken -Actin.  Statistical 
analysis was done using a Mann-Whitney test comparing siRNA RLORF6 JM 524 & 626 with 
siRNA Control #2.
Figure 4.5b:  RTqPCR data from gene-specific RLORF6 cDNA at 72 hours.  Raw data was 
normalized against the 75th percentile of the housekeeping gene Chicken Actin.  Statistical 
analysis was done using a Mann-Whitney test comparing siRNA RLORF6 JM 524 & 626 with 
siRNA Control #2.  Note that y-axis scale is 5-fold less than figure 4.5a.
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4.3.2 Protein Immunoblotting Studies to Determine Meq Protein Levels
The results of the previous experiment did not show clear evidence of reduction in Meq 
expression between the experimental groups.  These findings were encouraging, but 
were not conclusive.  In an attempt to expand on these results an experiment was 
designed to assess whether Meq protein synthesis was affected by transfection of siRNA 
targeting RLORF6 in RPL-1 cells.  Dr. Venugopal Nair (Institute of Animal Health, 
Compton, UK) kindly provided an antibody to the Meq protein for these studies (Meq 
Monoclonal Mouse Anti-Meq FD7, described in section 2.3.3).  A protein immunoblot 
was performed using the antibody to Meq protein to measure Meq protein produced in 
RPL-1 cells transfected with either siRNA JM RLORF6 524, siRNA JM RLORF626 or 
siRNA Control oligonucleotides.  
Three experimental groups of RPL-1 cells in log phase growth were prepared and 
transfected in triplicate as previously described (section 2.5.3) with SiGLO red 
(Dharmacon, Thermo Fisher Scientific) and 100 pmol of one of the following:  siRNA 
JM RLORF6 524, siRNA JM RLORF6 626 or siRNA Control #2.  Full descriptions of 
these siRNA oligonucleotides can be found in section 3.5.  Aliquots of cells were taken 
at 24 hours to determine transfection efficiency as described in section 2.5.3. Figure 4.6
shows the transfection efficiency results which varied from 8.5 to 29.9%.  This was low 
but within the general range of transfection rates reported previously in chapter 3.  One 
replicate from each experimental group was harvested at 24, 48 and 72 hours, washed 
two times in SPBS and stored in Western Blot Sample Buffer at -80ºC (section 2.10.2) 
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in preparation for protein immunoblotting which was carried out as detailed in section 
2.3.  Figure 4.7 shows the resulting protein blot comparing Meq expression levels in 
RPL-1 cells transfected with either non-targeting siRNA Control, siRNA JM RLORF6 
524 or siRNA JM RLORF6 626 at 24, 48 and 72 hours.  No quantification of the results 
was possible but the intensity of the band was assumed to be indicative of the relative 
amount of Meq protein present.  A common source of error in interpreting protein 
immunoblots is unequal loading of protein samples in the acrylamide gel which can 
result in variable intensity of immunoblot bands independent of antibody targeting.  The 
amounts of protein in each lane of the gel appeared approximately equal (figure 4.8) 
when treated with coomassie stain as described in section 2.3.1 to visualize total protein.  
The assumption was made that equal amounts of sample protein were loaded into the 
immunoblot protein gel based on these results and therefore any differences in intensity 
of the immunoblot bands were due to variable amounts of Meq protein.  Meq protein 
bands of samples treated with siRNA JM RLORF6 524 & 626 appeared less intense than 
cells transfected with siRNA Control at 24 hours indicating a degree of reduction of 
Meq protein in the siRNA JM RLORF6 treated samples compared to the siRNA Control 
samples.  No obvious differences were noted between the immunoblot bands at 48 and 
72 hours post-transfection.  
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Figure 4.6:  Transfection efficiency calculated at 24 hours for RPL-1 cells transfected with either 
RLORF6 JM 524 siRNA, RLORF6 JM626 siRNA or Control #2 siRNA and analyzed by protein 
immunoblotting with a MDV Meq antibody as described in Section 4.2.2.
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Figure 4.7:  Protein immunoblot for Meq expression (39 kDa) in RPL-1 cells transfected with a 
negative control siRNA, RLORF6 siRNA 524 or RLORF6 siRNA 626 at 24, 48 and 72 hours 
post-transfection.   Antibodies used for protein blotting were Meq Monoclonal Mouse Anti-Meq 
FD7 (Dr. Venugopal Nair) (primary) and Polyclonal Rabbit Anti-mouse Immunoglobulins HRP 
(Dako Cytomation) (secondary).  The proteins were visualized using chemiluminescence 
(Chemiglow West, Alpha Innotech) and photographed 3 minutes post-reaction. 
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Figure 4.8:  Coomassie stained protein gel with sample loading as in figure 5.5 which shows 
approximately equal loading of lanes with protein sample.   The Meq protein size is 
approximately 39-44 kDa as it exists in several different dimers.  The protein ladder used in far 
left lane was Pre-stained Protein Marker, Broad Range (7-175 kDa) (New England Biolabs).
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The interpretation of this experiment was that transfection of siRNA JM RLORF6 
oligonucleotides 524 and 626 appeared to reduce Meq protein expression at 24 hours 
post-transfection but not at 48 or 72 hours.  The protein immunoblot results were 
consistent with the results of the directional cDNA RTqPCR discussed previously 
(section 4.2.1) which found no significant differences in Meq gene expression between 
the siRNA RLORF6 and control siRNA groups at 48 or 72 hours post-transfection.  
Both of these findings appeared to disprove the hypothesis outlined previously in section 
4.2 that siRNA designed to target RLORF6 could inadvertently target Meq; however a 
definite conclusion could not be drawn from these studies alone due to the high 
variability observed between replicates.   
4.4 Determination of RLORF6 Cellular Localization using Confocal Laser 
Microscopy
As no data was available in the literature regarding the function of RLORF6 it was 
decided that determining its host cellular localization would be useful in defining its 
function.  An N-terminal EGFP fusion plasmid encoding the MDV strain Rb1b RLORF6 
gene was kindly provided by Ola Ali Hassanin (Division of Pathway Medicine, 
University of Edinburgh, UK) for use in confocal laser microscopy studies to determine 
the cellular localization of RLORF6.  The fusion plasmid was designated pEGFP Rb1b 
RLORF6 and was based on a pEGFP-C1 (Clontech) plasmid backbone.  The pEGFP-C1 
plasmid (GenBank U55763) encodes a red-shift variant of the wild-type green 
florescence (designated EGFP) optimized for brightness and high expression in 
mammalian cells (Cormack et al., 1996).  To prepare the pEGFP Rb1b RLORF6 
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plasmid Ola Ali Hassanin had inserted a GATEway® cassette (Invitrogen) encoding the 
strain Rb1b MDV RLORF6 gene into pEGFP-C1 at the multiple cloning site (MCS) 
between the EGFP and SV40 Poly A coding sequences. Genes cloned into the pEGFP-
C1 plasmid at the MCS would be over expressed as a fusion protein in transfected cells 
as long as they had been cloned in the same reading frame as EGFP (Clontech).  The 
resulting expression of fusion protein would be visible under UV green light and this 
feature was exploited in order to determine the cellular localization of RLORF6.  
CEF cells were prepared and grown to 70-80% confluence on glass coverslips as 
previously described (section 2.4.8) and transfected using electroporation (section 2.5.2) 
with either 1 or 2 g of the pEGFP Rb1b RLORF6 plasmid or the pEGFP-C1 control 
plasmid.  Three replicates were prepared for each of the four experimental groups.  One 
replicate from each experimental group was harvested at 24, 36 and 48 hours post-
transfection, stained using the nuclear stain TO-PRO-3 iodide (Suzuki et al., 1997) and 
fixed on lysine-coated glass microscope slides as previously described in section 2.7.1.  
The slides were photographed using a Leica Confocal Laser Scanning Microscope at 
either 63x or 100x power at the Impact Imaging Facility, University of Edinburgh with 
the assistance of Mrs. Trudi Gillespie.  
The control pEGFP-C1 transfected cells showed a diffuse distribution of the EGFP 
protein in the cytoplasm and occasionally also in the nucleus (figure 4.9).  The EGFP 
CVI988 RLORF6 fusion protein was clearly visible in the cell nucleoplasm, but not the 
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nucleolus at 24, 36 and 48 hours post-transfection (36 hour images shown in figure 
4.10).  The experiment was repeated using suspension Rb1b T Cells instead of adherent 
CEFs according to the protocol described in section 2.7.2.  Figure 4.11 shows the EGFP 
RLORF6 fusion protein was also visible in the Rb1b T cell nucleoplasm but not the 
nucleolus although the visualization was not as clear as in the CEF cells due to the large 
irregular nucleus present in transformed lymphoblasts.  The EGFP RLORF6 fusion 
protein was visible from 24 hours post-transfection onwards in all cell types tested.  No 
differences in cell viability or signal intensity were observed between cells transfected 
with either 1 g or 2 g of DNA.  Some degree of cytotoxicity and nuclear degradation 
was observed in pEGFP RLORF6 transfected cells from 48-72 hours post-transfection.
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Figure 4.9: Series of confocal laser microscopy images of CEF cells 36 hours post-transfection 
with pEGFP-C1 control plasmid at 63x objective.  Views depicted:  1) UV green filter showing 
EGFP control protein cytoplasmic localization  2)  DAPI filter showing TO-PRO-3 iodide nuclear 
stain  3)  Overlay image showing views 1 & 2  4)  UV green filter showing EGFP control protein 
cytoplasmic and nuclear localization  5)  DAPI filter showing TO-PRO-3 iodide nuclear stain.  6)  
Overlay image showing views 4 & 5.  Photos were taken at the Confocal Imaging Facility, 
University of Edinburgh with the assistance of Trudi Gillespie.
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Figure 4.10: Series of confocal laser microscopy images of CEF cells 36 hours post-
transfection with pEGFP Rb1b RLORF6 plasmid at 63x objective.  Views depicted:  1) UV green 
filter showing pEGFP RLORF6 fusion protein nucleoplasm localization  2) DAPI filter showing 
TO-PRO-3 iodide nuclear stain  3)  Overlay image showing views 1 & 2  4)  UV green filter 
showing pEGFP Rb1b RLORF6 control protein nucleoplasm localization  5)  DAPI filter showing 
TO-PRO-3 iodide nuclear stain  6)  Overlay image showing views 4 & 5.  Photos were taken at 
the Confocal Imaging Facility, University of Edinburgh with the assistance of Trudi Gillespie.
180
Figure 4.11: Series of confocal laser microscopy images of Rb1b T cells 48 hours post-
transfection with pEGFP Rb1b RLORF6 plasmid at 100x objective.  Views depicted:  1) UV 
green filter showing pEGFP RLORF6 fusion protein localization  2) White light showing cell 
outlines  3)  DAPI filter showing TO-PRO-3 iodide nuclear stain  4)  Overlay image showing 
views 1-3.  Photos were taken at the Confocal Imaging Facility, University of Edinburgh with the 
assistance of Trudi Gillespie.
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Due of the proximity of RLORF6 in the genome to Meq and since both genes appear to 
be expressed in latency it is possible that the two viral proteins may interact in the cell.  
To clarify whether this was the case a co-localization experiment was designed for Meq 
and RLORF6.  An N-terminal fusion plasmid based on the pDSRed (Clontech) plasmid 
backbone  encoding the strain Rb1b MDV Meq gene was kindly provided by Ola Ali 
Hassanin (Division of Pathway Medicine, University of Edinburgh, UK) for 
RLORF6/Meq co-localization studies.  The pDSRed plasmid encodes a red fluorescent 
protein first isolated from Discosoma sp. marine corals and fluoresces red at wavelength 
558-583 nm (Matz et al., 1999) which is spectrally distinct from EGFP which fluoresces 
green at 488-507 nm (Cormack et al., 1996).  Therefore both pEGFP-C1 and pDSRed 
fusion plasmids can be co-transfected into cells  and the encoded fusion proteins would 
be distinct using different filters in UV confocal laser microscopy.  
CEF cells were transfected in triplicate with one of the following:  2 g p-EGFP-C1 
control, 2 g pEGFP Rb1b RLORF6 or 1 g pDSRed Meq and 1g pEGFP Rb1b
RLORF6 as described in section 2.7.2.  Each experimental group was harvested, fixed 
and photographed at 24, 36 and 48 hours post-transfection as previously described.  Both 
pEGFP RLORF6 and pDSRed Meq appeared to localize to the nucleus from 24 hours in 
co-transfected cells, but the Meq fusion protein was apparent in both the nucleoplasm 
and nucleolus whereas the RLORF6 fusion protein was visible only in the nucleoplasm.  
In some of the co-transfected cells the pDSRed Meq fusion protein was also visible 
diffusely in the cytoplasm.  When the two plasmids were co-transfected a very marked 
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cytotoxic effect was observed with significant nuclear degradation and cell death 
occurring in some cells anywhere from 33-48 hours post-transfection (figure 4.12 and 
4.13).  This effect was not observed in cells transfected with pEGFP-C1 or pEGFP Rb1b 
RLORF6 even though they were transfected with an equivalent amount of plasmid DNA 
(2g).  
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Figure 4.12:  Series of confocal laser scanning microscopy images depicting two CEF cells co-
transfected with pEGFP Rb1b RLORF6 plasmid (green fluorescent) and pDSRed Meq plasmid 
(red fluorescent) and stained with TO-PRO-3 iodide (DAPI, nuclear stain) at 100x objective.  
C = cytoplasm, Nu = Nucleoplasm and No = Nucleolus.  Image series taken 33 hours post-
transfection at the Confocal Imaging Facility, University of Edinburgh with the assistance of Trudi 
Gillespie.
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Figure 4.13:  Series of confocal laser microscopy images of CEF cells co-transfected with 1 g 
pEGFP Rb1b RLORF6 plasmid and 1 g pDSRed Meq plasmid at 63x objective.  Note that 
some degree of nuclear degradation is apparent.  Views depicted:  1) UV red filter showing 
pDSRed Meq fusion protein diffuse localization  2) UV green filter showing pEGFP Rb1b 
RLORF6 control protein nucleoplasm localization  3)  DAPI filter showing TO-PRO-3 iodide 
nuclear stain  4)  Overlay image showing views 1-3  Photos were taken 33 hours post-




The efficacy of the siRNA JM RLORF6 oligonucleotides 524 and 626 were confirmed 
using a dual reporter luciferase assay which showed a reduction in luminescence of 57% 
for siRNA JM RLORF6 524 and 54% for siRNA JM RLORF6 626 when readings were 
adjusted to correct for variation in transfection rates, background luminescence and non-
specific targeting of siRNA oligonucleotides.  These results all supported the assumption 
that siRNA JM RLORF6 oligonucleotides were effective and specifically targeted 
RLORF6.  
As the RLORF6 and Meq genes extensively overlap in the MDV genome it was 
necessary to confirm that the siRNA JM RLORF6 specific oligonucleotides 524 and 626 
did not inadvertently cross-target the Meq gene in order to support the finding that post-
transcriptional targeting of RLORF6 using siRNA resulted in an increased cell growth 
rate in vitro (section 3.5).  cDNA specific to both RLORF6 and Meq was prepared using 
RNA isolated from RPL-1 cells 48 and 72 hours post-transfection as part of the third 
repetition of the RLORF6 cell growth studies which were presented previously (figure 
3.22c). This was used in a RTqPCR assay with primers specific to Meq only.  The 
results showed no significant differences in Meq expression between siRNA Control and 
siRNA JM RLORF6 oligonucleotides 524 or 626 at the 95% confidence interval (48 
hour p=0.0809/0.0809 and 72 hours p=1.00/0.1904 respectively).  Protein 
immunoblotting utilizing an antibody specific to Meq showed a small reduction in Meq 
protein expression in RPL-1 cells transfected with siRNA JM RLORF6 oligonucleotides 
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524 and 626 compared to siRNA Control at 24 hours but not at 48 or 72 hours post-
transfection.  
Confocal laser microscopy studies in CEF and Rb1b T cells utilizing a pEGFP RLORF6 
fusion plasmid showed localization of RLORF6 in the nucleoplasm but not the 
nucleolus.  A second fusion plasmid pDSRed Meq was also used in co-localization 
studies and appeared to localize mostly to the nucleus, but the interpretation of these 
results were complicated by a marked cytotoxic effect in CEF cells. 
Discussion
4.6 Introduction
The significant difference in growth rate (p=0.0094) found in RPL-1 cells 72 hours post-
transfection with oligonucleotide siRNA JM RLORF6 626 compared to a siRNA 
Control #2 reported in the previous chapter suggested that MDV RLORF6 may play a 
role in regulating cell growth rate in vitro but clarification was required before any final 
conclusions could be made as the RLORF6 ORF overlapped with other ORFs in the 
Meq loci and the siRNA oligonucleotides designed to target RLORF6 may have also 
inadvertently targeted one or more of the overlapping ORFs as they shared portions of 
the same sequences (figure 4.3). Additional experiments were also necessary to confirm 
that the cell growth results found were due to the actions of the siRNA oligonucleotides 
and not other extraneous factors.  
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4.7 Determination of siRNA Knockdown of RLORF6 
The dual reporter Luciferase assay demonstrated a >75% reduction of RLORF6 
expression in cells treated with siRNA JM RLORF6 524 & 626 in two independent 
repetitions of the experiment.  These findings were interpreted as confirmation that the 
siRNA JM RLORF6 oligonucleotides were effective in targeting RLORF6 post-
transcriptional expression.  However, a small reduction in luminescence was observed 
for the siRNA JM RLORF6 transfected groups in the control experiment utilizing pGL3 
rather than the RLORF6 Luc plasmid.  As the pGL3 plasmid and CEF cells should not 
encode either MDV or the MDV RLORF6 gene it was determined that there was some 
unintended cross-targeting of firefly luciferase by the siRNA JM RLORF6 
oligonucleotides independent of post-transcriptional targeting of RLORF6.  In an 
attempt to correct the siRNA efficiency results for this non-specific cross-targeting the 
percentage reduction in firefly luciferase luminescence observed in cells transfected with 
pGL3 was subtracted from the luminescence results of cells transfected with the 
RLORF6 Luc fusion plasmid.  Even with this correction there was a >50% efficiency 
calculated for both the siRNA JM RLORF6 oligonucleotides indicating that they were 
effective against their intended target gene RLORF6.   
4.8 Effect of RLORF6 Knockdown on Meq Expression
The overlapping nature of the multiple genes in the Meq loci (figure 4.3) made it very 
difficult and complex to confirm siRNA targeting of one gene without inadvertently 
measuring the expression of other overlapping genes.  The multi step approach utilizing 
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directional cDNA followed by RTqPCR utilizing a Meq primer set was laborious but 
appeared to be effective for detecting Meq gene expression.  The normalized results for 
the directional cDNA RTqPCR experiments in figure 4.5a superficially appeared to 
show some increase of Meq expression in cells treated with siRNA JM RLORF6 524 & 
626 over the siRNA Control at 48 hours (p = 0.0809) or 72 hours (p=1.0000 & 0.1904 
respectively) post-transfection, but these differences did not meet the criteria for 
significance.  This was probably due to a genuine lack of cross-targeting, however it can 
not be ruled out that the lack of significance was due to the low number of replicates 
(n=3) as well as a high degree of variability observed between the replicates.  The 
observation of replicate variability could be random or it could be due to variations in 
transfection efficiency which were discussed previously in section 4.5.  For definitive 
proof multiple replicates of the experiment would be necessary to give sufficient data for 
robust statistical analysis, but this was beyond the timescale and budget of the study.  
Because these results were not conclusive the decision was made to analyze the levels of 
Meq protein present to further assess siRNA targeting specificity.  
The results for protein immunoblotting showed a small degree of Meq protein reduction 
in the siRNA JM RLORF6 524 and 626 samples compared to the scrambled control 
siRNA samples at 24 hours but not at 48 or 72 hours.  These findings were interpreted as 
the presence of a limited amount of cross-targeting of Meq and the subsequent reduction 
of Meq protein by the siRNA RLORF6 oligoribonucleotides at 24 hours but not at 48 or 
72 hours post-transfection.  The reason why a reduction in Meq protein was observed 
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only at 24 hours but not at 48 or 72 hours could not be conclusively determined.   
Further assessment of knockdown efficiency utilizing additional means such as northern 
blots to assess relative amounts of Meq and RLORF6 mRNA was considered but not 
undertaken due to the timescale of the project.  
4.9 Determination of RLORF6 Cellular Localization using Confocal Laser 
Microscopy Studies
The confocal laser microscopy studies comparing the pEGFP-C1 control plasmid with 
the pEGFP-C1 CVI988 RLORF6 fusion plasmid showed an apparent nuclear 
localization of the RLORF6 fusion protein in both CEF and Rb1b T cells at 24, 36 and 
48 hours post transfection.  Some of the transfected cells fixed at 24 hours additionally
showed a nodular cytoplasmic localization of RLORF6.  This was most likely due to
cytoplasmic synthesis of the RLORF6 protein with subsequent export and sequestration 
to the nucleoplasm, but further studies would be required before any definitive 
conclusions could be reached.  Localization of the pEGFP-C1 control EGFP was 
observed in some cell nuclei as well as the expected cytoplasmic localization which 
could complicate interpretation of these results.  Nuclear localization of EGFP had been 
documented in the literature (Seibel et al., 2007) and the observation of some diffuse 
nuclear localization of small EGFP fusion proteins such as RLORF6 in isolation would 
not usually be sufficient for conclusive proof of nuclear localization.  It is important to 
note that EGFP RLORF6 strongly localized only to the nucleoplasm which was very 
different to the diffuse localization pattern seen in the pEGFP-C1 plasmid controls, and 
therefore the observation of nuclear localization was most likely genuine.  After 48 
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hours it was noted that in cells transfected with pEGFP RLORF6 the nucleus became 
increasingly degraded in proportion to the amount of RLORF6 sequestration.  Degraded 
cell nuclei did not have a clearly defined shape and in many cells the nucleus appeared 
to have ruptured and nuclear material was seen in the cytoplasm in images taken with 
the DAPI filter which illuminates the TO-PRO-3 iodide nuclear stain.  Cells displaying 
these changes were obviously not healthy and were probably dead or dying when the 
slide was fixed.  Interpretation of gene overexpression studies can be difficult as the 
gene product is often expressed at high levels and without normal degradation or in the 
context of any regulation that would be present in natural infections.  It is possible that 
the cytotoxic effects observed in pEGFP RLORF6 and pDSRed Meq transfected cells 
were due to the lack of context and regulation provided in natural MDV infections, but 
this could not be confirmed without further experiments which were beyond the 
timescale of the project.  It was noted that the cytotoxic effect was much more marked in 
cells transfected with the pDSRed Meq plasmid with nuclear degradation being noted
from 24 hours post-transfection rather than 48-72 hours observed in pEGFP RLORF6.  
This could have been due to overexpression effects as outlined above but other factors 
such as backbone plasmid cytotoxicity could not be ruled out.  The pDSRed plasmid 
vector was originally intended to be included in these transfection studies in order to 
investigate the possibility of backbone plasmid cytotoxicity but sufficient quantities of 
plasmid DNA for control studies could not be obtained in the timescale of the 
experiment.  This was due to the transformed E.coli bacteria used to prepare the pDSRed 
plasmid clone yielding very low amounts of plasmid DNA that was of poor quality.   In 
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any future repetitions of this experiment it would be worthwhile to include a control 
group transfected only with the pDSRed backbone plasmid in order to rule out backbone 
plasmid cytotoxicity.
4.10 Conclusions
The results of the directional cDNA RTqPCR and protein immunoblotting achieved the 
objective of assessing whether there was any cross-targeting of Meq by siRNA JM 
RLORF6 524 and 626 oligonucleotides.  Both experiments showed no significant 
differences in Meq protein expression at 48 or 72 hours post-transfection.  An 
unquantifiable reduction in Meq protein was seen at 24 hours only in the protein 
immunoblotting experiments.  As the significant differences in the cell growth studies 
outlined in chapter 4 were measured at 72 hours post-transfection the assumption was 
made that there was no cross-targeting of Meq by the siRNA JM RLORF6 
oligonucleotides at the time of the increased cell growth observation.  
The confocal laser microscopy studies also achieved their objectives by demonstrating 
that RLORF6 localizes in the cell nucleoplasm but not the nucleolus.  Meq also appeared 
to localise to the nucleus in co-transfection studies which correlates with prior studies 
demonstrating localization of Meq to the nucleus (Anobile et al., 2006). These findings 
indicate that the RLORF6 gene product and Meq localize to the cell nucleus making it 
theoretically possible for them to interact although much more detailed biological 
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studies would have to be undertaken for confirmation which was beyond the timescale 
of the current study.
Ideally a dual-reporter luciferase assay would have been undertaken for every gene 
screened in chapter 4, but due to timescale and the availability of luciferase fusion 
plasmids the decision was made to screen only RLORF6 as it was the gene identified 
with significant differences in cell growth rates.  The results of the RLORF6 dual 
reporter luciferase assays supported the hypothesis that the siRNA JM RLORF6 
oligonucleotides effectively targeted RLORF6 and therefore could be expected to reduce 
gene expression.  The findings in chapter 4 for RLORF6 were supported by these 
experiments and lent proof to the assumption that the siRNA JM RLORF6 
oligonucleotides used in these experiments were both effective and target-specific.
193
Chapter 5 – Final Summary and Future Work
The objective of these studies was to investigate the function of previously
uncharacterised genes during the MDV life cycle (chapters 3 and 4).    
Work described in this thesis used siRNA techniques to investigate the function of 
selected uncharacterised genes during the MDV life cycle.  It is established that certain 
well-characterised genes such as Meq play a large role in determining the outcome and 
establishment of latent infections in MDV, but relatively little is known about the role of 
other genes expressed during latent infection, many of which are unique to MDV.  It 
seems logical to assume that genes expressed during latency have a function.  This study 
focused on screening an initial list of 15 genes that were deemed under-characterised
and interesting (section 1.3) for expression in latent and lytic MDV infections using 
several different cell line models (section 3.3).  Out of the 15 genes screened for 
expression LORF1, LORF3, LORF11, LORF12, ANTISENSE, US2, MLTI, RLORF11, 
RLORF12, 23kDa and RLORF6 were all found to be expressed in MDV latently 
infected RPL-1 cells.  siRNA oligonucleotides were designed and obtained for post-
transcriptional gene targeting for the LORF1, LORF3, LORF11, ANTISENSE, MLTI, 
RLORF12 and RLORF6 genes as the timescale and budget of the project did not allow 
for screening of all the latently expressed genes identified.  siRNA transfection studies 
with RPL-1 cells were undertaken for each of these genes incorporating a transfection 
marker and measuring cell growth rate as the phenotypic marker (chapter 3).  The 
control group for each of these experiments was RPL-1 cells transfected with a non-
targeting siRNA oligonucleotide.  Only the RLORF6 gene was found to affect the cell 
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growth rate in one of the two oligonucleotides tested (adjusted p=0.0094, General Linear 
ANOVA).  None of the other targeted genes analyzed appeared to change cell growth 
parameters compared with the control group in the MDV-transformed latent cell lines 
tested (Chapter 3).  Confirmation of siRNA targeting efficacy and specificity was 
undertaken for RLORF6 (chapter 4).  The timescale of the project did not allow for 
confirmation of siRNA efficacy for oligonucleotides that did not produce any effect on 
growth rate in transformed cells.  Before any conclusions could be drawn regarding the 
effect of post-transcriptional targeting of these genes on growth rate in RPL-1 cells it 
would be necessary to confirm the efficacy of the siRNA oligonucleotides used for each 
gene with a dual-reporter luciferase assay (section 2.6). It is important to note that the 
reason no effect was observed in all but RLORF6 could be due to other factors such as 
inefficient gene targeting by the siRNA or low transfection rates instead of the function 
of the intended target gene not affecting cell growth rate in vitro.  The finding that post-
transcriptional targeting of RLORF6 positively affected cell growth (chapter 3 and 4) 
was unexpected as its location in the genome overlapping Meq, whose knock down had 
been shown to decrease cell growth rate in latent MDV infections (Brown et al., 2006).  
Analysis using confocal laser microscopy confirmed that RLORF6 localizes to the 
nucleus similar to Meq (chapter 4), which could be consistent with a regulatory gene.    
To continue the work in this study characterizing RLORF6 it would be desirable to
repeat the cell growth experiments outlined in chapter 4 with sufficient repetitions to 
give statistics that are more robust in a population of 90-100% transfected cells.  This 
would confirm whether the observed increase in cell growth when RLORF6 was 
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targeted in a partially-transfected latent cell population was due only to the effects of 
siRNA knockdown of the targeted gene.  The transfection efficiencies reported in 
chapters 4 and 5 were relatively low (<35%) and not consistent between groups or 
repetitions compared to the high transfection efficiencies reported in some transformed 
lymphocytic cell lines using similar methods (Maurisse et al., 2010).  One method of 
obtaining a completely transfected cell population would be to either transfect cells with 
a fluorescent transfection marker and isolate transfected cells 24-36 hours post-
transfection utilizing Fluorescence-activated cell sorting (FACS).  It might also be 
worthwhile to assess the effect of post-transcriptional targeting of RLORF6 on cell 
growth rate in other MDV transformed cells to confirm that the growth rates observed
were not exclusive to RPL-1 cells.  An assessment of RLORF6 activity during lytic 
infection could be done by transfecting CEF or DF-1 cells with siRNA followed by 
infection with MDV or co-transfection with MDV BAC and assess the effect on cell 
growth rate and viral plaque numbers.  This would help to clarify whether RLORF6 has 
a similar function in latent and lytic infection.  Construction of a double hairpin 
miRNA30-like plasmid expressing siRNA sequences targeting RLORF6 in a lentiviral 
plasmid similar to pRFPRNAiC Meq T1/T14 and making stable cell lines for testing in 
vitro would be another method of generating a population of cells all carrying siRNA 
targeting RLORF6.  This could be used to generate transgenic chickens allowing further 
studies on the function of RLORF6 in vivo if it were deemed worthwhile.  All of these 
methods would further characterize RLORF6 and clarify issues related to poor 
transfection rates but they were beyond the timescale of this project.  The definitive 
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function of MDV RLORF6 remains unknown at this time, but this study concluded that 
the RLORF6 gene product in both attenuated and very virulent MDV strains localizes to 
the nucleus but not the nucleolus.  Targeting of the RLORF6 gene product using siRNA 
in RPL-1 cells appears to increase cell growth.  These findings and the location of 
RLORF6 in the ‘Meq loci’ region of genome, associated with latent and transforming 
infection (Parcells et al., 2003), could be consistent with a gene regulating 
transformation between latent and lytic infection.  While this project could not prove 
that RLORF6 was involved with the regulation of cell growth, it introduced the 
possibility that it may have a regulatory effect on cell growth distinct from Meq and 
further study would be warranted.  
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Appendix 1 – Sequencing Results
LORF3
           18471    18520
Rb1b TTGTCGAGGT CTTGCTGCTG AATGCATGTT TACCGGAGGA GGAACTATTG
JM .......GGT CTTGCTGCTG AATGCATGTT TACCGGAGGA GGAACTATTG
CVI988 TTGTCGAGGT CTTGCTGCTG AATGCATGTT TACCGGAGGA GGAACTATTG
18261                                              18310 
            18521          18570
Rb1b CATTAATAGA ACGTCTAGCG ACTTCCTGGC TAACGGCCAT AAGATTGATT
JM CATTAATAGA ACGTCTAGCG ACTTCCTGGC TAACGGCCAT AAGATTGATT
CVI988  CATTAATAGA ACGTCTAGCG ACTTCCTGGC TAACGGCCAT AAGATTGATT
18311          18360
18571          18620
Rb1b TTATCCTGGC ATCCCATTCA CGCTCCCAAT CGTAATCAAG AGCCTCTCGA
JM TTATCCTGGC ATCCCATTCA CGCTCCCAAT CGTAATCAAG AGCCTCTCGA
CVI988 TTATCCTGGC ATCCCATTCA CGCTCCCAAT CGTAATCAAG AGCCTCTCGA
18361    18410
18621    18670
Rb1b TAGCTTATGC CGCGAAGGTC GCGAATATAT TGTAATGATT TCTGGGACGG
JM TAGCTTATGC CGCGAAGGTC GCGAATATAT TGTAATGATT TCTGGGACGG
CVI988 TAGCTTATGC CGCGAAGGTC GCGAATATAT TGTAATGATT TCTGGGACGG
18411                                              18460
            18671    18720
Rb1b TTCACCCACG ACATGCTACA TGGCCATTTT GGCAAGTGAT GCGGAAATGT
JM TTCACCCACG ACATGCTACA TGGCCATTTT GGCAAGTGAT GCGGAAATGT
CVI988 TTCACCCACG ACATGCTACA TGGCCATTTT GGCAAGTGAT GCGGAAATGT 
18461          18510
            18721    18770
Rb1b TTAGATTGGT GCTGCGCATT TCACCCACCT GATGACCACA GTTGTGAATT
JM TTAGATTGGT GCTGCGCATT TCACCCACCT GATGACCACA GTTGTGAATT
CVI988 TTAGATTGGT GCTGCGCATT TCACCCACCT GATGACCACA GTTGTGAATT
18511                                              18560
            18771      18820
Rb1b CGGAGCACCA CGCATTGGAA TCCGGCTAGA GGGCGAAAAT CATTTTTTCG
JM CGGAGCACCA CGCATTGGAA TCCGGCTAGA GGGCGAAAAT CATTTTTTCG
CVI988 CGGAGCACCA CGCATTGGAA TCCGGCTAGA GGGCGAAAAT CATTTTTTCG
18561                                              18610
           18821    18870
Rb1b CACCAATTTT GGGATTGTAT TCTGTAGTAA TGACATGGAG TCCAATTTCA
JM CACCAATTTT GGGATTGTAT TCTGTAGTAA TGACATGGAG TCCAATTTCA
CVI988 CACCAATTTT GGGATTGTAT TCTGTAGTAA TGACATGGAG TCCAATTTCA
18611                                              18660
18871    18920
Rb1b TGTTACCGAG AATTCCCAAT ACGTCAAAAT TCTAAGGAGC CTGATCCCCA
JM TGTTACCGAG AATTCCCAAT ACGTCAAAAT TCTAAGGAGC CTGATCCCCA
CVI988 TGTTACCGAG AATTCCCAAT ACGTCAAAAT TCTAAGGAGC CTGATCCCCA
18661                                              18710
198
LORF3
18921          18970
Rb1b ACCATCAACA TCATCCGAAC CTGAGCCTCA GCCATCGACA TCGTCTCATC
JM ACCATCAACA TCATCCGAAC CTGAGCCTCA GCCATCGACA TCGTCTCATC
CVI988 ACCATCAACA TCATCCGAAC CTGAGCCTCA GCCATCGACA TCGTCTCATC
18711                                              18760
        18971                                          19020
Rb1b GTAACATTCC CGTAGCACGT GTAAGACCTC TTGTCGCTCA GCAAAAGGTA
JM  GTAACATTCC CGTAGCACGT GTAAGACCTC TTGTCGCTCA GCAAAAGGTA
CVI988 GTAACATTCC CGTAGCACGT GTAAGACCTC TTGTCGCTCA GCAAAAGGTA
18761                                              18810
19021    19070
Rb1b  CCCAAAACTA GACCTTTGGA TACAGAAATA CACAGGCCCG GACCAATTGC
JM CCCAAAACTA GACCTTTGGA TACAGAAATA CACAGGCCCG GACCAATTGC
CVI988 CCCAAAACTA GACCTTTGGA TACAGAAATA CACAGGCCCG GACCAATTGC
18811                                              18860  
19071          19120            
Rb1b AATCCAGAAC CCAACAGATA CGGATGAACC TGAACTTCGC TTGAACCCGA
JM AATCCAGAAC CCAACAGATA CGGATGAACC TGAACTTCGC TTGAACCCGA
CVI988 AATCCAGAAC CCAACAGATA CGGATGAACC TGAACTTCGC TTGAACCCGA
18861                                              18910
19121    19170           
Rb1b GACCACGCCC GGGTCCTTCG GGGCAAAATA CACGTCCAAG GACTCCCACT
JM GACCACGCCC GGGTCCTTCG GGGCAAAATA CACGTCCAAG GACTCCCACT
CVI988 GACCACGCCC GGGTCCTTCG GGGCAAAATA CACGTCCAAG GACTCCCACT
18911                                              18960
            19171    19220
Rb1b TTGGACTTGG ATACCGTTGT CGTTCGAGAT CACCCAGTAA CACATCGTCG
JM  TTGGACTTGG ATACCGTTGT CGTTCGAGAT CACCCAGTAA CACATCGTCG
CVI988 TTGGACTTGG ATACCGTTGT CGTTCGAGAT CACCCAGTAA CACATCGTCG
18961                                              19010
            19221    19270
Rb1b TCCGCGTTCT CCTAGCCCAC CTGAGGAAGA TTATACTAAC CAAGATGAAA
JM  TCCGCGTTCT CCTAGCCCAC CTGAGGAAGA TTATACTAAC CAAGATGAAA
CVI988 TCCGCGTTCT CCTAGCCCAC CTGAGGAAGA TTATACTAAC CAAGATGAAA
19011    19060  
            19271    19320
Rb1b ATCTCTCATA TACTCCCCAA TTAATCCATT CTTCCCCAGA TAGTGAAGTT
JM ATCTCTCATA TACTCCCCAA TTAATCCATT CTTCCCCAGA TAGTGAAGTT
CVI988 ATCTCTCATA TACTCCCCAA TTAATCCATT CTTCCCCAGA TAGTGAAGTT
19061    19110
         19321                                              19370 
Rb1b GCTGAGGAGA TTTATGCTCA GCCCGACCCT TGGGGTACAC AAGAACTGCT
JM  GCTGAGGAGA TTTATGCTCA GCCCGACCCT TGGGGTACAC AAGAACTGCT
CVI988 GCTGAGGAGA TTTATGCTCA GCCCGACCCT TGGGGTACAC AAGAACTGCT
19111    19160
            19371     19420                                            
Rb1b ATTAGCAAAT CGTGAACGCA CTCCAGATGA TCAAACAGAT ATTACGGATG
JM ATTAGCAAAT CGTGAACGCA CTCCAGATGA TCAAACAGAT ATTACGGATG
CVI988 ATTAGCAAAT CGTGAACGCA CTCCAGATGA TCAAACAGAT ATTACGGATG
19161    19210
199
LORF3
19421                                              19470
Rb1b ATAGCGCAGA CTGGTCTGAG GGCGAAACAC GTCGACCATC ACATAGTGAA
JM ATAGCGCAGA CTGGTCTGAG GGCGAAACAC GTCGACCATC ACATAGTGAA
CVI988 ATAGCGCAGA CTGGTCTGAG GGCGAAACAC GTCGACCATC ACATAGTGAA
19211    19260
       
19471                                              19520
Rb1b  GTTGGGGAAC GTAGATTGTC CAGAGAAAAT AACAGTGAAG ATCCAAACCG
JM GTTGGGGAAC GTAGATTGTC CAGAGAAAAT AACAGTGAAG ATCCAAACCG
CVI988 GTTGGGGAAC GTAGATTGTC CAGAGAAAAT AACAGTGAAG ATCCAAACCG
19261    19310
           
   19521                                              19570
Rb1b TAGTCGGAGC CGGAGTCGAT CTAGGGAGCG TAGGCGAAGA CGGCCACGAG
JM TAGTCGGAGC CGGAGTCGAT CTAGGGAGCG TAGGCGAAGA CGGCCACGAG
CVI988 TAGTCGGAGC CGGAGTCGAT CTAGGGAGCG TAGGCGAAGA CGGCCACGAG
19311    19360
            19571                                              19620 
Rb1b TTAGGCCTGG GCGTAGGAGT ACGGCTACAA CTATACGAGA TCTTGTGGTT
JM TTAGGCCTGG GCGTAGGAGT ACGGCTACAA CTATACGAGA TCTTGTGGTT
CVI988 TTAGGCCTGG GCGTAGGAGT ACGGCTACAA CTATACGAGA TCTTGTGGTT
19361    19410
           19621    19670
Rb1b CTTGGGATGT CGAGTTCAGA TGATGAATAG CATTTGTGTA TATGTTGTGT
JM CTTGGGATGT CGAGTTCAGA TGATGAATAG CATTTGTGTA TATGTTGTGT
CVI988 CTTGGGATGT CGAGTTCAGA TGATGAATAG CATTTGTGTA TATGTTGTGT
19411    19460
            19671                                              19720
Rb1b GATTGCAAAT CCACTGTATG GTTATATAGT CAGAATTTAA TAAAATGTTC
JM GATTGCAAAT CCACTGTATG GTTATATAGT CAGAATTTAA TAAAATGTTC
CVI988 GATTGCAAAT CCACTGTATG GTTATATAGT CAGAATTTAA TAAAATGTTC
19461    19510
        19721                                              19770
Rb1b GAAGTTTACA CCTTCACGTA TTGTTATGGG TATTTATGGG TGGGCGAGGG
JM GAAGTTTACA CCTTCACGTA TTGTTATGGG .......... ..........
CVI988 GAAGTTTACA CCTTCACGTA TTGTTATGGG TATTTATGGG TGGGCGAGGG
19511    19560
            
Appendix 1a:  LORF3 nucleotide sequence of JM strain of MDV sequenced from DNA isolated 
from RPL-1 cells (Nazerian et al., 1976) aligned and compared with the attenuated CVI988 
Rispens MDV strain and the pathogenic Rb1b MDV strain.  100% consensus was found with 
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200
LORF3 AMINO ACID
1                                                  50
Rb1b  MFTGGGTIAL IERLATSWLT AIRLILSWHP IHAPNRNQEP LDSLCREGRE
JM  MFTGGGTIAL IERLATSWLT AIRLILSWHP IHAPNRNQEP LDSLCREGRE
CVI988  MFTGGGTIAL IERLATSWLT AIRLILSWHP IHAPNRNQEP LDSLCREGRE
     51                                                 100 
Rb1b  YIVMISGTVH PRHATWPFWQ VMRKCLDWCC AFHPPDDHSC EFGAPRIGIR
JM  YIVMISGTVH PRHATWPFWQ VMRKCLDWCC AFHPPDDHSC EFGAPRIGIR
CVI988  YIVMISGTVH PRHATWPFWQ VMRKCLDWCC AFHPPDDHSC EFGAPRIGIR
            101                                                150 
Rb1b  LEGENHFFAP ILGLYSVVMT WSPISCYREF PIRQNSKEPD PQPSTSSEPE
JM  LEGENHFFAP ILGLYSVVMT WSPISCYREF PIRQNSKEPD PQPSTSSEPE
CVI988  LEGENHFFAP ILGLYSVVMT WSPISCYREF PIRQNSKEPD PQPSTSSEPE
            151                                                200
Rb1b  PQPSTSSHRN IPVARVRPLV AQQKVPKTRP LDTEIHRPGP IAIQNPTDTD
JM  PQPSTSSHRN IPVARVRPLV AQQKVPKTRP LDTEIHRPGP IAIQNPTDTD
CVI988  PQPSTSSHRN IPVARVRPLV AQQKVPKTRP LDTEIHRPGP IAIQNPTDTD
            201                                                250 
Rb1b  EPELRLNPRP RPGPSGQNTR PRTPTLDLDT VVVRDHPVTH RRPRSPSPPE
JM  EPELRLNPRP RPGPSGQNTR PRTPTLDLDT VVVRDHPVTH RRPRSPSPPE
CVI988  EPELRLNPRP RPGPSGQNTR PRTPTLDLDT VVVRDHPVTH RRPRSPSPPE
            251                                                300
Rb1b  EDYTNQDENL SYTPQLIHSS PDSEVAEEIY AQPDPWGTQE LLLANRERTP
JM  EDYTNQDENL SYTPQLIHSS PDSEVAEEIY AQPDPWGTQE LLLANRERTP
CVI988  EDYTNQDENL SYTPQLIHSS PDSEVAEEIY AQPDPWGTQE LLLANRERTP
            301                                                350
Rb1b  DDQTDITDDS ADWSEGETRR PSHSEVGERR LSRENNSEDP NRSRSRSRSR
JM  DDQTDITDDS ADWSEGETRR PSHSEVGERR LSRENNSEDP NRSRSRSRSR
CVI988  DDQTDITDDS ADWSEGETRR PSHSEVGERR LSRENNSEDP NRSRSRSRSR
            351                                 385
Rb1b  ERRRRRPRVR PGRRSTATTI RDLVVLGMSS SDDE.
JM  ERRRRRPRVR PGRRSTATTI RDLVVLGMSS SDDE.
CVI988  ERRRRRPRVR PGRRSTATTI RDLVVLGMSS SDDE.
Appendix 1b:  LORF3 aa sequence of JM strain of MDV sequenced from DNA isolated from 
RPL-1 cells (Nazerian et al., 1976) aligned and compared with the attenuated CVI988 Rispens 
MDV strain and the pathogenic Rb1b MDV strain.  
201
LORF11  
  124194                                            124243
Rb1b TTGTATCATC GTATGTGGGC AACAGTGCGG AATTATTGTA TCTGGTAACC
JM TTGTATCATC GTATGTGGGC AACAGTGCGG AATTATTGTA TCTGGTAACC
CVI988 TTGTATCATC GTATGTGGGC AACAGTGCGG AATTATTGTA TCTGGTAACC
123861   123910
            124244                                            124293
Rb1b GATTCTAATT GTAAATGGAT ATATTCTGTG TGTCTATGTC TACATGTAAA
JM GATTCTAATT GTAAATGGAT ATATTCTGTG TGTCTATGTC TACATGTAAA
CVI988 GATTCTAATT GTAAATGGAT ATATTCTGTG TGTCTATGTC TACATGTAAA
123911   123960
           124294                                            124343
Rb1b GAGCTTTCTG CATATTTTTG AGCTTCGGTC AATGCACGTG TTAGTATAGC
JM GAGCTTTCTG CATATTTTTG AGCTTCGGTC AATGCACGTG TTAGTATAGC
CVI988 GAGCTTTCTG CATATTTTTG AGCTTCGGTC AATGCACGTG TTAGTATAGC
123961   124010
           124344                                            124393
Rb1b CACGATCCGG CTCTCCCTCT CTGGGGTCGG AACACAATGC ATATGAAATA
JM CACGATCCGG CTCTCCCTCT CTGGGGTCGG AACACAATGC ATATGAAATA
CVI988 CACGATCCGG CTCTCCCTCT CTGGGGTCGG AACACAATGC ATATGAAATA
124011   124060
            124394                                            124443
Rb1b ATATGCCACA GCCAAAAAAG TTATTAGTCA TGCAAGCATC TGTCAAATAG
JM ATATGCCACA GCCAAAAAAG TTATTAGTCA TGCAAGCATC TGTCAAATAG
CVI988 ATATGCCACA GCCAAAAAAG TTATTAGTCA TGCAAGCATC TGTCAAATAG
124061   124110
            124444                                            124493
Rb1b  CAATCACATA ATGGAATCAA ATGCCTCAAA GCTGCATAAT GAGGGGAACC
JM CAATCACATA ATGGAATCAA ATGCCTCAAA GCTGCATAAT GAGGGGAACC
CVI988 CAATCACATA ATGGAATCAA ATGCCTCAAA GCTGCATAAT GAGGGGAACC
124111   124160
            124494                                            124543
Rb1b TTCTCCCCAT TGAAACCATT TATGGAACCT ACGAGTATAT TCTGCCAACC
JM TTCTCCCCAT TGAAACCATT TATGGAACCT ACGAGTATAT TCTGCCAACC
CVI988  TTCTCCCCAT TGAAACCATT TATGGAACCT ACGAGTATAT TCTGCCAACC
124161   124210
            124544                                            124593
Rb1b ATCGTTTGGT TTCTGCAGTT ATCACCCGAA ATCCTTTAAA TGGAAAGAAT
JM ATCGTTTGGT TTCTGCAGTT ATCACCCGAA ATCCTTTAAA TGGAAAGAAT
CVI988 ATCGTTTGGT TTCTGCAGTT ATCACCCGAA ATCCTTTAAA TGGAAAGAAT
124211   124260
            124594                                            124643
Rb1b AAGCCCAAGT ACCAGTCATT ATTTTCAGGC TTTAGGGGGC ATCGTGTCGT
JM AAGCCCAAGT ACCAGTCATT ATTTTCAGGC TTTAGGGGGC ATCGTGTCGT
CVI988 AAGCCCAAGT ACCAGTCATT ATTTTCAAGC TTTAGGGGGC ATCGTGTCGT
124261   124310
            124644                                            124693
Rb1b TAAATGGGTA ACAAATTCGA TCTGAGAAGG TATGTATGTC AAATATTCAG
JM TAAATGGGTA ACAAATTCGA TCTGAGAAGG TATGTATGTC AAATATTCAG
CVI988 TAAATGGGTA ACAAATTCGA TCTGAGAAGG TATGTATGTC AAATATTCAG
124311   124360
202
LORF11
124694                                            124743
Rb1b AGCTTCTAAC AATACACTCT TCCCAGTGAG ATTGCAATAC ATTATAATTC
JM AGCTTCTAAC AATACACTCT TCCCAGTGAG ATTGCAATAC ATTATAATTC
CVI988 AGCTTCTAAC AATACACTCT TCCCAGTGAG ATTGCAATAC ATTATAATTC
124361   124410
124744                                            124793
Rb1b TCACATCTAA CTACCTTGGG TGTCATACAA GCCGTAATAT GTGTTGTTCG
JM TCACATCTAA CTACCTTGGG TGTCATACAA GCCGTAATAT GTGTTGTTCG
CVI988 TCACATCTAA CTACCTTGGG TGTCATACAA GCCGTAATAT GTGTTGTTCG  
124411   124460
124794                                            124843
Rb1b TTGTAGAATA CACCTATACG GACTTGTTCC AATATCAGGA ATCGATTCGA
JM TTGTAGAATA CACCTATACG GACTTGTTCC AATATCAGGA ATCGATTCGA
CVI988 TTGTAGAATA CACCTATACG GACTTGTTCC AATATCAGGA ATCGATTCGA
124461   124510
            124844                                            124893
Rb1b TGGTTGAGAG CCTACGTATT CCTGATACTG CTAAGAGATC ACACAAAACA
JM TGGTTGAGAG CCTACGTATT CCTGATACTG CTAAGAGATC ACACAAAACA
CVI988 TGGTTGAGAG CCTACGTATT CCTGATACTG CTAAGAGATC ACACAAAACA   
124511   124560
        124894                                            124943
Rb1b AGTAACTTAT TAATTCCATC AATCAAAGTT GTCATATCTA TTGCAGCACC
JM AGTAACTTAT TAATTCCATC AATCAAAGTT GTCATATCTA TTGCAGCACC
CVI988 AGTAACTTAT TAATTCCATC AATCAAAGTT GTCATATCTA TTGCAGCACC
124561   124610
           124944                                            124993
Rb1b CCCAAAAGAA AATAATGTTT CTGTACATGT TCTAGCACCG TTTTCAACAT
JM CCCAAAAGAA AATAATGTTT CTGTACATGT TCTAGCACCG TTTTCAACAT
CVI988 CCCAAAAGAA AATAATGTTT CTGTACATGT TCTAGCACCG TTTTCAACAT
124611   124660
          124994                                            125043
Rb1b TGCTCGTTAC GACCGAAAGA CTAAAAATAA AAGCCAATTC CGGTTTAGAC
JM TGCTCGTTAC GACCGAAAGA CTAAAAATAA AAGCCAATTC CGGTTTAGAC
CVI988 TGCTCGTTAC GACCGAAAGA CTAAAAATAA AAGCCAATTC CGGTTTAGAC
124661   124710
        125044                                            125093
Rb1b TTCTCAAGTG GGACGCTTAT GCGGCGCACT GTACTTTCCA GCTCTTTCCT
JM TTCTCAAGTG GGACGCTTAT GCGGCGCACT GTACTTTCCA GCTCTTTCCT
CVI988 TTCTCAAGTG GGACGCTTAT GCGGCGCACT GTACTTTCCA GCTCTTTCCT
124711   124760
            125094                                            125143
Rb1b GAAGTTAGAC CTCCCACATT TTCCAGCTCT GCTCCAATCT GCTGAAAAAA
JM GAAGTTAGAC CTCCCACATT TTCCAGCTCT GCTCCAATCT GCTGAAAAAA
CVI988 GAAGTTAGAC CTCCCACATT TTCCAGCTCT GCTCCAATCT GCTGAAAAAA
124761   124810
          125144                                            125193
Rb1b ATTTACGTAC AATTGGGGTT ATAGACGTAC CAATGAACAC CTTAAAACAT
JM ATTTACGTAC AATTGGGGTT ATAGACGTAC CAATGAACAC CTTAAAACAT
CVI988 ATTTACGTAC AATTGGGGTT ATAGACGTAC CAATGAACAC CTTAAAACAT
124811   124860
203
LORF11
            125194                                            125243
Rb1b AAATCCTGTG GAGGGTATAC TTCAGTATTA TCGATATCTA GATCTTCTAA
JM AAATCCTGTG GAGGGTATAC TTCAGTATTA TCGATATCTA GATCTTCTAA
CVI988 AAATCCTGTG GAGGGTATAC TTCAGTATTA TCGATATCTA GATCTTCTAA
124861   124910
           125244                                            125293
Rb1b CTTTTGTTTC ATCGATAGTA GAACACGTTC ACAATCTCTA TTCGCGGGCG
JM CTTTTGTTTC ATCGATAGTA GAACACGTTC ACAATCTCTA TTCGCGGGCG
CVI988 CTTTTGTTTC ATCGATAGTA GAACACGTTC ACAATCTCTA TTCGCGGGCG
124911   124960
125294                                            125343
Rb1b GGTTGCACAA TCTTCTCAAA AAAGGTTTGA TCAATGCAAC TGCACCGCAT
JM GGTTGCACAA TCTTCTCAAA AAAGGTTTGA TCAATGCAAC TGCACCGCAT
CVI988 GGTTGCACAA TCTTCTCAAA AAAGGTTTGA TCAATGCAAC TGCACCGCAT
124961    125010
  125344                                            125393
Rb1b CTCGACACAT GTAACGGGGG CATAGTTGAA CGTGCAACAG GTCTTTCTGT
JM CTCGACACAT GTAACGGGGG CATAGTTGAA CGTGCAACAG GTCTTTCTGT
CVI988 CTCGACACAT GTAACGGGGG CATAGTTGAA CGTGCAACAG GTCTTTCTGT
125011   125060
      125394                                            125443
Rb1b AAACAAATCT AGACGTATAC GCCGGGAGCT GCGATACTGT ATATTATGTT
JM AAACAAATCT AGACGTATAC GCCGGGAGCT GCGATACTGT ATATTATGTT
CVI988 AAACAAATCT AGACGTATAC GCCGGGAGCT GCGATACTGT ATATTATGTT
125061   125110
125444                                            125493
Rb1b CGGCTGTATA CGTAGAATGA CTACGATGGA GCCAATCATC CCATGTGCCA
JM CGGCTGTATA CGTAGAATGA CTACGATGGA GCCAATCATC CCATGTGCCA
CVI988 CGGCTGTATA CGTAGAATGA CTACGATGGA GCCAATCATC CCATGTGCCA
125111   125160
            125494                                            125543
Rb1b GTGAAGTACA TTATAGGTGG AACTTTTTTT CTTTGCCTCA CCTTAGAAGT
JM GTGAAGTACA TTATAGGTGG AACTTTTTTT CTTTGCCTCA CCTTAGAAGT
CVI988 GTAAAGTACA TTATAGGTGG AACTTTTTTT CTTTGCCTCA CCTTAGAAGT
125161   125210  
            125544                                            125593
Rb1b GATGGTGGTA CTATCCCCAC TGATGTGTAA ATTGAGGGTT TCTTTCCAGG
JM GATGGTGGTA CTATCCCCAC TGATGTGTAA ATTGAGGGTT TCTTTCCAGG
CVI988 GATGGTGGTA CTATCCCCAC TGATGTGTAA ATTGAGGGTT TCTTTCCAGG
125211   125260
            125594                                            125643
Rb1b GTTTTAGTTT TTCGGATATT AACATATCGT TTGCCCGTCG ACAACACTCT
JM GTTTTAGTTT TTCGGATATT AACATATCGT TTGCCCGTCG ACAACACTCT
CVI988 GTTTTAGTTT TTCGGATATT AACATATCGT TTGCCCGTCG ACAACACTCT
125261   125310
            125644                                            125693
Rb1b TCAACTACCC ATTTTAAATC GTCTAAGTAC ACTTCAGATA ATTCCTTGAC
JM TCAACTACCC ATTTTAAATC GTCTAAGTAC ACTTCAGATA ATTCCTTGAC
CVI988 TCAACTACCC ATTTTAAATC GTCTAAGTAC ACTTCAGATA ATTCCTTGAC
125311   125360
204
LORF11
           125694                                            125743
Rb1b ATAGCTTTCA TCTGCATCGC AATCACAACC ATTCGGAAAA TAATTGCCCT
JM ATAGCTTTCA TCTGCATCGC AATCACAACC ATTCGGAAAA TAATTGCCCT
CVI988 ATAGCTTTCA TCTGCATCGC AATCACAACC ATTCGGAAAA TAATTGCCCT
125361   125410
            125744                                            125793
Rb1b GATTATTATG TGTAGCTGCG GAACCATCAA GCTCCATTTT ATGATATAAG
JM GATTATTATG TGTAGCTGCG GAACCATCAA GCTCCATTTT ATGATATAAG
CVI988 GATTATTATG TGTAGCTGCG GAACCATCAA GCTCCATTTT ATGATATAAG  
125411   125460
125794                                            125843   
Rb1b CGAGATACAG TATCCCTGGT ATAACGATAA CAGGGGGCAA TATCCTTACT
JM CGAGATACAG TATCCCTGGT ATAACGATAA CAGGGGGCAA TATCCTTACT
CVI988 CGAGATACAG TATCCCTGGT ATAACGATAA CAGGGGGCAA TATCCTTACT
125461   125510
      125844                                            125893
Rb1b AGGGTATAAC ATGCATTCTG GAGAAACGGA CGTTATATAT GTGTTTGGAT
JM AGGGTATAAC ATGCATTCTG GAGAAACGGA CGTTATATAT GTGTTTGGAT
CVI988 AGGGTATAAC ATGCATTCTG GAGAAACGGA CGTTATATAT GTGTTTGGAT
            125511   125560
125894                                            125943
Rb1b CTCTGGGTTC TAAATTTTCA CTCGCTCGTA TCCAGCCATA TTTATCCTCT
JM CTCTGGGTTC TAAATTTTCA CTCGCTCGTA TCCAGCCATA TTTATCCTCT
CVI988 CTCTGGGTTC TAAATTTTCA CTCGCTCGTA TCCAGCCATA TTTATCCTCT
125561   125610
         
125944                                            125993
Rb1b ACGGGTTGGA GTATATCGGA ATGTTTCGGT GGGGGAGGAT CCTCTATCAG
JM ACGGGTTGGA GTATATCGGA ATGTTTCGGT GGGGGAGGAT CCTCTATCAG
CVI988 ACGGGTTGGA GTATATCGGA ATGTTTCGGT GGGGGAGGAT CCTCTATCAG
125611   125660
            125994                                            126043
Rb1b AAAATCAATT TTCGAGATTT CTGATGTTCT AGTATTTGAG CTATGTGGTT
JM AAAATCAATT TTCGAGATTT CTGATGTTCT AGTATTTGAG CTATGTGGTT
CVI988 AAAATCAATT TTCGAGATTT CTGATGTTCT AGTATTTGAG CTATGTGGTT
125661   125710
126044                                            126093
Rb1b TATCCACCGT AGCTGCCGAA TCATACATTA ACATCTCAGC TAGCATGACG
JM TATCCACCGT AGCTGCCGAA TCATACATTA ACATCTCAGC TAGCATGACG
CVI988 TATCCACCGT AGTTGCCGAA TCATACATTA ACATCTCAGC TAGCATGACG
125711   125760
            126094                                            126143
Rb1b TCAATATTTT CAAATGCCCC TGCATACACC GCACCCATTC CCATTTGTGT
JM TCAATATTTT CAAATGCCCC TGCATACACC GCACCCATTC CCATTTGTGT
CVI988 TCAATATTTT CAAATGCCCC TGCATACACC GCACCCATTC CCATTTGTGT
125761   125810
            126144                                            126193
Rb1b ACAAGTATTT GTGTCGACAT CGAGCTCCCA AAACGTTGTT AGGTAATCTC
JM ACAAGTATTT GTGTCGACAT CGAGCTCCCA AAACGTTGTT AGGTAATCTC
CVI988 ACAAGTATTT GTGTCGACAT CGAGCTCCCA AAACGTTGTT AGGTAATCTC
125811   125860
205
LORF11
126194                                            126243
Rb1b CATAGAGAGC AAAATCTGCA TCTGTGGTAT TTCGTACAAA GTTGACCACA
JM CATAGAGAGC AAAATCTGCA TCTGTGGTAT TTCGTACAAA GTTGACCACA
CVI988 CATAGAGAGC AAAATCTGCA TCTGTGGTAT TTCGTACAAA GTTGACCACA
125861   125910
            126244                                            126293
Rb1b TGACTCCACC GGGTAGATCC CAGGCGTATA TTGAGCCATG CTATTGAGTT
JM TGACTCCACC GGGTAGATCC CAGGCGTATA TTGAGCCATG CTATTGAGTT
CVI988 TGACTCCACC GGGTAGATCC CAGGCGTATA TTGAGCCATG CTATTGAGTT
125911   125960
            126294                                            126343
Rb1b TCTCAATTCA TCATAATCAT TTCCGTGAAA TGTTTTATGA TCCCATTCCA
JM TCTCAATTCA TCATAATCAT TTCCGTGAAA TGTTTTATGA TCCCATTCCA
CVI988 TCTCAATTCA TCATAATCAT TTCCGTGAAA TGTTTTATGA TCCCATTCCA
125961   126010
126344                                            126393
Rb1b GTAAAATTAT TGTATACAAT TTAGACTTGT ATAAAGAGCG AAGATATGCC
JM GTAAAATTAT TGTATACAAT TTAGACTTGT ATAAAGAGCG AAGATATGCC
CVI988 GTAAAATTAT TGTATACAAT TTAGACTTGT ATAAAGAGCG AAGATATGCC
126011   126060
            126394                                            126443
Rb1b AAATCTGTGG AAGGGTTTGT AGACTCAGGC AGGGGTGTCA CTGTAACAGC
JM AAATCTGTGG AAGGGTTTGT AGACTCAGGC AGGGGTGTCA CTGTAACAGC
CVI988 AAATCTGTGG AAGGGTTTGT AGACTCAGGC AGGGGTGTCA CTGTAACAGC
126061   126110
126444                                            126493
Rb1b CTCGAGATTT CTACCAAAGT GAGTCCTACG TTCGAATCGT ATCAAACCTG
JM CTCGAGATTT CTACCAAAGT GAGTCCTACG TTCGAATCGT ATCAAACCTG
CVI988 CTCGAGATTT CTACCAAAGT GAGTCCTACG TTCGAATCGT ATCAAACCTG
126111   126160
            126494                                            126543
Rb1b GCATACCCGC AGCATCGGTA ACCTGAACAC ATCGTAGGAC TGTGACTTCT
JM GCATACCCGC AGCATCGGTA ACCTGAACAC ATCGTAGGAC TGTGACTTCT
CVI988 GCATACCCGC AGCATCGGTA ACCTGAACAC ATCGTAGGAC TGTGACTTCT
126161   126210
           
126544                                            126593
Rb1b GTTCTTATCC TTCCCAATAA TGACCATGGA GGCCCACAAT TTATGTTATA
JM GTTCTTATCC TTCCCAATAA TGACCATGGA GGCCCACAAT TTATGTTATA
CVI988 GTTCTTATCC TTCCCAATAA TGACCATGGA GGCCCACAAT TTATGTTATA
126211   126260
126594                                            126643
Rb1b TAAAGCTTGG ATTATGGTAG ATCTGGTTGA CGTACATTGA AATTCTGGAA
JM TAAAGCTTGG ATTATGGTAG ATCTGGTTGA CGTACATTGA AATTCTGGAA
CVI988 TAAAGCTTGG ATTATGGTAG ATCTGGTTGA CGTACATTGA AATTCTGGAA
126261   126310
            126644                                            126693
Rb1b ACCATTCTGC AGACGGTTTA GGTGGGTTTA AATTCTGAAT TGGCCCGCTT
JM ACCATTCTGC AGACGGTTTA GGTGGGTTTA AATTCTGAAT TGGCCCGCTT
CVI988 ACCATTCTGC AGACGGTTTA GGTGGGTTTA AATTCTGAAT TGGCCCGCTT
126311   126360
206
LORF11
            126694                                            126743
Rb1b ACTTGCATCC ATTCATACAT TGAGCAAATT AGAGTATGAG GATCGGGAAC
JM ACTTGCATCC ATTCATACAT TGAGCAAATT AGAGTATGAG GATCGGGAAC
CVI988 ACTTGCATCC ATTCATACAT TGAGCAAATT AGAGTATGAG GATCGGGAAC
126361   126410
126744                                            126793
Rb1b ATCGTCAAAA TGGGCAAATA GAGCTATTGT ACTACGTTCC GCCGGTACGG
JM ATCGTCAAAA TGGGCAAATA GAGCTATTGT ACTACGTTCC GCCGGTACGG
CVI988 ATCGTCAAAA TGGGCAAATA GAGCTATTGT ACTACGTTCC GCCGGTGCGG
126411   126460
           126794                                            126843
Rb1b AGCCTATAGA CATAACATAT CTCGGATTTG ATGGCAATCT TTTGAGTTGG
JM AGCCTATAGA CATAACATAT CTCGGATTTG ATGGCAATCT TTTGAGTTGG
CVI988 AGCCTATAGA CATAACATAT CTCGGATTTG ATGGCAATCT TTTGAGTTGG
126461   126510
126844                                            126893
Rb1b TCCAGGAACA ACACTGCACC CGATGAGAAT ACAGTCCTTT CAGGATCGTT
JM TCCAGGAACA ACACTGCACC CGATGAGAAT ACAGTCCTTT CAGGATCGTT
CVI988 TCCAGGAACA ACACTGCACC CGATGAGAAT ACAGTCCTTT CAGGATCGTT
126511   126560
126894                                            126943
Rb1b GTCTTGGTTG GGGTGCCTAT TACAATCCAC CTTTTTTCTC CTTATAGAAG
JM GTCTTGGTTG GGGTGCCTAT TACAATCCAC CTTTTTTCTC CTTATAGAAG
CVI988 GTCTTGGTTG GGGTGCCTAT TACAATCCAC CTTTTTTCTC CTTATAGAAG
126561   126610
126944                                            126993
Rb1b AAGCGAAGCA AGACATCCTG GCGCAGCTCT CGCCAACAGT TGTCTGAAAC
JM AAGCGAAGCA AGACATCCTG GCGCAGCTCT CGCCAACAGT TGTCTGAAAC
CVI988 AAGCGAAGCA AGACATCCTG GCGCAGCTCT CGCCAACAGT TGTCTGAAAC
126611   126660
           126994                                            127043
Rb1b AAGCAATATA TTCTTAAGTT ATAGGTACGT CAAACCACAT CAAGGTATAT
JM AAGCAATATA TTCTTAAGTT ATAGGTACGT CAAACCACAT CAAGG.....
CVI988 AAGCAATATA TTCTTAAGTT ATAGGTACGT CAAACCACAT CAAGGTATAT
126661   126710
Appendix 1c:  LORF11 nucleotide sequence of JM strain of MDV sequenced from DNA isolated 
from RPL-1 cells (Nazerian et al., 1976) aligned and compared with the attenuated CVI988 
Rispens MDV strain and the pathogenic Rb1b MDV strain.  100% consensus with strain Rb1b
and 4 one bp substitutions with strain CVI988 were found.  Note that the LORF11 sequence is 
complimentary. Start and stop codons are shown in purple
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LORF11 AMINO ACID
1                                                   50
Rb1b  MSCFASSIRR KKVDCNRHPN QDNDPERTVF SSGAVLFLDQ LKRLPSNPRY
JM  MSCFASSIRR KKVDCNRHPN QDNDPERTVF SSGAVLFLDQ LKRLPSNPRY
CVI988  MSCFASSIRR KKVDCNRHPN QDNDPERTVF SSGAVLFLDQ LKRLPSNPRY
            51                                                 100
Rb1b  VMSIGSVPAE RSTIALFAHF DDVPDPHTLI CSMYEWMQVS GPIQNLNPPK
JM  VMSIGSVPAE RSTIALFAHF DDVPDPHTLI CSMYEWMQVS GPIQNLNPPK
CVI988  VMSIGSAPAE RSTIALFAHF DDVPDPHTLI CSMYEWMQVS GPIQNLNPPK
            101                                                150 
Rb1b  PSAEWFPEFQ CTSTRSTIIQ ALYNINCGPP WSLLGRIRTE VTVLRCVQVT
JM  PSAEWFPEFQ CTSTRSTIIQ ALYNINCGPP WSLLGRIRTE VTVLRCVQVT
CVI988  PSAEWFPEFQ CTSTRSTIIQ ALYNINCGPP WSLLGRIRTE VTVLRCVQVT
            151                                                200 
Rb1b  DAAGMPGLIR FERRTHFGRN LEAVTVTPLP ESTNPSTDLA YLRSLYKSKL
JM  DAAGMPGLIR FERRTHFGRN LEAVTVTPLP ESTNPSTDLA YLRSLYKSKL
CVI988  DAAGMPGLIR FERRTHFGRN LEAVTVTPLP ESTNPSTDLA YLRSLYKSKL
            201                                                250 
Rb1b  YTIILLEWDH KTFHGNDYDE LRNSIAWLNI RLGSTRWSHV VNFVRNTTDA
JM  YTIILLEWDH KTFHGNDYDE LRNSIAWLNI RLGSTRWSHV VNFVRNTTDA
CVI988  YTIILLEWDH KTFHGNDYDE LRNSIAWLNI RLGSTRWSHV VNFVRNTTDA
          251                                                300
Rb1b  DFALYGDYLT TFWELDVDTN TCTQMGMGAV YAGAFENIDV MLAEMLMYDS
JM  DFALYGDYLT TFWELDVDTN TCTQMGMGAV YAGAFENIDV MLAEMLMYDS
CVI988  DFALYGDYLT TFWELDVDTN TCTQMGMGAV YAGAFENIDV MLAEMLMYDS
            301                                                350 
Rb1b  AATVDKPHSS NTRTSEISKI DFLIEDPPPP KHSDILQPVE DKYGWIRASE
JM  AATVDKPHSS NTRTSEISKI DFLIEDPPPP KHSDILQPVE DKYGWIRASE
CVI988  ATTVDKPHSS NTRTSEISKI DFLIEDPPPP KHSDILQPVE DKYGWIRASE
            351                                                400
Rb1b  NLEPRDPNTY ITSVSPECML YPSKDIAPCY RYTRDTVSRL YHKMELDGSA
JM  NLEPRDPNTY ITSVSPECML YPSKDIAPCY RYTRDTVSRL YHKMELDGSA
CVI988  NLEPRDPNTY ITSVSPECML YPSKDIAPCY RYTRDTVSRL YHKMELDGSA
            401                                                450 
Rb1b  ATHNNQGNYF PNGCDCDADE SYVKELSEVY LDDLKWVVEE CCRRANDMLI
JM  ATHNNQGNYF PNGCDCDADE SYVKELSEVY LDDLKWVVEE CCRRANDMLI
CVI988  ATHNNQGNYF PNGCDCDADE SYVKELSEVY LDDLKWVVEE CCRRANDMLI
            451                                                500 
Rb1b  SEKLKPWKET LNLHISGDST TITSKVRQRK KVPPIMYFTG TWDDWLHRSH
JM  SEKLKPWKET LNLHISGDST TITSKVRQRK KVPPIMYFTG TWDDWLHRSH
CVI988  SEKLKPWKET LNLHISGDST TITSKVRQRK KVPPIMYFTG TWDDWLHRSH
            501                                                550 
Rb1b  STYTAEHNIQ YRSSRRIRLD LFTERPVARS TMPPLHVSRC GAVALIKPFL
JM  STYTAEHNIQ YRSSRRIRLD LFTERPVARS TMPPLHVSRC GAVALIKPFL
CVI988  STYTAEHNIQ YRSSRRIRLD LFTERPVARS TMPPLHVSRC GAVALIKPFL
            551                                                600 
Rb1b  RRLCNPPANR DCERVLLSMK QKLEDLDIDN TEVYPPQDLC FKVFIGTSIT
JM  RRLCNPPANR DCERVLLSMK QKLEDLDIDN TEVYPPQDLC FKVFIGTSIT
CVI988  RRLCNPPANR DCERVLLSMK QKLEDLDIDN TEVYPPQDLC FKVFIGTSIT
208
LORF11 AMINO ACID
            601                                                650 
Rb1b  PIVRKFFSAD WSRAGKCGRS NFRKELESTV RRISVPLEKS KPELAFIFSL
JM  PIVRKFFSAD WSRAGKCGRS NFRKELESTV RRISVPLEKS KPELAFIFSL
CVI988  PIVRKFFSAD WSRAGKCGRS NFRKELESTV RRISVPLEKS KPELAFIFSL
            651                                                700 
Rb1b  SVVTSNVENG ARTCTETLFS FGGAAIDMTT LIDGINKLLV LCDLLAVSGI
JM  SVVTSNVENG ARTCTETLFS FGGAAIDMTT LIDGINKLLV LCDLLAVSGI
CVI988  SVVTSNVENG ARTCTETLFS FGGAAIDMTT LIDGINKLLV LCDLLAVSGI
701                                                750 
Rb1b  RRLSTIESIP DIGTSPYRCI LQRTTHITAC MTPKVVRCEN YNVLQSHWEE
JM  RRLSTIESIP DIGTSPYRCI LQRTTHITAC MTPKVVRCEN YNVLQSHWEE
CVI988  RRLSTIESIP DIGTSPYRCI LQRTTHITAC MTPKVVRCEN YNVLQSHWEE
            751                                                800 
Rb1b  CIVRSSEYLT YIPSQIEFVT HLTTRCPLKP ENNDWYLGLF FPFKGFRVIT
JM  CIVRSSEYLT YIPSQIEFVT HLTTRCPLKP ENNDWYLGLF FPFKGFRVIT
CVI988  CIVRSSEYLT YIPSQIEFVT HLTTRCPLKL ENNDWYLGLF FPFKGFRVIT
            801                                                850 
Rb1b  AETKRWLAEY TRRFHKWFQW GEGSPHYAAL RHLIPLCDCY LTDACMTNNF
JM  AETKRWLAEY TRRFHKWFQW GEGSPHYAAL RHLIPLCDCY LTDACMTNNF
CVI988  AETKRWLAEY TRRFHKWFQW GEGSPHYAAL RHLIPLCDCY LTDACMTNNF
            851                                                900
Rb1b  FGCGILFHMH CVPTPERESR IVAILTRALT EAQKYAESSL HVDIDTQNIS
JM  FGCGILFHMH CVPTPERESR IVAILTRALT EAQKYAESSL HVDIDTQNIS
CVI988  FGCGILFHMH CVPTPERESR IVAILTRALT EAQKYAESSL HVDIDTQNIS




Appendix 1d:  LORF11 aa sequence of JM strain of MDV sequenced from DNA isolated from 
RPL-1 cells (Nazerian et al., 1976) aligned and compared with the attenuated CVI988 Rispens 
MDV strain and the pathogenic Rb1b MDV strain.  
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LORF12                                    
            127040                                            127089
Rb1b TGTATCACAT ACGTCAATTA TGTTTCTGTG ATAATAGTTA CAAGGGTTGC
JM TGTATCACAT ACGTCAATTA TGTTTCTGTG ATAATAGTTA CAAGGGTTGC
CVI988 TGTATCACAT ACGTCAATTA TGTTTCTGTG ATAATAGTTA CAAGGGTTGC
126801   126850
            127090                                            127139
Rb1b AGAAACTACC GTCAAAAAAA GTATTAATAA TGTAGCGATC GCACATCCAT
JM AGAAACTACC GTCAAAAAAA GTATTAATAA TGTAGCGATC GCACATCCAT
CVI988 AGAAACTACC GTCAAAAAAA GTATTAATAA TGTAGCGATC GCACATCCAT
126851   126900
            127140                                            127189
Rb1b CATGTCGAAT GATAAAACGC AAGTCAACTT CTGCGCAACT TTCAGAATTG
JM CATGTCGAAT GATAAAACGC AAGTCAACTT CTGCGCAACT TTCAGAATTG
CVI988 CATGTCGAAT GATAAAACGC AAGTCAACTT CTGCGCAACT TTCAGAATTG
126901   126950
            127190                                            127239
Rb1b TTAACATTAT GTATCGGGGA TAGGGAATCG TATGAAGGGG GTGGGTCAAC
JM TTAACATTAT GTATCGGGGA TAGGGAATCG TATGAAGGGG GTGGGTCAAC
CVI988 TTAACATTAT GTATCGGGGA TAGGGAATCG TATGAAGGGG GTGGGTCAAC
126951   127000
            127240                                            127289
Rb1b TGCATCATCG TATGTGGGCA ACAGTGCGGA ATTATTGTAT CTGGTAACCG
JM TGCATCATCG TATGTGGGCA ACAGTGCGGA ATTATTGTAT CTGGTAACCG
CVI988 TGCATCATCG TATGTGGGCA ACAGTGCGGA ATTATTGTAT CTGGTAACCG
127001   127050
            127290                                            127339
Rb1b ATTCTAATTG TAAATGAATA TATTCTGATT GTTCATCAAT ATCTGAAAGC
JM ATTCTAATTG TAAATGAATA TATTCTGATT GTTCATCAAT ATCTGAAAGC
CVI988 ATTCTAATTG TAAATGAATA TATTCTGATT GTTCATCAAT ATCTGAAAGC
127051   127100
            127340                                            127389
Rb1b ACAGGTTCTT CCTCGATTGG TGGGGAGATA GTCTCGGGTA TAGAAACGGC
JM ACAGGTTCTT CCTCGATTGG TGGGGAGATA GTCTCGGGTA TAGAAACGGC
CVI988 ACAGGTTCTT CCTCGATTGG TGGGGAGATA GTCTCGGGTA TAGAAACGGC
127101   127150
           127390                                            127439
Rb1b ATCTGCATCC AAATCGAGAC TTTCGTGCTG CAGCTGTCCA TTTTCCATTT
JM ATCTGCATCC AAATCGAGAC TTTCGTGCTG CAGCTGTCCA TTTTCCATTT
CVI988 ATCTGCATCC AAATCGAGAC TTTCGTGCTG CAGCTGTCCA TTTTCCATTT
127151   127200
127440                                            127489
Rb1b TTTGGTCTTT GTCTGCACCA ATATTCGTAA AGGTGAGAAT TCGCTTAATC
JM TTTGGTCTTT GTCTGCACCA ATATTCGTAA AGGTGAGAAT TCGCTTAATC
CVI988 TTTGGTCTTT GTCTGCACCA ATATTCGTAA AGGTGAGAAT TCGCTTAATC
1227201   127250
Appendix 1e: LORF12 nucleotide sequence of JM strain of MDV sequenced from DNA isolated 
from RPL-1 cells (Nazerian et al., 1976) aligned and compared with the attenuated CVI988 
Rispens MDV strain and the pathogenic Rb1b MDV strain.  Note that the LORF12 sequence is 
complimentary. Start and stop codons are shown in purple
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LORF12 AMINO ACID
1                                                   50
Rb1b  MENGQLQHES LDLDADAVSI PETISPPIEE EPVLSDIDEQ SEYIHLQLES
JM  MENGQLQHES LDLDADAVSI PETISPPIEE EPVLSDIDEQ SEYIHLQLES
CVI988  MENGQLQHES LDLDADAVSI PETISPPIEE EPVLSDIDEQ SEYIHLQLES
            51                                                 100
Rb1b  VTRYNNSALL PTYDDAVDPP PSYDSLSPIH NVNNSESCAE VDLRFIIRHD
JM  VTRYNNSALL PTYDDAVDPP PSYDSLSPIH NVNNSESCAE VDLRFIIRHD
CVI988 VTRYNNSALL PTYDDAVDPP PSYDSLSPIH NVNNSESCAE VDLRFIIRHD
            101                         127
Rb1b  GCAIATLLIL FLTVVSATLV TIITET.
JM  GCAIATLLIL FLTVVSATLV TIITET.
CVI988 GCAIATLLIL FLTVVSATLV TIITET.
Appendix 1f:  LORF12 aa sequence of JM strain of MDV sequenced from DNA isolated from 
RPL-1 cells (Nazerian et al., 1976) aligned and compared with the attenuated CVI988 Rispens 
MDV strain and the pathogenic Rb1b MDV strain.  
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ANTISENSE              
       151770                                            151819
Rb1b  GCGAGCGTTG TCCATGGTAA CTGGAGTGGG GGCGGTATGT ACCCGATTGT
JM  .......... ..CATGGTAA CTGGAGTGGG GGCGGTATGT ACCCGATTGT
CVI988 GCGAGCGCTG TCCATGGTAA CTGGAGTGGG GGCGGTATGT ACCCGATTGT
151801   151850
            151820                                            151869
Rb1b CCGGCTAGCG ATGGTACGGG GACACAGGGT GTTTGCAGCG AGACGCCTTG
JM  CCGGCTAGCG ATGGTACGGG GACACAGGGT GTTTGCAGCG AGACGCCTTG
CVI988 CCGGCTAGCG ATGGTACGGG GACACAGGGT GTTTGCAGCG AGACGCCTTG
151851   151900
           151870                                            151919
Rb1b  ATAAGGGTCC CCCGGAGTGG CTGGCGTATG TGGAAAAATC CCCACGTCTT
JM ATAAGGGTCC CCCGGAGTGG CTGGCGTATG TGGAAAAATC CCCACGTCTT
CVI988  ATAAGGGTCC CCCGGAGTGG CTGGCGTATG TGGAAAAATC CCCACGTCTT
151901   151950
        
151920                                            151969
Rb1b  CGTCAAAAGC TGCCAACAAG CTGTCGAAAT CAGGCGGGTT GTCCATTTTT
JM  CGTCAAAAGC TGCCAACAAG CTGTCGAAAT CAGGCGGGTT GTCCATTTTT
CVI988 CGTCAAAAGC TGCCAACAAG CTGTCGAAAT CAGGCGGGTT GTCCATTTTT
151951   152000 
         
151970                                            152019
Rb1b  AGGGTTTAGG AGGGGCGCAA ATAGATGGTG GGTGGGCCGA TGTGAGGGGA
JM AGGGTTTAGG AGGGGCGCAA ATAGATGGTG GGTGGGCCGA TGTGAGGGGA
CVI988  AGGGTTTAGG AGGGGCGCAA ATAGATGGTG GGTGGGCCGA TGTGAGGGGA
152001   152050
           152020                                            152069
Rb1b  ATACGGAAGG CGTAGCTGTC TATGACTCCC TTTGGGGGTC TCGTGGAAAT
JM  ATACGGAAGG CGTAGCTGTC TATGACTCCC TTTGGGGGTC TCGTGGAAAT
CVI988  ATACGGAAGG CGTAGCTGTC TATGACTCCC TTTGGGGGTC TCGTGGAAAT
152051   152100
      152070                                            152119 
Rb1b  GGCCCTCCCA TGCTAGACCA CAAGATGTGG GGGGAGGGAA GCTACGGTTC
JM  GGCCCTCCCA TGCTAGACCA CAAGATGTGG GGGGAGGGAA GCTACGGTTC
CVI988  GGCCCTCCCA TGCTAGACCA CAAGATGTGG GGGGAGGGAA GCTACGGTTC
152101   152150
           152120                                            152169
Rb1b  AAGTGCGGAA ATTTCGATGT GCTGAAAGTC GAAACATAAA TGTAGGTGTC
JM AAGTGCGGAA ATTTCGATGT GCTGAAAGTC GAAACATAAA TGTAGGTGTC
CVI988  AAGTGCGGAA ATTTCGATGT GCTGAAAGTC GAAACATAAA TGTAGGTGTC
152151   152200
152170                                            152219 
Rb1b  AGCTGCGGAT ATAATCCCGA ACAGCTAGCA TCTGGTTTTG TATTTAGGCC
JM  AGCTGCGGAT ATAATCCCGA ACAGCTAGCA TCTGGTTTTG TATTTAG...
CVI988 AGCTGCGGAT ATAATCCCGA ACAGCTAGCA TCTGGTTTTG TATTTAGGCC
152201   152250
  
Appendix 1g:  ANTISENSE nucleotide sequence of JM strain of MDV sequenced from DNA 
isolated from RPL-1 cells (Nazerian et al., 1976) aligned and compared with the attenuated 
CVI988 Rispens MDV strain and the pathogenic Rb1b MDV strain.  Start and stop codons are 
shown in purple.  
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1                                                   50
Rb1b  MYPIVRLAMV RGHRVFAARR LDKGPPEWLA YVEKSPRLRQ KLPTSCRNQA
JM MYPIVRLAMV RGHRVFAARR LDKGPPEWLA YVEKSPRLRQ KLPTSCRNQA
CVI988  MYPIVRLAMV RGHRVFAARR LDKGPPEWLA YVEKSPRLRQ KLPTSCRNQA
            51                                                 100
Rb1b  GCPFLGFRRG ANRWWVGRCE GNTEGVAVYD SLWGSRGNGP PMLDHKMWGE
JM  GCPFLGFRRG ANRWWVGRCE GNTEGVAVYD SLWGSRGNGP PMLDHKMWGE
CVI988 GCPFLGFRRG ANRWWVGRCE GNTEGVAVYD SLWGSRGNGP PMLDHKMWGE




Appendix 1h:  ANTISENSE aa sequence of JM strain of MDV sequenced from DNA isolated 
from RPL-1 cells (Nazerian et al., 1976) aligned and compared with the attenuated CVI988 
Rispens MDV strain and the pathogenic Rb1b MDV strain.  
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US2
           158302              158351
Rb1b AATTATATCT AATTGGTAGC AAGTAGGTCT GTCGAATAAC AGCTAATGAC
JM .......... ......TAGC AAGTAGGTCT GTCGAATAAC AGCTAATGAC
CVI988  AATTATATCT AATTGGTAGC AAGTAGGTCT GTCGAATAAC AGCTAATGAC
158551   158600
            158352   158401                                            
Rb1b TACCGGCTCT ACATTTTTTC TGTATTCGTG ACTTTCCTGT CGCAGTGTAA
JM TACCGGCTCT ACATTTTTTC TGTATTCGTG ACTTTCCTGT CGCAGTGTAA
CVI988  TACCGGCTCT ACATTTTTTC TGTATTCGTG ACTTTCCTGT CGCAGTGTAA
158601   158650
    158402   158451                                               
Rb1b CGAACCGGAA TTGCAATCGC ATCTCTATCT TCTTTCTTGC AACATTTTCC
JM CGAACCGGAA TTGCAATCGC ATCTCTATCT TCTTTCTTGC AACATTTTCC
CVI988 CGAACCGGAA TTGCAATCGC ATCTCTATCT TCTTTCTTGC AACATTTTCC
158651   158700
           158452   158501                                              
Rb1b ACAACAGAAT AATCTGCCGG GTGTACTACT CATTTGAGGT GGTTCGATTT
JM ACAACAGAAT AATCTGCCGG GTGTACTACT CATTTGAGGT GGTTCGATTT
CVI988 ACAACAGAAT AATCTGCCGG GTGTACTACT CATTTGAGGT GGTTCGATTT
158701   158750
158502   158551
Rb1b CCGGAGGTTT TAGAGGATTG GGTGGGGACC CGAGGATTTT GTATACACAT
JM CCGGAGGTTT TAGAGGATTG GGTGGGGACC CGAGGATTTT GTATACACAT
CVI988  CCGGAGGTTT TAGAGGATTG GGTGGGGACC CGAGGATTTT GTATACACAT
158751   158800
            158552                                            158601
Rb1b ACCATATCAC TGTCGCAAAA ATGCGCTCTA TCTTCTGGGG TGTCGAACTT
JM ACCATATCAC TGTCGCAAAA ATGCGCTCTA TCTTCTGGGG TGTCGAACTT
CVI988  ACCATATCAC TGTCGCAAAA ATGCGCTCTA TCTTCTGGGG TGTCGAACTT
158801   158850
            158602                                            158651
Rb1b CGGTTCCCAT GTAGATGTCA AGAGAGTTTG AATATTGTCG GGAATGGCCC
JM CGGTTCCCAT GTAGATGTCA AGAGAGTTTG AATATTGTCG GGAATGGCCC
CVI988  CGGTTCCCAT GTAGATGTCA AGAGAGTTTG AATATTGTCG GGAATGGCCC
158851   158900
      158652   158701
Rb1b ACGGCATACC GGACCAGGTC CCAGACACTT TGATTGCAAG TAACCTTTTT
JM ACGGCATACC GGACCAGGTC CCAGACACTT TGATTGCAAG TAACCTTTTT
CVI988 ACGGCATACC GGACCAGGTC CCAGACACTT TGATTGCAAG TAACCTTTTT
158901   158950
            158702                   158751
Rb1b GGCAAAGGAA TACATTCGAG CGCAATGCGA CATATATCTG CCGCCCCAAC
JM GGCAAAGGAA TACATTCGAG CGCAATGCGA CATATATCTG CCGCCCCAAC
CVI988 GGCAAAGGAA TACATTCGAG CGCAATGCGA CATATATCTG CCGCCCCAAC
158951   159000
158752   158801
Rb1b TATCCACAAG CTATGTGGAG CATTACCAGA AACTTCAGAT TCCAACATCA
JM TATCCACAAG CTATGTGGAG CATTACCAGA AACTTCAGAT TCCAACATCA
CVI988 TATCCACAAG CTATGTGGAG CATTACCAGA AACTTCAGAT TCCAACATCA
159001   159050
214
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158802   158851
Rb1b AATATCCAGA TAGAACATCC TGCCATTCTG TGGAACATCC TGCAACATCT
JM AATATCCAGA TAGAACATCC TGCCATTCTG TGGAACATCC TGCAACATCT
CVI988 AATATCCAGA TAGAACATCC TGCCATTCTG TGGAACATCC TGCAACATCT
159051   159100
          
158852   158901
Rb1b TCAAATAGCC GCACTATAAA CGAATCCCTA GTTCCGGCCA ATCCGGTACC
JM TCAAATAGCC GCACTATAAA CGAATCCCTA GTTCCGGCCA ATCCGGTACC
CVI988 TCAAATAGCC GCACTATAAA CGAATCCCTA GTTCCGGCCA ATCCGGTACC
159101   159150
         158902   158951
Rb1b  ACGAACTCCA GTTCCATCTG GTGGCTTTGT CCTTACTATC GGTCGATGTT
JM ACGAACTCCA GTTCCATCTG GTGGCTTTGT CCTTACTATC GGTCGATGTT
CVI988 ACGAACTCCA GTTCCATCTG GTGGCTTTGT CCTTACTATC GGTCGATGTT
159151   159200
            158952   159001
Rb1b GCCGAGGAAG AATTAACATG GGTTTGGCAA AACGGAATAG GTCTGCAGCT
JM GCCGAGGAAG AATTAACATG GGTTTGGCAA AACGGAATAG GTCTGCAGCT
CVI988 GCCGAGGAAG AATTAACATG GGTTTGGCAA AACGGAATAG GTCTGCAGCT
159201   159250
159002   159051
Rb1b  CTGACGATTA TGGGCACACC CACATCATCC TGTATTTGTT CCATACATTG
JM CTGGCGATTA TGGGCACACC CACATCATCC TGTATTTGTT CCATACATTG
CVI988 CTGGCGATTA TGGGCACACC CACATCATCC TGTATTTGTT CCATACATTG
159251                                            159300
         159052   159101
Rb1b CTTTATAAGG AATATCCATA AAGTAGATGC AGCATCTCTA GATCTTCCTG
JM CTTTATAAGG AATATCCATA AAGTAGATGC AGCATCTCTA GATCTTCCTG
CVI988 CTTTATAAGG AATATCCATA AAGTAGATGC AGCATCTCTA GATCTTCCTG
159301                                            159350
      159102   159151
Rb1b GCAATCGATC GCATTCATCT AGAAGTGTGA CTATAGTTAT CATGGACACA
JM GCAATCGATC GCATTCATCT AGAAGTGTGA CTATAGTTAT CATGGACACA
CVI988 GCAATCGATC GCATTCATCT AGAAGTGTGA CTATAGTTAT CATGGACACA
159351   159400
            159152   159201
Rb1b CCCATCTTCA CCTCCACCAA TAATCTTTTT TATTGTTAAT AACTGGGCCG
JM CCCATCTTCA CCTCCACCAA TAATCTTT.. .......... ..........
CVI988 CCCATCTTCA CCTCCACCAA TAATCTTTTT TATTGTTAAT AACTGGGCCG
159401   159450
Appendix 1i:  US2 nucleotide sequence of JM strain of MDV sequenced from DNA isolated 
from RPL-1 cells (Nazerian et al., 1976) aligned and compared with the attenuated CVI988 
Rispens MDV strain and the pathogenic Rb1b MDV strain.  Note that the US2 sequence is 
complimentary. Start and stop codons are shown in purple and mutations are denoted in green. 
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US2 AMINO ACID
1                                                   50
Rb1b  MGVSMITIVT LLDECDRLPG RSRDAASTLW IFLIKQCMEQ IQDDVGVPII
JM  MGVSMITIVT LLDECDRLPG RSRDAASTLW IFLIKQCMEQ IQDDVGVPII
CVI988  MGVSMITIVT LLDECDRLPG RSRDAASTLW IFLIKQCMEQ IQDDVGVPII
          51                                                 100
Rb1b  VRAADLFRFA KPMLILPRQH RPIVRTKPPD GTGVRGTGLA GTRDSFIVRL
JM  ARAADLFRFA KPMLILPRQH RPIVRTKPPD GTGVRGTGLA GTRDSFIVRL
CVI988  ARAADLFRFA KPMLILPRQH RPIVRTKPPD GTGVRGTGLA GTRDSFIVRL
            101                                                150
Rb1b  FEDVAGCSTE WQDVLSGYLM LESEVSGNAP HSLWIVGAAD ICRIALECIP
JM  FEDVAGCSTE WQDVLSGYLM LESEVSGNAP HSLWIVGAAD ICRIALECIP
CVI988  FEDVAGCSTE WQDVLSGYLM LESEVSGNAP HSLWIVGAAD ICRIALECIP
           151                                                200 
Rb1b  LPKRLLAIKV SGTWSGMPWA IPDNIQTLLT STWEPKFDTP EDRAHFCDSD
JM  LPKRLLAIKV SGTWSGMPWA IPDNIQTLLT STWEPKFDTP EDRAHFCDSD
CVI988  LPKRLLAIKV SGTWSGMPWA IPDNIQTLLT STWEPKFDTP EDRAHFCDSD
   201                                                250
Rb1b  MVCVYKILGS PPNPLKPPEI EPPQMSSTPG RLFCCGKCCK KEDRDAIAIP
JM  MVCVYKILGS PPNPLKPPEI EPPQMSSTPG RLFCCGKCCK KEDRDAIAIP
CVI988  MVCVYKILGS PPNPLKPPEI EPPQMSSTPG RLFCCGKCCK KEDRDAIAIP
            251                   271
Rb1b  VRYTATGKSR IQKKCRAGSH .
JM  VRYTATGKSR IQKKCRAGSH .
CVI988  VRYTATGKSR IQKKCRAGSH .
Appendix 1j:  US2 aa sequence of JM strain of MDV sequenced from DNA isolated from RPL-1 
cells (Nazerian et al., 1976) aligned and compared with the attenuated CVI988 Rispens MDV 
strain and the pathogenic Rb1b MDV strain.
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Appendix 2 – Supplier Information
Alpha Innotech Inc.
2401 Merced Street, 
San Leandro, California  94577, USA
Amersham Biosciences












Hertfordshire HP2 7DX, UK
Bio Gene Ltd.
BioGene House






1290 Terra Bella Avenue
Mountain View, California  94043, USA
Daco Cytomation UK Ltd. 
Cambridge House, 
St Thomas Place, Ely, 










Invitrogen Ltd. (incorporating Gibco, Ambion and Applied Biosystems)
Life Technologies Corporation
European Headquarters 
3 Fountain Drive, 
Inchinnan Business Park, 
Paisley PA4 9RF, UK
Li-Cor Biosciences
St. John's Innovation Centre
Cowley Road, Cambridge






Merck & Co., Inc.
One Merck Drive
P.O. Box 100
Whitehouse Station, New Jersey
08889-0100, USA
Minitab Ltd.
Brandon Court, Unit E1-E2
Progress Way
Coventry CV3 2TE, UK
New England Biolabs 
75-77 Knowl Piece 
Wilbury Way 
Hitchin, 
Hertsfordshire SG4 0TY, UK
218
Promega Corporation
2800 Woods Hollow Road
Madison, Wisconsin
53711-5399  USA











Cambrex Bio Science Rockland, Inc., 
191 Thomaston Street, 
Rockland, Maine 04841 USA
Sera Laboratoires International
Unit 44, Bolney Grange Business Park
Haywards Heath, West Sussex
RH17 5PB  UK
Severn Biotech, Ltd.




Sigma-Aldrich (incorporating Fluka Chemicals)
3050 Spruce Street, 
St. Louis, MO 63103 USA
Stratagene
Aligent Technologies, 
11011 N. Torrey Pines Road, 
La Jolla, California 92037, USA
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Thermo Fisher Scientific (incorporating Nunclon and Dharmacon)
Fisher Scientific UK Ltd
Bishop Meadow Road, 
Loughborough, 
Leicestershire, LE11 5RG UK 
VWR International Ltd




30 Ingold Road, 
Burlingame, California 94010, USA
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Short Optimization with the Cell Line Optimization Protocol (VCO-1001): 
Cell Line: RPL-1 
Clone/origin: Researcher:  G. Hunter
Passage no.:  P8 after thawing
Used culture medium: RPMI, 10%FCS, Tryptose Phosphate Broth, Sodium Pyruvate,  
University of Edinburgh
Density/confluence before Nucleofection: Short Protocol   
Cell no./sample: 3.5 million Total cells needed: 57   million
Max. centrifugal force: 200g, 10min, Room Temperature
6-well plates for plating out cells after Nucleofection,
1 well per Nucleofection (2-4 plates needed);   2 ml media per well
DNA/RNA:
Used construct, supplier (e.g. pEGFP, Clontech): pmaxGFP reporter gene (e.g. eGFP): maxGFP
Used promoter (e.g. CMV):   CMV   size: 3,5kb special sequences (e.g. IRES, LTR): no
Used amount:2µg      purification method: endotoxin-free
A260/A280: >1.8
RESULTS post Nucleofection: 
Time point of analysis:  16-24h method: fluorescent. Microscope
Sample                             Solution: Cell Line Nucleofector Solution V 
# Program: plasmid Trans. Efficiency (%):
V                  
Viability (%):
V                    
1 A-033 pmaxGFP 35.7 18.3
2 X-002 pmaxGFP 29.0 14.9
3 T-001 pmaxGFP 35.0 16.6
4 U-001 pmaxGFP 32.8 9.1
5 X-001 pmaxGFP 13.4 11.4
6 w/o Nucleofection pmaxGFP 0 100
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